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Abstract 
 
Chronic pain is a global medical-health problem. It is estimated that approximately 
20% of the adult population suffer from some form of chronic pain. Along with the 
physical and emotional burden that living with chronic pain brings to the individual, 
there is also a huge socio-economic cost implication currently estimated at more 
than €200 million per annum in Europe and at over $150 million in the USA. 
Unfortunately, because of a lack of efficacious treatments, chronic pain is poorly 
managed. Current therapies for chronic pain act upon well-established targets and 
have been shown not only to be inadequate for the majority of patients, with only 1 
in 4 patients only finding up to 50% relief from their painful syndromes There is, 
therefore, a continued need for novel analgesic drugs that act at novel therapeutic 
targets. With the elucidation of the role of α1 glycine receptor (α1 GlyR) plays in 
nociceptive pathways it has become an attractive target for novel analgesic 
compounds. 
Previous work with the group has identified a series of potent bi-phenyl compounds 
targeting the α1 GlyR with EC50 values in the low nM range. However, these 
compounds suffered from poor physicochemical and pharmacokinetic properties.    
Work in this thesis describes the rational design and synthesis of a library of 
compounds which selectively target the α1 GlyR with EC50 values in the sub nano-
molar range. We have successfully progressed from hit to lead stage with improved 
efficacy and DMPK properties.  The lead compound has shown excellent PK profiles, 
CNS penetration properties and no toxicity issues. We have obtained proof-of 
concept for the lead compound in a rat model of neuropathic pain and are currently 
moving forward with lead optimisation.  
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1 Introduction 
 
1.1 Pain 
 
The perception of pain is not uniform throughout the population, and the term 
“pain” can mean very different things to different people. Pain has described as “an 
unpleasant multidimensional sensory and emotional experience that is linked to 
potential or actual tissue damage”1. Acute pain is the pain we feel when we cut 
ourselves, touch a hotplate, break a bone etc.; this is an evolutionary alarm system 
that tells us of potential or actual damage to our body. If we are unfortunate 
enough to suffer an insult or injury the acute pain will persist as a warning to allow 
the injured area to heal. Once the body is healed the pain will subside and we can 
go about our lives as normal. Acute pain is therefore, an adaptive protective 
response in order to prevent injury or to allow damaged tissues to heal. What if the 
pain persists beyond the period of healing? What if the pain spreads to other parts 
of the body? This pain is termed chronic; it is maladaptive, that is to say, it is no 
longer a protective supportive process, but is a dysfunctional process thought to be 
a consequence of abnormalities within the somatosensory system2,3. Chronic pain 
may result from damage to the nervous system itself (neuropathic pain) this could 
be as a result of viral infections such as, herpes, HIV, or as the results of tumours, 
cancer or even through surgical procedures and therapeutic interventions4,5. In 
many chronic pain syndromes such as, fibromyalgia, irritable bowel syndrome and 
osteoarthritis the aetiology is not so discernible6,7,8. One thing that is clear however 
is the devastating and debilitating effects chronic pain has upon sufferers. 
1 in 5 adults in Europe suffer from chronic pain, this equates to ~8 million people in 
the UK alone9. In the US it is thought that 100 million adults, more than the total 
number affected by cancer, diabetes and heart disease, are afflicted with some 
form of chronic pain10.  
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Evidence indicates that chronic pain conditions can severely impact on quality of life 
with up to 50% of suffers struggling with daily tasks such as, household chores, 
exercise, walking or driving9. Unsurprisingly anxiety disorders and depression are 
also associated with chronic pain; a review by Bair, Robinson, Katon, & Kroenke,  
found the prevalence of major depression in chronic pain sufferers was as high as 
85%11.  
Unfortunately, because of a lack of efficacious treatments chronic pain is poorly 
managed.  Current therapies for chronic pain act upon well-established targets and  
have been shown not only to be inadequate for the majority of patients, with only 1 
in 4 patients only finding up to 50% relief from their painful syndromes, but they 
also have a high side effect burden and abuse potential12,13. Crucially current 
medications used to treat chronic pain are symptomatic only, they are not curative 
or disease modifying, therefore, there exists an urgent unmet need for effective 
novel analgesic drugs with reduced side effects, abuse liability and tolerance issues 
which can target chronic pain states12.     
Pain can be described as four major states: Nociceptive, inflammatory, neuropathic 
and dysfunctional as described below. 
1.1.1 Nociceptive pain 
Nociceptive pain can be thought of as our alarm system, an early warning sign of 
contact with noxious stimuli14. The receptors which detect such noxious stimuli are 
termed nociceptors, which are highly specialised, high threshold sensory receptors 
found within the peripheral nervous system15. Nociceptors transduce noxious 
stimuli into an action potential from receptors or ion channels which are sensitive 
to thermal, chemical or mechanical stimuli16. The impulses travel along both the 
large calibre rapidly conducting myelinated Aδ fibres, and the slower conducting 
unmyelinated C-fibre nociceptors. The input is conducted along the ascending 
pathway (Figure 1.1) to the spinal cord via the dorsal root ganglion (DRG) and then 
on to the higher regions of the central cortex where the sensation of pain is 
experienced16,17.  
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The cortex activates descending pain control pathways which releases a variety of 
chemical mediators including, norepinephrine (NE), serotonin (5-HT), gamma-
aminobutyric acid (GABA) and peptides such as endorphins and enkephalins, (Figure 
1.2). These mediators activate a complicated cascade of interactions that inhibit the 
excitatory activity. The result is the formation of a pain-processing loop, activated 
by nociceptive input, ultimately inhibited by a descending antinociceptive output18. 
 
Figure 1.119. The nociceptive pain pathway. Detection of noxious stimuli by 
nociceptors generates signals which travel to the dorsal horn of the spinal cord. The 
signals are transduced along the ascending pain pathway to the sensory cortex of 
the brain. The cortex releases a variety of chemical mediators to inhibit excitatory 
activity creating a pain processing loop. 
 
Figure 1.2. Serotonin, norepinephrine and  gamma-aminobutyric acid. 
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Nociception is an adaptive protective process. It helps prevent injury by generating 
a reflex withdrawal response from a stimulus that could cause tissue damage. It also 
elicits a sensation so unpleasant it results in complicated behavioural strategies that 
help prevent future contact with such stimuli20. Under normal circumstances 
nociceptive pain is not a clinical problem and should only be suppressed under the 
context of clinical procedures that involve noxious stimuli and result in tissue 
damage such as surgery.  
In the rare autosomal condition Congenital Insensitivity to Pain with Anhidrosis 
(CIPA) loss of function of the nociceptive system is a problem. CIPA arises as a result 
gene alterations which encode for the Nav1.7 voltage gated sodium channel. Nav1.7 
plays a crucial role in the production and propagation of action potentials and 
individuals who suffer from CIPA have an inability to feel pain. This typically leads to 
problems of mutilation, multiple scars, osteomyelitis, bone fractures, joint 
deformities, amputations, and early death21,22. 
 Although powerful analgesics are used clinically to reduce pain, a careful balance 
must be maintained between the need of the individual to be pain free and 
comfortable and our requirement for the nociceptive system to warn us of 
impending tissue damage or sever trauma. It is, therefore,  imperative that the 
nociceptive system is not so suppressed by analgesia that its protective role is lost23. 
1.1.2 Inflammatory pain 
 
 Inflammatory pain is another form of an adaptive protective response of the 
nociceptive system. As a result of particularly powerful noxious input nociceptors 
are exposed to a host of inflammatory mediators including prostaglandins (PGE2), 
nerve growth factor (NGF) and bradykinin (B2). These compounds act upon tyrosine 
kinase receptors and G-protein coupled receptors expressed at the terminals of the 
nociceptors24. Activation of these receptors begins an intracellular phosphorylation 
cascade resulting in the lowering of the threshold of activation leading to an 
increase in excitability, an increase in sensitivity, and also, a decrease in inhibition of 
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the nociceptive system25. Activation of peripheral receptors also modulates the 
release of neuropeptides such as substance P and cholecystokinin, which mediate 
further activation of inflammatory pathways26. Allodynia (elicitation of pain from an 
innocuous stimulus) and hyperalgesia (increased sensation of pain brought about by 
noxious stimuli) are both hallmarks of inflammatory pain. Allodynia and 
hyperalgesia can be thought of as protective, adaptive processes i.e. they help to 
prevent  movement of an injured joint or broken limb during the healing process. In 
the majority of cases the peripheral sensitisation state is transient and as the 
injured tissue heals over time the system will return to baseline levels which require 
high intensity stimuli to innervate the nociceptive system once again20. If the 
symptoms of allodynia and hyperalgesia persist beyond healing, however, they can 
be thought of as maladaptive. Maladaptive plasticity of normal physiological 
mechanisms can lead to chronic pain27. 
1.1.3 Neuropathic pain 
 
Neuropathic pain is defined as ‘‘pain caused by a lesion or disease of the 
somatosensory system’’28. The main characteristic of neuropathic pain is that the 
input of noxious stimuli is no longer required to generate pain. When exposed to 
inflammatory mediators after insult or injury the nociceptive system can undergo 
significant change or plasticity. These changes occur most readily in nociceptors 
that have been sensitised during the inflammation process23. Axons whose 
membrane potential has been significantly altered by the plasticity changes can 
become sufficiently hyperexcitable as to generate spontaneous action potentials29.  
This increase in activity of the nociceptors in the dorsal horn of the spinal cord is 
termed central sensitisation30. Synapses at the spinal cord level are subject to 
modulation by ligand gated ion channels such as, N-methyl-D-aspartate receptor 
(NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
(AMPAR) and metabotropic receptors. The synapses are also modulated by several 
growth factors including brain-derived neurotrophic factor (BDNF) and nerve 
growth factor (NGF).  
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This gives rise to a complex phosphorylation cascade which ultimately leads to 
plasticity changes of the synapse at the spinal cord level31. It is possible for almost 
any pathological process known to create damage or dysfunction of neural tissue to 
be considered as potential causes for neuropathic pain (Table 1.1) 32.  
Table 1.1. Potential causes of neuropathic pain32. 
 
Polyneuropathy 
Diabetes 
Alcoholism 
Human immunodeﬁciency virus 
Hypothyroidism 
Renal failure 
Chemotherapy (vincristine, cisplatinum, paclitaxel, and metronidazole) 
Anti-HIV drugs 
B-12 and folate deﬁciencies 
Fluoroquinolones (peripheral neuropathy) 
Small-ﬁber neuropathy 
Mononeuropathy 
Entrapment syndromes 
Traumatic injury 
Tumour 
Compressive lesions 
Neuropathic low back pain 
Inﬂammatory 
Postherpetic neuralgia 
Trigeminal neuralgia 
Phantom limb pain 
 
1.1.4 Dysfunctional pain 
 
Dysfunctional pain can be described as maladaptive low threshold pain in the 
absence of noxious stimuli, inflammation or neural damage33. Dysfunctional pain 
manifests itself in a number of painful syndromes including Fibromyalgia (FM), 
irritable bowel syndrome (IBS) and intestinal cystitis (IC). Disequilibrium between 
excitation and inhibition in the central nervous system (CNS) gives rise to 
spontaneous amplification of the nociceptive signals34. This gives rise to a change in 
sensory processing which has been detected by functional imaging35.  
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Having briefly defined the various states of pain there now follows a brief review of 
the current treatments for these types of pain. 
 
1.2 Current Treatments 
The cornerstone of treatment for acute nociceptive (adaptive) pain and 
inflammatory pain are analgesics such as paracetamol (acetaminophen, Figure 1.3) 
and non-steroidal anti-inflammatory drugs (NSAIDs).  
1.2.1 Paracetamol 
 
 Paracetamol has both analgesic and anti-pyretic activity and although its 
mechanism of action is still to be fully elucidated it is thought to act via both 
peripheral and central pathways36.  
 
Figure 1.3. Paracetamol  
Although paracetamol is globally one of the most widely prescribed analgesics for 
mild to moderate pain, in high doses paracetamol is acutely hepatotoxic. Studies 
have shown paracetamol overdose is the highest cause of acute liver failure in Great 
Britain, Europe and the USA37. Paracetamol is extensively metabolised in the liver by 
various cytochrome P450 enzymes including, CYP2E1 and 1A2. Small quantities of 
the drug are N-hydroxylated to from N-acetyl-p-benzoquinone imine (NAPQI, Figure 
1.4), which under normal circumstances conjugates with glutathione and is excreted 
via the kidneys36.  
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Upon ingestion of large amounts of paracetamol glutathione becomes depleted 
NAPQI reacts with hepatic proteins which, in severe cases, can lead to liver necrosis 
and death38.    
 
 
Figure 1.4. Paracetamol metabolic pathway 
 
1.2.2 Non-Steroidal Anti Inflammatory Drugs (NSAIDs) 
 
NSAIDs such as ibuprofen, naproxen, asprin and diclofenac (Figure 1.6) are 
commonly used in the treatment of acute and inflammatory pain. NSAIDs are 
inhibitors of the pro-inflammatory enzymes cyclooxygenase 1&2 (COX, 
prostaglandin H2 synthase), which are involved in the conversion of arachidonic 
acid to inflammatory mediators such as prostaglandins, prostacyclin and 
thromboxanes39(Figure 1.5). 
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 Following tissue injury or insult the release of pro-inflammatory mediators 
contributes to peripheral sensitisation and hyperalgesia, blockade of COX enzymes 
prevents prostaglandin production and relives the symptoms of hyperalgsia.  
 
Figure 1.5. Pro-inflammatory mediators; prostaglandins, prostacyclin and 
thromboxanes, contribute to peripheral sensitisation. 
As a consequence of their mechanism of action NSIADs have a ceiling effect upon 
their analgesic efficacy and as such, this  limits their use in cases of severe pain40. 
Chronic NSAID use has been linked to gastrointestinal (GI) adverse effects such as 
abdominal pain, heartburn, nausea, vomiting, or dyspepsia41. Approximately 50% of 
NSAID users develop gastric erosion and up to 30% of those receiving long term 
NSAID therapy will develop peptic ulcers42.  
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Figure 1.6. NSAIDs used to treat inflammatory pain. 
 
1.3 Current Treatment for Neuropathic Pain 
 
The current treatment strategy for neuropathic pain begins with a thorough 
assessment and diagnosis, and then progresses in a stepwise manner through the 
various treatment options available.  
 
1.3.1 Tricyclic Antidepressants  
 
One of the first line of treatments available for neuropathic pain are tricyclic 
antidepressants (TCAs) such as nortriptyline and desipramine43 (Figure 1.7). TCAs 
have been shown to be effective in randomised clinical trials (RTC) for several 
different forms of neuropathic pain44. The exact mechanisms involved in 
antinociception for TCAs have not yet been fully elucidated.  
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The main mechanism of action of antidepressants is thought to  involve blockade of 
the sodium channel Nav1.7 and also enhancement of descending inhibitory 
pathways by increasing the levels of noradrenaline and serotonin (5-HT)  at both 
supraspinal and spinal levels45. 
 
 
Figure 1.7. Tricyclic antidepressants nortriptyline and desipramine. 
Depression is a common comorbidity in individuals suffering with neuropathic pain, 
but the analgesic effect of TCAs has been established in those who are classed as 
nondepressed44,46.  Adverse effects of TCAs are common and include dry mouth, 
urinary retention, orthostatic hypotension and sedation47. TCAs have also been 
linked with an increased risk of myocardial infarction and current guidelines 
recommend caution in prescribing TCAs to individuals with cardiac disease48,49.   
 
1.3.2 Selective Serotonin Norepinephrine Reuptake Inhibitors 
 
Selective serotonin norepinephrine reuptake inhibitors (SSNRI) duloxetine and 
venlafaxine, are also used as first line treatments for neuropathic pain43. Duloxetine 
has shown effectiveness in peripheral neuropathic pain particularly against diabetic 
peripheral neuropathy (DPN), but its effectiveness at treating other forms of 
neuropathic pain have not yet been tested50,51.  Venlafaxine has also shown efficacy 
against DPN and various other painful polyneuropathies52.  
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Whilst the most common adverse effect of both duloxetine and venlafaxine (Figure 
1.8) is nausea, venlafaxine has also been shown to have cardiac conduction 
abnormalities in a number of individuals and is advised in patients with pre-existing 
cardiac problems53,54 . When treatment with venlafaxine is discontinued withdrawal 
should be tapered as withdrawal syndrome has been indicated32.  
 
 
Figure 1.8. Selective serotonin norepinephrine reuptake inhibitors (SSNRI) 
duloxetine and venlafaxine. 
 
1.3.3 Anticonvulsants 
 
The anticonvulsant drugs gabapentin and pregabalin (Figure 1.9) are also prescribed 
as first line medications to combat neuropathic pain. Both of these compounds 
have been shown to target the α2-δ subunit of voltage-gated calcium channels of 
activated neurons, thereby,  reducing the release of inflammatory mediators 
glutamate, norepinephrine, and substance P55.  The pharmacokinetics of gabapentin 
are nonlinear, therefore, it has a complex dosing regimen when compared with 
other drugs in its class. As a consequence of this it can take much longer (up to two 
weeks) before the analgesic activity takes effect56. Gabapentin also displays several 
dose limiting side effects such as dizziness, drowsiness, sedation and peripheral 
oedema and both drugs require careful monitoring in patients with renal 
impairments57. 
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 Pregabalin has shown efficacy against post herpetic neuralgia (PHN) and DPN in 
three RCTs and efficacy for neuropathic pain in a separate trial58-61. Pregabalin has a 
similar side effect profile as gabapentin but due to linear pharmacokinetics the 
analgesic effects are achieved much quicker59.  
 
Figure 1.9. Anticonvulsant drugs gabapentin and pregabalin. 
1.3.4 Topical Treatments 
 
Other first line treatment options include topical medications such as lidocaine 
patches and capsaicin patches (Figure 1.10) which have both shown localised 
efficacy against some forms neuropathic pain62,63.  
 
Figure 1.10. Capsaicin and lidocaine. 
 
1.3.5 Opioids 
 
Opioid analgesics such as morphine, methadone, oxycodone, levorphanol and 
tramadol (Figure 1.11) are generally considered to be the second line treatment 
option for neuropathic pain.  
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Three primary opioid receptor subtypes μ, δ and κ have been identified which have 
clearly established roles in analgesia. These receptors are found in higher regions of 
the CNS, and once innervated they have roles in descending inhibitory pathways. 
This is where the antinociceptive properties are of opioids are thought to stem from 
64,65.  Opioids have demonstrated efficacy against neuropathic pain, PHN, DPN and 
phantom limb pain. In head to head trails against TCAs and gabapentin, opioids 
have shown a higher rate of long term adverse events, with the most common 
reported events being nausea, constipation and sedation. Studies have shown the 
prevalence of opioid misuse among patients suffering with neuropathic pain can be 
as high as 25%66. Because of the adverse effects and the risk of misuse outlined 
above, opioids are reserved for individuals who have either failed to respond to, or 
who cannot tolerate first line medications67. 
 
 
Figure 1.11. Opioid analgesics. 
Having discussed some of the current therapies for pain management there follows 
an overview of some of the major drug targets within both the peripheral 
nociceptive system and central nervous system.  
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1.4 Potential drug targets 
 
1.4.1 Nav channels 
 
Voltage gated sodium channels (Nav) are responsible for the generation and 
propagation of action potentials in response to membrane depolarization. Nav 
channels are heteromultimers of α-subunits, which form the pore, and smaller 
auxiliary β-subunits. The α-subunit is arranged into four domains each consisting of 
six transmembrane segments that are connected by linkers. The β-subunits are type 
I membrane proteins, each with a single transmembrane unit and a larger 
extracellular domain68. Nine genes encode for the Nav 1.1- Nav 1.9 channels 
(SCN1A–5A, SCN8A–11A), of which only Nav1.7, Nav1.8 and Nav1.9 are expressed in 
peripheral neurons68. Studies have indicated that alterations in the properties of 
Nav1.7 can profoundly impact pain sensitivity. Based on these results, it is thought 
that Nav1.7 is likely to play an important role in neuropathic pain syndromes69,70. 
 
There are many current medications used for the treatment of neuropathic pain 
which possess sodium channel blocking properties. These include tricyclic 
antidepressants, amitriptyline (Figure 1.12), nortriptyline (Figure 1.7) and local 
anaesthetic lidocaine (Figure 1.10) has activity at sodium channels also.  However, 
some of the sodium channel blockers that are currently available (e.g. tricyclic 
antidepressants) are associated with cardio-toxicity and adverse CNS effects, which, 
in part can be explained by their lack of selectivity for sodium channel isoforms71,72.  
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Figure 1.12. Tricyclic antidepressant amitriptyline. 
Recently several novel, benzodiazepine based, selective inhibitors of Nav1.7 have 
been developed, several of which have shown a complete inhibition of spontaneous 
neuronal firing in the rat model of spinal nerve ligation (SNL). Although these 
compounds were highly efficacious they suffered from low oral exposure, high 
clearance rates. In an effort to combat the poor pharmacokinetic (PK) properties of 
the of the benzodiazepine compounds researchers developed a series of   
imidazopyridine-based sodium channel blockers (Figure 1.13) which showed 
improved PK and good efficacy in the SNL model73.  
 
 
 
Figure 1.13. Imidazopyridine based Nav1.7 channel blocker. 
 
XEN402 (Figure 1.14) is also a selective Nav1.7 channel blocker and is currently in 
phase II clinical trials.  In phase I trials XEN402, a spiro-indole derivative, was found 
to be well tolerated and showed no significant safety issues.  
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Currently phase II trials have only been conducted with a small cohort of patients 
and for short dosing periods (2 days).  Although results from the trial showed 
reduced pain induction times and reduced overall pain experienced, further studies 
with larger patient numbers over an increased time frame, are required to give 
more accurate results of the analgesic properties of XEN402. 
 
 
Figure 1.14. Spiro-indole Nav1.7 channel blocker. 
 
1.4.2 Serotonin (5 HT)  
 
5HT (fig. 1.1) has a direct effect on the activation and sensitisation of nociceptive 
neurons and is released from platelets in the periphery as a result of tissue damage 
or insult. 5-HT has been shown to bind to 7 distinct receptors (5-HT1-7) which can 
be further subdivided into 14 separate subtypes (5-HT1AF, 5-HT2A-C, 5-HT3, 5-HT4, 
5-HT5A, 5-HT6, 5-HT7). So far 5HT has been the target for several pharmacological 
treatments for depression, anxiety and obsessive compulsive disorder74. It is known 
that 5HT plays a modulatory role in the analgesic effects of several compounds 
(TCAs and duloxetine, Figure 1.8). The complex nature of the mechanisms 
controlling 5-HT function and the contradicting nature of clinical trial results 
combine to make the design of an analgesic targeting the 5HT without severe side 
effects very challenging. 
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 To date the only successful analgesics known to target  the 5HT system are the 
triptan (Figure 1.15) family which have success in treating migraines75. 5HT has 
functional roles in both ascending and descending nociceptive pathways, but the 
exact role has yet to be elucidated44.     
 
 
Figure 1.15. 5HT agonists, sumatriptan and rizatriptan have both had success 
treating migraine headaches. 
 
1.4.3 Calcium channels 
 
Voltage-gated calcium channels (Cav) are the primary sources for depolarisation-
induced calcium entry into neurons. Cav regulate intracellular processes such as 
gene expression and neurotransmission.  The calcium channel family can be broadly 
split into two subgroups based upon their voltage dependence of activation. The 
high voltage-activated channels, which can be further subdivided into the L,N,P,Q 
and R subtypes76. The different cav isoforms show a diverse range of specific 
functions and have a distinct distribution throughout the cellular and subcellular 
levels. The N-type, P-type and Q-type channels are expressed on presynaptic nerve 
terminals were they modulate neurotransmitter release. The L-type channel is 
found in muscle and heart were they support excitation-contraction coupling77. The 
diverse nature of the functional roles of the HVA calcium channels poses a challenge 
when designing a therapeutic agent with low risk of side effects.  
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Recently a number of inhibitors of N-type calcium channels inhibitors have been 
developed, aminopiperidine-sulfonamide78, pyrazolpiperidines79, TROX-180 and 
cilnidipine81 (Figure 1.16) which have all shown efficacy in various models of pain. 
 
Figure 1.16. N-type calcium channels inhibitors.  
 A series of piperazine based compounds have been synthesised which, not only, 
display a high level of inhibition at inactivated calcium channels but also have a 
strong analgesic effect. Currently one of these compounds, Z160 (Figure 1.17), is in 
phase ll clinical trials82. 
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Figure 1.17. Piperazine based calcium channel blocker, Z160. 
The Cavα2δ1 has been found to be an important accessory subunit for HVA 
channels. It promotes the movement of HVA α1 subunits to the plasma membrane. 
There is evidence that Cavα2δ1 is up regulated in neuropathic pain states and that 
this up regulation is linked to tactile allodynia. The Cavα2δ1 subunit is the primary 
target for gabapentinoids such as pregabalin and gabapentin (Figure 1.9). This 
target was confirmed by studies in transgenic knockout (KO) mice with a point 
mutation (R217A) in the Cavα2δ1 subunit. This rendered the KO mouse insensitive 
to the analgesic effects pregabalin.  
Low voltage-activated T-type channels are activated by weak depolarisation and are 
transient. They are expressed in a diverse range of cell types and are involved in the 
control of repetitive firing and the shaping of action potentials. T-type channels 
contribute to neuronal signalling via multiple cellular mechanisms and 
pharmacological intervention of any of these may give rise to analgesia83. 
 
1.4.4 Vanilloid receptor (TRPV1)  
 
The vanilloid receptor type 1 (TRPV1) is a ligand-gated nonselective cation channel 
and a member of the transient receptor potential (TRP) family of ion channels.  
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There are around 28  TRP channels discovered so far, 7 of which are known to 
detect hot or warm temperatures (TRPV1 - TRPV4, TRPM2, TRPM4, and TRPM5) and 
2 which sense cold (TRPA1, TRPM8).  All of the TRP channels share a topology that 
consists of 6 transmembrane domains (TM1-TM6) with the pore residing between 
TM5 and TM6. The C terminus is associated with the temperature sensing portion of 
the protein84. TRPV1 channels are activated by a wide range of both exogenous and 
endogenous stimuli, including heat (>43oC) capsaicin (the active ingredient in 
chillies) (fig. 1.5) and low pH (<pH5)85. The ion channel is activated upon detection 
of noxious stimuli which allows the influx of cations including Na+ and Ca2+. TRPV1 
plays an important role in nociceptive pathways and can be modulated by 
inflammatory mediators including prostaglandins and bradykinin. TRPV1 receptors 
are found in both the peripheral central nervous systems localised on dorsal root 
ganglion neurons86. 
Capsaicin patches are used to treat localised neuropathic pain and typically include 
low concentrations of the active ingredient, containing between 1% and 8%. 
Although capsaicin, when applied to the skin, causes localised pain repeated 
applications causes a desensitisation of the nociceptor C fibres producing an 
analgesic effect84. This desensitising effect is thought to be caused by the 
destruction of terminal axons and the dysfunction of localised nociceptors87. New 
capsaicinoid therapies are in development such as the high-concentration 10% and 
20% liquid capsaicin 
1.4.5 Potassium Channels 
 
Potassium (K+) channels are the most populous, diverse and widely distributed of all 
ion channels in the neurons. In humans their expression is governed by 
approximately 78 genes and further diversity is accomplished through the assembly 
various K+ channel subunits88. K+ channels modulate an extremely rapid 
transmembrane K+ efflux which can not only influence the threshold of action 
potentials but can also modulate their frequency89.  
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 Several of the voltage-gated K+ channels (Kv) have a role in nociceptive pathways 
including Kv 9.1 and Kv2.1 which are down regulated in neuropathic pain models and 
Kv1.1 and Kv1.2  which may act together to reduce mechanical allodynia. It has long 
be known that G protein-coupled  inwardly rectifying K+ (GiRK) channels play a role 
in pain signalling and also contribute to the analgesic effect of opioids. With the 
multitude of K+ channels distributed throughout the nervous system and the varying 
roles they play in pain pathways, there are many potential therapeutic targets to 
explore. Many of the K+ channels, however, are expressed in the brain and various 
excitable tissues. The challenge will be to selectively target K+ that are expressed in 
sensory neurons to avoid a host of adverse effects83.  
 
1.4.6 Nerve growth factor 
 
Nerve growth factor NGF is a target derived neurotrophin secreted from cells of 
sympathetic and sensory neurons, and is involved in the growth, signalling, and 
survival of said neurons. The primary role of NGF in the developing system is one of 
neuronal survival, but in adults this role shifts to a more protective role by 
mediating pain from noxious stimuli.  NGF signalling in these nociceptor neurons is 
mediated through two different receptors, the 75 kDa neurotrophin receptor 
(p75NTR) and the tropomyosin-related kinase A (TrkA) receptor90. Levels of NGF are 
known to be elevated in a variety of neuropathic pain states, including rheumatoid 
arthritis, spondyloarthritis, and endometriosis. Evidence has shown that NGF is 
important in the potentiation and mediation of pain and this has led to the 
development of NGF antagonists as potential analgesic agents. Several compounds 
have been developed to target NGF, the most successful being the humanised 
antibody   IgG2 tanezumab, which has entered phase lll clinical trials for the 
treatment of osteoarthritis.  Whilst the initial results of the trials looked very 
encouraging several patients who took part in the trails have suffered from 
worsening of osteoarthritis probably due to over use of the joints. This has led the 
FDA to put a hold on the clinical trials for tanezumab91. 
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1.4.7 Glycine Receptor 
 
Fast inhibitory neurotransmission in the spinal cord, caudal brain and brain stem are 
mediated by glycinergic synapses. Glycine receptors (GlyRs) are prominent in 
postsynaptic membranes, where they mediate a variety of motor and sensory 
functions including vision, audition and suppression of the nociceptive signals92. 
Activation of GlyRs, either by presynaptically released glycine or by an 
extracellularly applied agonist, facilitates the opening of the anion-selective pore. 
This allows an influx of Cl- ions in to the cell which results in a hyperpolarization of 
the postsynaptic membrane resulting in a stabilisation of the resting potential of the 
cell and, therefore, an inhibition of neuronal firing93.  
 It is of interest to note, however, that during embryonic development GlyRs are not 
inhibitory but are in fact excitatory. This effect is due to a more positive equilibrium 
potential in embryonic neurons. Subsequently activation of the GlyR results in an 
efflux of Cl- ions and a depolarisation of the membrane, which allows the activation 
of voltage gated Ca2+ channels. The rise in Ca2+ levels appears to be instrumental in 
the formation of the synapse as blockade of the Ca2+ channel disrupts localisation of 
the GlyRs at the nerve terminals. The Cl- equilibrium potential shifts to a negative 
hyperpolarising value after birth94,95. 
GlyRs are members of the group I ligand-gated ion channel (LGIC) family, which also 
includes the anionic γ-amino-butyric acid (GABAA and GABAC) receptors and the 
cationic nicotinic acetylcholine (nACh) and serotonin (5HT) receptors. GlyRs have a 
pentameric arrangement of transmembrane domains which are arranged 
symmetrically around a central pore96. To date five genes encoding for GlyR 
subunits have been cloned from mammalian tissue Glra1-4 code for α subunits (α1–
α4) and a single Glrb codes for the β subunit. The α subunits share a high sequence 
identity of ~ 80% whilst the β subunit shows significant sequence differences 
compared with the α subunits of less than 50% identity97.  
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Each GlyR subunit contains an N-terminal extracellular domain (ECD) which contains 
the agonist binding site, four transmembrane segments (TM1-TM4), a large 
intracellular loop between TM3 and TM4 which houses the phosphorylation sites 
and also the binding motifs for intracellular proteins. TM2 is amphiphilic and forms 
the anionic permeable pore98.  In adult mammalian CNS most GlyRs are 
heteropentameric and are composed of α1 and β subunits whose stoichiometry is 
thought to be 2(α1)/3β99. 
Many GlyRs are colocalised with the submembraneous scaffold protein gephryn, 
which interacts with intracellular components such as tubulin and proteins 
implicated in membrane protein transport95.  
GlyRs are modulated by a wide range of endogenous ligands including cations, Zn2+ 
and Ni, and the cannabinoid anandamide (Figure 1.18). Although to date no drugs 
have been developed to primarily target the GlyR a number of pharmaceuticals 
agents are known to modulate the receptor including, alcohols (ethanol and 
trichloroethanol), tropines (tropisetron), and general anaesthetics (propofol and 
iosflurane) (Figure 1.18)100,101.  
 
 Figure 1.18. Modulators of the GlyR. 
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The binding site of propofol has been studied in vivo in transgenic and knock-in 
murine models. Zn2+ and tropines are thought to bind at or in close proximity to the 
extra cellular agonist binding site whilst the hydrophobic modulators, cannabinoids, 
anaesthetics and ethanol are thought to bind at the transmembrane domain 
whereas channel blockers such strychnine are thought to bind close to the 
intracellular domain (Figure 1.19) 102-104,107.  
 
Figure 1.18. Ribbon model of the glycine receptor showing binding sites for 
propofol (anaesthetic binding) and strychnine (channel blocker binding). ECD - Extra 
cellular domain. TMD - Transmembrane domain. ICD – Intracellular domain (Taken 
from ref 107).  
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Immunocytochemistry has revealed that the α1 and α3 GlyRs are distinctly 
expressed in the superficial layers of the spinal cord, specifically laminae I and II of 
the dorsal horn (the primary site of synaptic integration in the nociceptive 
pathway)105.  
From here a network of glycinergic interneurones regulates the transduction of pain 
signals to higher regions of the brain. Inflammatory pain originates from the 
disinhibit ion of dorsal horn neurons. Activation of prostaglandin E (EP2 subtype) 
receptors, via PGE2 release, leads to phosphorylation and subsequent inhibition of 
GlyRs specifically the α3 subtype. In addition Glra3 knock out studies have abolished 
dorsal horn glycinergic inhibition in the presence of PGE2 in spinal cord slice 
preparations and PGE2 mediated sensitisation in the animal model.  It has also been 
shown that intrathecal injections of the GlyR antgonist strychnine (a convulsive 
indole alkaloid which is a powerful antagonist of GlyRs, (Figure 1.20) can elicit 
exaggerated nociceptive responses. It is, therefore, postulated that compounds 
which enhance glycinergic responses within the dorsal horn could have therapeutic 
potential as analgesic agents105.  
 
Figure 1.20. Indole alkaloid strychnine. 
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1.4.8 Gamma-Aminobutyric acid receptor 
 
As with GlyRs, GABA receptors (GABARs) also inhibit fast inhibitory synaptic 
transmission throughout the brain and CNS. GABAA and GABAB are the two major 
isoforms of the receptor. The GABAB receptor is a G protein coupled receptor and is 
found on both pre and post synaptic terminals. Activation of GABAB receptors 
modulates a second messenger phophorylation cascade which produces a variety of 
responses including modulation of calcium and potassium channels106.  
GABAA  receptors are members of the LGIC superfamily and as such are structurally 
related to  GlyRs. To date 19 subunits of GABARs have been cloned, this underlies 
the diverse nature and complex pharmacology of these receptors107. 
 GABAA receptors are the primary site of action for many therapeutic agents 
including anxiolytics (alprazolam and ocinaplon, Figure 1.21), hypnotics (zolpidem 
and indiplon, Figure 1.21) and anaesthetics (propofol, Figure 1.19 and thiopental, 
Figure 1.21)108. Many of the compounds that target the GABAA receptors are 
associated with a range of unwanted side effects, tolerance and withdrawal issues. 
Although not a target for analgesia, it is important to understand the side effect 
burden which stems from potentiating the GABAA
109. 
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Figure  1.19. Modulators of the GABAA receptor. 
1.5 Propofol 
 
The introduction of general anaesthetics in the mid-19th century revolutionised 
surgical procedures. What were once considered painful dangerous and often 
unsuccessful procedures have now become much safer, less painful and have much 
more predictable outcomes. For over a century anaesthesia was achieved using 
volatile gaseous anaesthetics such as, ether, nitrous oxide and chloroform (Figure 
1.20).  
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Figure 1.20. Early volatile gaseous anaesthetics 
More recently intravenous anaesthetics have become the most popular method of 
inducing and maintain anaesthesia110. 2, 6-diisopropylphenol (propofol, Diprivan, 
Figure 1.18) is a fast acting sedative agent which was first introduced clinically in 
1985111. Since its approval for the induction and maintenance of general 
anaesthesia by the food and drug administration (FDA) in 1989, propofol has 
become the most widely used intravenous general anaesthetic agent in the 
world112.  
Propofol is a highly lipophilic alkyl phenol and as such has a low solubility in water 
and was originally prepared as 1% solution in Cremophor EL (CrEL). CrEL is a 
heterogeneous non-ionic surfactant which is produced by the reaction of castor oil 
with ethylene oxide. CrEL has been deemed as an unsuitable solvent in America, 
therefore, propofol is now prepared as an oil in water emulsion with  1% propofol, 
10% soybean oil, 2.25% glycerol, and 1.2% egg lecithin110,113.  
Propofol is renowned for a rapid onset of sedation, approximately 40 seconds after 
administration; this is due to a rapid equilibration between plasma and highly 
perfused brain tissues. With the peak effect occurring within 1-2 minutes and 
duration of effect between 4-8 minutes (following a single intravenous dose of 1.5-
2.5 mg/kg), propofol has a rapid emergence from sedation with little nausea or 
vomiting114.  
In an effort to overcome the innate solubility issues seen with propofol, several 
water soluble alternatives have been synthesised. Propofol phosphate, propofol 
ethyl dioxy phosphate and fospropofol (Aquavan®, Lusedra) are all phosphate 
prodrugs of propofol (Figure 1.23).  Collectively they all rely upon enzymatic 
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cleavage of the phosphate moiety to release the parent drug and consequently they 
all have a markedly slower onset of sedation than the parent compound. 
 
Figure 1.23. Phosphate prodrugs of propofol. 
A major drawback to both propofol ethyl dioxy phosphate and fospropofol is that 
they liberate toxic compounds upon metabolism. Propofol ethyl dioxy phosphate 
liberates acetaldehyde, which has been linked to gastrointestinal tract cancer, 
whereas, fospropofol releases formaldehyde which is further metabolised to 
formate (Figure 1.24). Whilst formaldehyde is a naturally occurring metabolite from 
many cellular processes, elevated levels are thought to alter homeostasis within 
cells and may also play a role in enzyme induction, metabolic switching and cell 
proliferation115.  The rapid conversion of formaldehyde to formate is mediated by 
aldehyde dehydrogenase in the liver and in erythrocytes and formate is further 
metabolised by 10-formyltetrahydrofolate dehydrogenase and tetrahydrofolate. On 
the basis of this the liberation of formaldehyde is not thought to be toxic in patients 
with normal levels of tetrahydrofolate 116,117. 
 
 
Figure 1.24. By-products of phosphate prodrug metabolism 
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The most common adverse effect associated with propofol use is pain at the 
injection site (occurring in 80-90% of patients). Although this is often attributed to 
propofol’s lipid formulation, studies have shown that propofol can activate the 
TRPA1 receptor which is co-associated with TRVP1 receptors in 30% of nociceptive 
neurons. As a consequence the local anaesthetic lidocaine is generally administered 
prior to propofol use114,118.   
Studies have shown propofol exerts its sedatory effects by modulating the 
inhibitory function of the GABAA receptor, specifically by decreasing cerebral 
metabolism in the hippocampus, parietal, frontal and occipital lobes. This involves 
areas of sensory, motor and limbic systems119,120. Clinical relevant concentrations of 
propofol can markedly increase GABA induced Cl- current and a report published in 
2003 showed that a point mutation in the β3 subunit of the GABAA  receptor could 
eliminate propofol activity121,122.  
Propofol is also known to be a positive allosteric modulator of the strychnine 
sensitive glycine receptor123. With the role the GlyRs play in nociceptive pathways it 
is thought that the binding of propofol to GlyRs and the subsequent increase in Cl- 
could contribute to analgesia124. Reports have shown that sub-hypnotic doses of 
propofol (0.25mg/Kg) can reduce laser induced pain in human volunteers and 
intravenous administration of 0.25mg/Kg followed by 25μg/Kg/min can significantly 
reduce pain intensity125,126.  
The short duration of action of propofol is due to a rapid redistribution and 
metabolism, primarily by the liver, into a range of inactive metabolites. The major 
route of metabolism for propofol is glucuronidation of the parent compound at the 
phenolic hydroxyl site (50-60% of the overall dose).  The remaining is metabolised 
via ring hydroxylation to give the 4- hydroxyl propofol which is further subject to 
glucuronidation and sulfation. Glucuronidation is catalysed by uridine diphosphate-
glucuronosyltransferases (UGT) such as UGT1A9, whereas sulfation is catalysed by 
sulfotransferases (SULTs). Oxidative metabolism of propofol is mediated via a range 
of cytochrome P450 enzymes (CYP450) including, CYP2C9 (removes around 50%), 
CYP2A6, 2C8, 2C18, 2C19, and 1A2 (Figure 1.25)127,128.      
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Figure 1.25. The metabolic pathway of propofol in humans. UGT— uridine 
diphosphateglucuronosyltransferase, SULT — sulfotransferases, CYP — cytochrome 
P450 isozymes, GLU — glucuronide.  
Propofol modulates receptors within the CNS, but in order for propofol to access 
the CNS it must first cross the blood brain barrier. 
 
1.6 Blood brain barrier 
 
As propofol is a small lipophilic molecule it can freely diffuse through the barrier. 
For novel neurotherapeutics, however, the blood brain barrier has become 
somewhat of a bottle neck of drug development129.   
Figures indicate that less than 11% of novel pharmaceutical entering clinical 
development actually made it into the marketplace. The probability of CNS drug 
entering the marketplace, however, is considerably lower at around 7%.   
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Figures show that the average development timescale for drugs targeting 
cardiovascular or gastrointestinal indications is between 6-7.5 years, whereas on 
average the development of CNS indicated drugs took 12.6 years130.  
The attrition rate for CNS drug development is higher than average for several 
reasons; the complexity of the CNS, the lack of a mechanistic understanding for 
many of the CNS disorders and the inclination toward CNS mediated side effects 
such as dizziness and nausea131. Perhaps the biggest hurdle for many novel 
pharmaceutical agents is the penetration of the blood brain barrier (BBB), 
approximately 98%  of small-molecule (~100 Da molecular mass or less) compounds 
and 100% of large-molecule (>750 Da) compounds never reaches the marketplace 
because of their inability to cross the BBB129. 
The BBB acts as a physical barrier between the CNS and the periphery. Consisting of 
tightly fenestrated endothelial cells, which line a network of capillaries which form 
the microvessels of the brain, the BBB is the largest interface for blood-brain 
exchange. The surface area of the vessels of the BBB are, on average, between 150-
200 cm2g-1 which for the average human adult gives between 12-18 m2 of tissue for 
exchange within the brain132. The tight intracellular junctions of the endothelial cells 
regulate the exposure of the brain to xenobiotics and also minimises paracellular 
transport133,134 (Figure 1.26). Small gaseous molecules such as O2 and CO2 have the 
ability to freely diffuse across lipid membranes and this is also the route taken by 
small lipophilic drug molecules such as barbiturates and propofol 135.  Astrocytes 
and pericytes also aid in the compartmentalisation of the CSF. Astrocytes are glial 
cells which interact closely with endothelial cells and have an essential role in 
maintenance of cerebral blood flow enzymatic systems and polar transporters. The 
tight junctions which make up the unique phenotype of the BBB are determined by 
the interaction of astrocytes and the cerebral endothelial cells.  Pericytes are 
associated with the stabilisation of small vessels and angiogenesis. They are 
separated from the cerebral endothelial cells by the basal lamina132.  
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Figure 1.26. Blood brain barrier and transport mechanisms 136. 
The BBB serves several functional roles. It supplies essential nutrients to the brain 
and mediates the efflux of waste some waste products. It controls the ionic 
composition of interstitial fluid (ISF) and cerebrospinal fluid (CSF) which provides a 
stable environment for neural functioning and synaptic signalling. This is important 
for preventing fluctuations of ion levels, especially after exercise or a meal. The BBB 
also helps to keep the pools of neurotransmitters that act peripherally and centrally 
separate, thus, preventing ‘crosstalk’ between similar agents used in both systems. 
The protein compositions of plasma and CSF are very different, the levels of protein 
in CSF is much lower than that of the plasma. The BBB also prevents 
macromolecules such as albumin, pro-thrombin and plasminogen from entering the 
CSF where they would cause severe pathological damage135,137 .  
The high prevalence of active transporters, both uptake and efflux, combined with 
high concentrations of metabolising enzymes and low rates of passive diffusion 
present a complex biological barrier to the design of pharmaceutical agents 
targeting diseases of the CNS.  
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1.7 Aims 
 
This thesis addresses the longstanding urgent, unmet medical need of chronic pain. 
Recent surveys have found that chronic pain affects up to 20% of adults in Europe 
and the USA9. One key issue is the fact that the symptomatic medication currently 
available is effective only in about 40% of chronic pain sufferers and even these 
patients struggle to maintain the balance between adequate pain relief and their 
ability to cope with substantial drug-induced adverse effects138. This creates a 
vicious cycle of insufficient analgesia and unbearable side effects ultimately leading 
to discontinuation of treatment. A greater understanding of the underlying 
mechanisms of chronic pain has revealed the key role the glycine receptor (GlyR) 
plays in nociceptive pathways97.  
 
The aims of this research were to synthesise a series of novel analgesic compounds, 
based around a propofol core, with favourable DMPK and toxicity profiles which 
selectively target the α1 subtype of the GlyR. Selected compounds will be 
investigated in the Chung Lesion model of neuropathic pain to assess their analgesic 
activities.  
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2 Introduction (previous work) 
 
The glycine receptor (GlyR) is known to play an important role in the modulation of 
pain signals at the dorsal root ganglion (DRG) level via the inhibition of neuronal 
firing1. The α1 and α3 isoforms of the GlyR are found in high concentration within 
the laminae l and ll of the dorsal horn and as such are of particular interest as 
targets for novel analgesic drugs2.      
Whilst studies have shown that propofol exerts its anaesthetic action by modulation 
of the GABAA receptor (Ec50 3.9 µM)
3, it has also been shown to be a positive 
allosteric modulator of GlyRs (Ec50 4.8 µM). Several studies have suggested that 
modulation of the GlyR may be responsible for propofols analgesic properties4-7.  
Sedation, drowsiness and mental impairment are all unwanted side effects linked to 
therapeutic compounds which target the GABAA receptor
8. In order to alleviate this 
potential side effect it is, therefore, a priority that prospective analgesic compounds 
selectively target the GlyR and do not modulate the GABAA. 
 Initial studies within the group focused on optimising the phenolic core of propofol 
at the α1 GlyR in an effort to increase potency  which, provided that high µM 
activity at the GABAAR could be at least be maintained, would decrease the risk of 
activation of the GABAAR resulting in unwanted off-target effects. A series of 
substituted analogues were synthesised which explored both the steric (additional 
substituents on the ring) and electronic (addition of halogens to modulate electron 
richness/deficiency around the ring) effects of a variety of moieties around the 
phenolic core of propofol. These compounds were tested for efficacy against the α1 
GlyR (Table 2.1). 
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2.1 Biological Testing (previous work cont) 
 
The in vitro activities of the phenolic analogues were evaluated using 
electrophysiology whole-cell voltage-clamp techniques. The voltage recordings 
were made from human embryonic kidney cells (HEK 293 cells) which were 
transfected with cDNA to express recombinant α1β glycine receptors upon the cell 
surface. Figure 2.1 shows representative current traces for the determination of the 
EC50 value for 4-chloropropofol.  The top trace shows the effect of a maximal glycine 
concentration (1000 µM), whilst the second trace shows a submaximal glycine 
concentration (10 µM). Each subsequent trace shows the effect of 10µM glycine 
with increasing concentrations of 4-chloropropofol (1-100nM). The chart in Figure 
2.1 shows the potentiation of the chloride ion current in response to 10 µM glycine 
and the varying concentrations of 4-chloropropofol.  The EC50 value is determined 
at 50% of the maximal potentiation of chloride ion response. 
 
Figure 2.1. Representative trace showing the determination of EC50 values for 
positive allosteric modulators of the α1 glycine receptor. 
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Due to the time consuming nature of developing a stable cell line and the large 
amounts of cells required, only a small selection of compounds synthesised were 
tested. Exact EC50 values were not determined for any compounds whose 
preliminary results showed no activity at 1µM.  All in vitro electrophysiology testing 
was carried out at the University of Tübingen under the supervision of Prof. Bodo 
Laube. 
2.2 Substituted Phenols (previous work cont) 
 
Table 2.1 contains several commercially available phenols with alkyl and chloro 
substituents at various positions around the phenyl ring. Compounds 2 and 4 were 
significantly less potent than propofol at the α1GlyR with EC50 values in the high µM 
region. Both the ortho and meta monomethyl substituted analogues (compounds 3 
and 6) showed increased potency, with respect to the dimethyl analogues, but 
neither analogue was as potent as the parent drug. Interestingly when the 3-methyl 
and 3,5-dimethyl analogues were chlorinated at the 4-position both EC50 values 
were reduced dramatically to the low µM region (compounds 5 and 7)3.  
Table 2.1. Commercially available phenols tested for efficacy against the α1 GlyR. 
Compound Structure EC50 (µM) 
1 
 
4.8 ± 1.2 
 
2 
 
226 ± 104 
3 
 
70 ± 19 
4 
 
254 ± 139 
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5 
 
13 ± 4 
6 
 
59 ± 19 
7 
 
8 ± 5 
 
 
An additional potential advantage of substitution at the 4-position of the phenyl 
ring is the blockade of a major route of phenol metabolism. Propofol itself is subject 
to extensive cytochrome P450 (CYP 450) mediated metabolism and rapid 
elimination. The major route of propofol metabolism is via glucuronidation of the 
parent drug, which consumes ~50-60% of the total dose. 
 Propofol also undergoes CYP 450 mediated ring hydroxylation at the 4-position via 
CYP2C9 and CYP2B6 which allows for further glucuronidation and sulfation of the 
hydroxylated metabolite. Substitution of propofol at the 4 position will block the 
CYP 450 mediated ring hydroxylation, slowing the metabolic clearance of the 
compound and in turn increasing the half-life of the drug (Figure 2.2)9,10.  
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Figure 2.2. The metabolic pathway of propofol in humans. UGT— uridine 
diphosphate glucuronosyltransferase, SULT — sulfotransferases, CYP — cytochrome 
P450 isozymes, GLU — glucuronide.  
2.2.1 Halogenated Propofol Derivatives (previous work cont) 
 
 
 
Figure 2.3. Halogenated propofol 
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In light of these results it was decided to examine the effect of halogenation at the 
4-position of propofol in order to determine if the same increase in potency at the 
α1 GlyR and reduction in EC50 values as seen in the substituted phenol series could 
be replicated with the parent compound (Table 2.2). The physicochemical 
parameters of the 4-halogenated compounds were also evaluated in silico to 
determine the potential for good oral absorption, potential toxicity and systemic 
distribution of the 4-halogenated compounds (8-10).    
Table 2.2. Halogenated compounds tested for efficacy against the α1 GlyR11. 
 
Compound EC50 (µM)
a ClogPb CogDd LogS 
Aq sol 
(µM) 
MW 
 
8 
0.00066 ± 0.0038 4.49 4.4 -3.68 18.37 212 
 
9 
0.00062 ± 0.0018 4.63 4.67 -4.0 10.81 257 
 
10 
0.00067 ± 0.0033 4.82 4.82 -4.23 14.85 304 
a, α1 GlyR EC50 values determination was carried out at the University of Tübingen under the 
supervision of Prof. Bodo Laube. b, ClogP values were determined using chembiodraw ultra 12 
software. c, In house algorithm. 
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The results showed that halogenation at the 4-position of propofol (Table 2.2) could 
significantly enhance efficacy at the α1 GyR isoform with low nM EC50 values giving 
1000 fold increase in potency, in comparison with propofol. Halogenation also kept 
the ClogP value within the acceptable parameters of < 512. Solubility of any novel 
drug is an important consideration in the design of a drug candidate. A poorly water 
soluble drug can lead to slow drug absorption, inadequate or variable bioavailability 
and, in some cases, gastrointestinal mucosal toxicity. It is, therefore, vital that 
potential pharmacological agents display optimal solubility parameters to achieve 
their desired concentration in systemic circulation in order to generate the desired 
pharmacological response13. The halogenated compounds all show poor aqueous 
solubility of <20 µM, whereas the ideal solubility would be in the region of >50 
µM138.  
The low nM EC50 values of the halogenated analogues may also confer selectivity, 
with respect to, the GABAAR by reducing the dose required to activate the α1 GyR 
compared to the GABAAR by ~ 3 orders of magnitude
14. Whilst the ClogP is still on 
the high side, it was decided to profile compound 8 in pharmacokinetic studies to 
enable proof of principle studies in a neuropathic pain model to follow should 
sufficient drug exposure be achieved.  
2.2.2 In vivo results of  compound 8 (previous work cont) 
The pharmacokinetic parameters of 4-chloropropofol were calculated following a 
formal in vivo PK study in the rat (Table 2.3).  Analogues were dosed by p.o and i.v. 
routes in the rat. Whole blood samples were taken from a lateral tail vein for 
plasma separation at time points 0 min, 30 min, 1 h, 2 h and 4 after p.o. dosing; and 
0 min, 15 min, 30 min, 1 h, and 2 h after i.v. dosing, while the terminal samples at 
time point 6 h after dosing (p.o and i.v.) were taken by cardiac puncture. All 
experiments were carried out in triplicate.  
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Table 2.3.  Pharmacokinetic profile of compound 8 in the Rat.                                   
AUC - area under the concentration time curve, AUC 0-6 - area under the 
concentration time curve from 0-6hrs, Cmax – maximum concentration of drug, 
Tmax – time to maximum concentration of drug, t1/2 – half-life, CL/F – apparent 
total clearance of drug from plasma after oral admission, CL – drug clearance, Vd/F 
– volume of distribution of drug after oral admission, Vd - volume of distribution, 
MRT – mean residence time.  
 
Parameter 
i.v. p.o. F (%) 
Mean SE Mean SE  
1 mg/kg 8 mg/kg  
AUC min*µg/mL 7.39 1.68 42.8 8.78 72.4 
AUC 0-6 min*µg/mL 6.29 3.18 18.7 5.8  
Cmax µg/mL 0.11 0.03 0.1 0.02  
Tmax min 15 0 30 0  
t1/2 min 48.8 18.9 398 96.4  
CL/F mL/min/kg 14.8 27.8 201 34.3  
CL mL/min/kg 14.8 27.8 146 24.8  
Vd/F L/kg 11.8 5.64 110 27.4  
Vd L/kg 11.8 5.64 79.6 19.8  
MRT min 48.7 16 609 152  
 
As can be seen from Table 2.3 an 8mg/kg oral dose of compound 8 demonstrated a 
very high clearance rate (146 mL/min/kg with ideal values in the rat model of 10-45 
mL/min/kg) in comparison to rat liver blood flow (55.2 ml/min)11. Despite the high 
clearance, the half-life (398 min) is high (ideal in the rat model would be in the 
range of 30-180 min) which could be due to the high volume of distribution of the 
compound (80.6 L/kg with the range of 0.5-10 L/kg acceptable)11. The oral 
bioavailability is high at 72.4% (in the rat model F > 30% is good) and absorption is 
rapid with the time to achieve maximum concentration of drug (Tmax) being only 
30 min ( Tmax < 3hrs is desirable) which is a desirable attribute for an analgesic 
agent11,15.  
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Figure 2.4. Plasma concentrations of individual animals for Compound 8 after p.o. 
(broken lines) and i.v. (solid lines) administration of 8 mg/kg and 1 mg/kg, 
respectively. Inset depicts the same data on a semi logarithmic scale. 
 
Figure 2.4 shows the plasma concentrations for the individual test subjects. The 
apparent limited first pass extraction may be a consequence of the rapid absorption 
giving rise to a high concentration of drug in the portal vein saturating liver 
metabolism.    
Whilst the results from the electrophysiology testing of compound 8 showed an 
increase in potency at the α1 GyR (EC50 0.6 nM) and the results from the in vivo 
studies from the rat indicated good oral bioavailability (72.4%) and rapid absorption 
(Tmax = 30 min), the validity of the α1 GyR as an analgesic target had still to be 
demonstrated in vivo. 
 Due to the innate solubility issues seen with propofol and the halogenated 
analogues, it was decided to include a water soluble phosphate prodrug of 
compound 8 (Figure 2.6) in the in vivo testing.  
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Several water soluble propofol prodrugs have previously been synthesised including 
fospropofol (11), propofol ethyl dioxy phosphate (12) and propofol phosphate (13) 
(Figure 2.5)16-18. 
 
 
Figure 2.5. Propofol prodrugs. 
 
Both Fospropofol and propofol ethyl dioxy phosphate release toxic compounds 
(acetone and acetaldehyde respectively) upon enzymatic activation, whereas 
propofol phosphate only releases inorganic phosphate. Propofol phosphate 
however, does have a slower onset of action compared to the fospropofol and 
propofol ethyl dioxy phosphate19. 
To date Fospropofol is the only propofol prodrug licensed by the Food and Drug 
Administration (FDA) for monitored anaesthesia care20. Fospropofol itself is an 
inactive form of the drug, and as such, fospropofol relies upon enzymatic cleavage 
of the phosphate moiety by endothelial cell alkaline phosphatases to release the 
active compound21. Addition of the phosphate moiety to propofol has been shown 
to increase the solubility by ~3 orders of magnitude from 0.15 mg/mL for propofol 
to 500mg/mL for fospropofol18.      
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Therefore it was decided to determine the effects, not only of compound 8 but, in 
an effort to increase anticipated oral bioavailability, the effects of the phosphate 
prodrug of compound 8  (Figure 2.6) were also tested for in vivo activity against 
hyperalgesia, the increased sensitivity to a painful stimulus, and allodynia, the 
painful response to normally innocuous stimuli22.   
 
 
 
Figure 2.6. Phosphate prodrug of compound 8. 
 
The in vivo pharmacodynamic investigation was carried out by Dr Laiche Djouhri in 
the Department of Pharmacology at the University of Liverpool, using the Chung 
lesion rat model of neuropathic pain. 
Neuropathic pain was induced in the animals by partial ligation of the sciatic nerve 
as set out by Chung14 and co-workersl. For thermal hyperalgesia the animals were 
placed on a hot plate set at a predetermined temperature and the animals were 
observed for paw withdrawal behaviours of the injured limb, the time taken to 
withdraw the injured limb is given as the paw withdrawal latency. Mechanical 
allodynia was examined by measuring paw withdrawal thresholds (PWT) to 
increasing mechanical force applied to the dorsal surface of the rat paw.  
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Figure 2.7. Effects of oral administrations of Compound 8 (8mg/Kg, n=6) and 
prodrug (8mg/Kg, n=6) were compared with those of vehicle (control) and 
gabapentin (positive control, 30mg/Kg, i.p). data are expressed as mean ± SEM and 
comparisons between pre spinal nerve axotomy (SNA) (time 0) and post SNA (7 
days) values were made with one way repeated measures ANOVA with Dunnets 
multiple comparison. Comparisons between post drug values and vehicle values 
were made with two way repeated measures ANOVA followed by post Bonferroni 
tests (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P 0.001)   
As can be seen from Figure 2.7 (A), compound 8 reversed heat hyperalgesia and was 
as effective, as the current ‘gold standard’ treatment for neuropathic pain, 
gabapentin at 2-3 hours post dosing and outperformed gabapentin at 6-7 hours 
post dosing. The prodrug of compound 8, predictably had a slower onset of action 
due to the fact that the prodrug relies upon enzymatic cleavage of the phosphate 
moiety by alkaline phosphatases in the liver to release the active drug. At 6-7 hours 
post dosing the prodrug was also more effective than gabapentin.   
The results of the mechanical allodynia test (Figure 2.7, B) showed that compound 8 
had no effect in the paw withdrawal threshold levels indicating no analgesic activity 
in the mechanical allodynia arm of the study. 
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Crucially during these tests no sedation was observed in any of the rats. This is 
strongly supportive of the fact  that 4-chloropropofol is selectively targeting the 
GlyR not the GABAAR, achieving analgesic activity without producing the sedative or 
hypnotic side effects seen with other therapeutics used to treat neuropathic pain 
i.e. amitriptyline and gabapentin. 
2.3 Substituted bi-phenyl series (previous work cont) 
 
With the results from the initial electrophysiology and in vivo studies of the 
halogenated compounds showing that substitution at the 4-position of propofol 
could substantially increase Cl- current and reduce the EC50 value by ~3 orders of 
magnitude at the GlyR, it was decided to explore further the effects of substitution 
at the 4-position. It can be seen from the results of the electrophysiology assays 
with compound 10 that larger groups can be tolerated at the 4-position. The van 
der Waals volume of the iodo group is approximately 34.78 Å3, therefore, in order 
to probe the constraints of the hypothetical binding pocket a series of phenyl 
analogues were synthesised (Van der Waals volume 99.17Å3*, Figure 2.8).  
 
 
Figure 2.8. Space filled models of the 4-iodo propofol and 4-phenyl propofol 
showing the similarity in size of iodine and phenyl groups. *Values measured using 
Spartan 14 software. 
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The number of possible analogues of substituted aromatic rings with accessible 
functional groups is extremely large. Therefore in order to explore the chemical 
space based upon substitution of the phenyl ring, a rational approach in deciding 
which substituents to use was employed in the form of the Craig plot (Figure 2.10). 
2.3.1 The Craig plot (previous work cont) 
 
Craig plots can be utilised to give a visual representation of the relative 
independence or interdependence of a range of physicochemical parameters 
including electronic effects (σ) hydrophobic effects (π), molar refractivity (MR) and 
steric effects (Es)
23.  The Craig plot was used to determine the electronic effects (σ, y 
axis) vs. the hydrophobic effects (π, x axes) of variety of possible substituents. From 
this plot it is possible to visualise the various combinations of both electronic and 
hydrophobic contributions each substituent will make when attached to the 
benzene ring. There are many examples in the literature of the Craig plot being 
utilised to drive compound design and selection forward24-28. Most of the 
substituents chosen for this study resided in the top right quadrant of the plot, such 
as the halogens and trifluoromethyl ether. These substituents have positive σ values 
and positive π values (+σ, + π) which show an increase in both electron withdrawing 
and hydrophobic effects compared with hydrogen.  
Substituents in the in the lower right quadrant (Me, Et, NMe2) show an increasing 
electron donating effect while the hydrophobic effect remains positive (-σ, + π). 
These substituents tend to be unstable to metabolism when on aromatic rings; 
therefore, they were not included in this investigation. Those substituents (OH, NH2, 
OCH3) residing in the lower left quadrant (-σ, - π) of the plot were also disregarded 
due to possible formation of toxic metabolites, such as benzoquinone imines (15) 
and quinones (16) when introduced para to a hydroxyl group, (Figure 2.9)29,30.  
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Figure 2.9. Toxic metabolites, quinone (top) and quinoneimine (bottom) formed 
from para hydroxylation or para amination of a phenol.   
The electron withdrawing, less hydrophobic substitutes (+σ, - π) in the top left 
quadrant were due to be incorporated but the project moved in a different 
direction and other target compounds were developed.   
 
Figure 2.10. The Craig plot14. 
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2.3.2 Biological results of the bi-phenyl series (previous work cont) 
 
 
Figure 2.11. Bi-phenyl template  
Several of the bi-phenyl series showed remarkable in vitro potency against the α1 
GlyR, with Ec50 values in the low picomolar range. Again compounds with chloro 
substituents at the 4-position, in this case of the terminal ring, were among the 
most potent compounds. 
Table 2.4. Biological results of bi-phenyl compounds previously synthesised within 
the group. 
 
Compound R1 R2 R3 ClogPa EC50 (µM)
b 
17 Cl H H 6.5 0.0002 ± 0.0003 
18 t-Butyl H H 7.6 0.00005 ± 0.03 
19 Cl F H 6.7 0.00007 ± 0.00025 
20 H F H 4.9 0.00014 ± 0.00009 
21 Ph H H 7.7 0.0008 ± 0.0002 
22 Cl Cl H 7.2 0.00063 ± 0.00012 
23 H F F 6.1 0.00038 ± 0.00039 
a, ClogP values were determined using chembiodraw ultra 12 software. b, α1 GlyR EC50 values 
determination was carried out at the University of Tübingen under the supervision of Prof. Bodo 
Laube. 
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The di-halogenated 4-chloro-5-fluoro-diphenyl analogue (19) was the most potent 
compound with an EC50 value of 70 picomolar.  
Interestingly compound 18 containing the 4- t-butyl moiety which is electron 
donating and hydrophobic, as can be seen from the Craig plot (Figure 2.10), was 
also extremely potent (EC50 50 pM) indicating the possibility of a large hydrophobic 
binding pocket for these molecules.  
  Although several of the bi-phenyl series showed remarkable in vitro potency 
against the α1 GlyR, with Ec50 values in the low picomolar range (Table 2.4), some 
of the physicochemical properties of the compounds fall outside the optimal ranges 
(Table 2.4). In particular the ClogP values of these highly lipophilic molecules are all 
>6.0 with the optimal range being <5.012. The pharmacokinetic profile of the most 
potent of the bi-phenyl analogue (compound 19) was investigated in the same in 
vivo model as compound 8 (Table 2.5). 
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Table 2.5. Pharmacokinetic profile of compound 19 in the Rat. Analogues were 
dosed p.o and i.v. into the rat. Whole blood samples were taken from a lateral tail 
vein for plasma separation at time points 0 min, 30 min, 1 h, 2 h and 4 after p.o. 
dosing; and 0 min, 15 min, 30 min, 1 h, and 2 h after i.v. dosing, while the terminal 
samples at time point 6 h after dosing (p.o and i.v.) were taken by cardiac puncture. 
All experiments were carried out in triplicate. 
 
Parameter 
i.v p.o F (%) 
Mean SE Mean SE  
2 mg/kg 20 mg/kg  
AUC min*µg/mL 69.2 5.72 123 42 17.8 
AUC 0-6 min*µg/mL 64.1 6.88 34.6 12.6  
Cmax µg/mL 0.77 0.17 0.15 0.04  
Tmax min 15 0 30 0  
t1/2 min 91 5.01 789 185  
CL/F mL/min/kg 29.3 2.28 231 103  
CL mL/min/kg 29.3 2.28 41.1 18.3  
Vd/F L/kg 3.87 0.5 306 195  
Vd L/kg 3.87 0.5 54.4 34.7  
MRT min 104 19.1 1160 256  
 
The results of the in vivo testing show that compound 19 is poorly absorbed with a 
low AUC giving a bioavailability of ~ 18%. Clearance (CL) and volume of distribution 
(Vd) are both reduced whilst the plasma concentrations are increased (t1/2> 780 
mins), with respect to compound 8. The reduced CL and Vd could be due to the 
poor solubility of compound 19.   
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Figure 2.12. Plasma concentrations of individual animals for 19 after p.o. (broken 
lines) and i.v. (solid lines) administration of 20 mg/kg and 2 mg/kg, respectively. 
Inset depicts the same data on a semi logarithmic scale. 
Figure 2.12 shows the poor absorption of compound 19 leading a low Cmax (0.15 
µg/mL). From the pharmacokinetic data it appears that compound 19 suffers from 
solubility limited absorption as the compound appears to flat line at around 2 hours.   
2.4   Results and discussion 
 
The optimisation of propofol (Figure 2.13) has led to the generation of an extremely 
potent hit compound with an EC50 value of 70pM against the α1 GlyR. From 
preliminary animal studies it was apparent that the ClogP needed to be reduced and 
that the aqueous solubility needed to be improved in order to increase 
bioavailability. 
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Figure 2.13. Optimisation of propofol to early lead generation. 
The α1 GlyR is predominantly found within the CNS of the mammalian system. In 
order for a therapeutic agent to successfully cross the blood brain barrier (BBB) and 
enter the CNS the guidelines for the pharmacokinetic parameters are different to 
the standard Lipinski’s guidelines (Table 2.6)12,31. 
Table 2.6. Comparison of Lipinski’s guidelines and those for CNS penetration.    
ClogP is the calculated partition coefficient; this gives a measure of the 
hydrophobicity of a compound. ClogD is the calculated distribution coefficient; this 
gives a measure of the distribution of a compound throughout various biological 
systems. Topological polar surface area (TPSA) is the surface sum of all polar atoms, 
this gives a measure of a compounds ability to permeate cells. MW is the molecular 
weight of the compound. Hydrogen bond donors (HBD) is the sum of all of the 
oxygen-hydrogen and nitrogen-hydrogen bonds, whereas hydrogen bond acceptors 
(HBA) is the sum of all of the oxygen and nitrogen atoms within the compound. pKa 
gives a measure of the acidity of the compound . Rotatable bond is any single non-
ring bond, bounded to nonterminal heavy (i.e., non-hydrogen) atom. 
PK Parameter Lipinski’s guidelines CNS Penetrant guidelines 
ClogP ≤5 ≤5 
ClogD  ≤3 
TPSA  60-70Å2 
MW (Da) ≤500 ≤450 
HBD ≤5 ≤3 
HBA ≤10 ≤7 
pKa  7.5-10.5 
Number of rotatable Bonds  ≤8 
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 The preliminary studies have shown that substitution at the 4-position of propofol 
can dramatically increase potency at the α1GlyR, although it is apparent from Table 
2.7  that the predicted pharmacokinetic and physicochemical parameters of the 
templates need to be improved in order to deliver a metabolically stable and orally 
available analgesic compound. As hepatic metabolism is the primary elimination 
pathway for the majority of drugs it is, therefore, vital that new chemical entities 
are tested against liver microsomes and hepatocytes to determine their stability to 
metabolic degradation32,33. 
 Hepatic metabolism impacts oral bioavailability and the half-life of a drug which in 
turn affects the dose and frequency of administration. Microsomes are generally 
inexpensive and robust; therefore, they are typically used in high throughput 
screens. Microsomes contain both CYP 450’s and UDP-glucouronosyltransferases 
enzymes which are responsible for the metabolism of the many drug compounds. 
Hepatocytes contain the full complement of both phase I and phase II metabolising 
enzymes including cytosolic enzymes such as, methyltransferases and aldehyde 
oxidases35. The ideal rate of clearance would be below 15 µl/min/mg for 
microsomes and below 20 µl/min/106 cells for hepatocytes11. 
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The radar plots give a good visual representation of the ideal values vs. the 
predicted values for ClogD, solubility, human microsomes and rat hepatocytes.  
Figure 2.14 shows an ideal radar plot, the shaded area represents were the 
optimum values for each parameter would lie whilst the red line represents the 
calculated value for each parameter. If the line falls outside of the shaded areas this 
shows the predicted value lies outside of the optimal  range for that particular 
parameter. 
 
Figure 2.14. An Ideal radar plot 
 
Table 2.7. Pharmacokinetic and physicochemical parameters of compound 8 and 
the most potent bi-phenyl analogues11. Human Microsomes,  0-30 green, 30-60 
yellow, 60 and above red. Rat Hepatocytes, 0-30 green, 30-60 orange, 60 and above 
red. ClogD7.4, 1-4 green, <1 OR >4 red.  
Compound Parameters Radar plot 
 
8 
 ClogD 7.4 4.4 
 
Human 
Mic 
(µl/min/mg) 
91.87 
Rat Hep 
(µl/min/1E6) 
386.8 
Chapter II 
 
 
72 | P a g e  
 
Compound Parameters Radar plot 
 
17 
 ClogD 7.4 5.84 
 
Human 
Mic 
(µl/min/mg) 
121 
Rat Hep 
(µl/min/1E6) 
226 
 
18 
 ClogD 7.4 5.84 
 
Human 
Mic 
(µl/min/mg) 
121 
Rat Hep 
(µl/min/1E6) 
226 
 
19 
 ClogD 7.4 6.0 
 
Human 
Mic 
(µl/min/mg) 
131 
Rat Hep 
(µl/min/1E6) 
343.5 
 
In particular the lipophilicity coefficient, ClogP, the 4-aryl series needs to be 
reduced. Highly lipophilic molecules are, in general, poorly absorbed, have low 
solubility and have a high metabolic turnover and therefore have a low 
bioavailability.  
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Highly lipophilic molecules also have a higher probability of becoming partitioned in 
lipid membranes and being retained there. If the ClogP values are too low the 
compounds will not pass through the blood brain barrier in sufficient concentration 
to achieve therapeutic levels at the site of action. Ideally for maximum probability 
of CNS penetration the ClogP needs to be between 1.5- 3.031.  
The consideration of ClogP values is of vital importance to the medicinal chemist 
when designing a new molecular entity; but ClogP values do have their limitations. 
ClogP measurements do not consider the ionisation of a molecule. Many novel drug 
candidates contain basic or acidic centres which can become ionised as they pass 
through various biological systems i.e. stomach and gastrointestinal tract (pH-1-2), 
blood plasma (pH-7.4). Therefore it is important to measure a distribution ratio 
(ClogD) which takes into account the ratio of ionised/unionised compound at 
various pH values. To ensure maximum penetration of the BBB the ClogD values 
should be kept between 1-336,37. 
Topological polar surface area (TPSA) is defined as the sum of contributions to the 
molecular surface area of polar atoms, such as oxygen and nitrogen. In order to 
maximise the chances of intestinal absorption the TPSA of a molecule should be in 
the region of 60-140 Å2. Once again the values for optimal CNS penetration are 
more stringent at <90 Å2, 36,38.       
Therefore, this study will focus upon optimisation of the 4-substituted propofol 
template and will aim to drive the compound not only to increased potency but also 
to correlate activity with improved physicochemical characteristics such as ClogP, 
ClogD, TPSA in order to maximise the potential for CNS penetration.  
2.4.1 Toxicological screening 
Toxicological adverse events are one of the primary reasons for compound attrition 
within the drug discovery pipeline. Therefore our lead compounds will be screened 
for potential adverse effects in several toxicity assays. The following sections give an 
overview of the key points the toxicological screens will cover.   
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2.4.2  hERG testing 
To investigate possible cardiotoxic effects the lead compounds will be tested in the 
human ether a-go-go related gene (hERG) assay. hERG encodes the inward 
rectifying voltage-gated potassium channel in the heart (IKr) which is involved in 
cardiac repolarisation. Inhibition of the hERG current causes QT interval 
prolongation (the QT interval represents electrical depolarisation and repolarisation 
of the ventricles) resulting in potentially fatal ventricular tachyarrhythmia 
called Torsade de Pointes (TdP). A number of drugs have been withdrawn from the 
market (prenylamine, terodiline, sertindole and astemizole) due to these 
cardiotoxic effects, therefore it is important to identify inhibitors as early as 
possible in the drug discovery process39.  The data from hERG assays is usually 
categorised into the following classification bands (Table 2.8). 
 
Table 2.8. Classification bands for hERG IC50 values. 
 
Highly potent IC50 < 0.1µM 
Potent IC50 between 0.1 - 1µM 
Moderately potent IC50 between 1µM - 10µM 
Weak or no inhibition IC50 >10µM 
 
 
Amitriptyline (24), a tricyclic antidepressant prescribed for the treatment of 
neuropathic pain (Figure 2.15), is known to be a moderately potent hERG channel 
blocker with an IC50 4.78 µM. As such patients prescribed amitriptyline need to have 
regular check-ups to assess whether the medication is affecting their QT 
interval40,41. 
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Figure 2.15. Tricyclic antidepressant amitriptyline (24); a known hERG blocker 
 
2.4.3 The Ames test 
 
The Ames assay is designed to examine possible mutagenic/carcinogenic effects of 
chemical compounds. The Ames Salmonella/microsome mutagenicity assay is a 
short-term bacterial reverse mutation assay. It has been specifically designed to 
detect a wide range of chemical substances that can produce genetic damage 
leading to gene mutations. The test uses several histidine dependent Salmonella 
strains each carrying different mutations in various genes in the histidine operon. 
These mutations act as hot spots for mutagens that cause DNA damage. When the 
Salmonella tester strains are grown on an agar plate containing a trace of histidine, 
only those bacteria that revert to histidine independence (his(+)) are able to form 
colonies. However, when a mutagen is added to the plate, the number of revertant 
colonies per plate is increased, usually in a dose-related manner. The Ames test is 
used world-wide as an initial screen to determine the mutagenic potential of new 
chemicals and drugs42. 
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2.4.4 Cytotoxicity  
 
  In vitro cytotoxicity is an effective indicator of human toxicity potential that must 
be addressed early in the drug discovery pipeline in order to maximise the 
successful progression of compounds into development. Our compounds will be 
screened for cytotoxic effects in hepatocytes (hepG2) assays to evaluate for key 
toxicity markers including, cell number, nuclear condensation, total nuclear 
intensity, cell permeability, mitochondrial membrane potential and cytochrome C 
release35,43 
2.4.5 Metabolism and adverse drug reactions 
 
Metabolism serves the important function of chemically modifying a compound to 
make it more polar and, therefore, more readily cleared into the bile and urine. An 
unfortunate consequence of metabolism is the possible formation of a reactive 
metabolite or metabolic intermediate which can lead to toxicity44. The occurrence 
of idiosyncratic adverse drug reactions (ADRs) during late clinical trials or after a 
drug has been released can lead to a severe restriction in its use and even in its 
withdrawal. Metabolic activation of relatively inert functional groups to reactive 
electrophilic intermediates is considered to be an essential component in many 
drug-induced adverse reactions. A thorough examination of the biochemical 
reactivity of functional groups in all new drug candidates is essential from a safety 
viewpoint45.  
Modifications of proteins can elicit many ADRs from DNA mutations (with 
carcinogenic outcomes) to immune responses, causing severe hypersensitivity 
reactions (skin rashes) as in the case of the sulphonamide containing drug 
Sulfamethoxazole (25) and the antiretroviral drug abacavir (26) (Figure 2.16)46,47. 
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Figure 2.16. Sulfamethoxazole and abacavir, both drugs are responsible for 
hypersensitivity reactions. 
 
 Often ADRs occur in the liver, leading to hepatotoxicity, but the reactive 
metabolites can also cause damage at distal sites. There are many publications 
detailing the biochemical activation pathways of common functional groups utilised 
in drug discovery48-50;  
Table 2.9 contains a partial list of structural motifs that may initiate toxicity44.   
 
Table 2.9. A partial list of structural motifs that may result in toxic metabolites. 
Substrate Proposed reactive metabolite 
Aromatic amine Hydroxyl amine, nitroso, quinone-imine 
Hydroxyl amine Nitroso 
Aromatic nitro Nitroso 
Alkyl halide Acylhalide 
Hydroquinones p-Benzoquinone 
Acetamide Radical 
Thioamide Thiourea 
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A target product profile outlining the desired criterion for our novel analgesic 
compound was developed taking in to account the CNS penetrant physicochemical 
properties described in Table 2.16, the selectivity required for the GlyR over the 
GABA A R to ensure no sedative effects, the desirable pharmacokinetic parameters 
to ensure maximum absorption with minimum metabolism and to reduce the 
possibility of attrition due to safety issues as described in section 2.4.1.11 . 
Table 2.10. Target product profile for novel analgesic compounds 
Assay/Model Desired Criterion 
Physicochemical properties  
Aqueous solubility >0.05 mg/mL (pH 7.4) 
ClogP <4 
MW <450 (Da) 
TPSA < 90Å2 
Number of rotable bonds <8 
ClogD 1-3 
Pka 3-9 
Selectivity  
GABAAR (Ec50) GABAA EC50 >100x GlyR EC50 
Pharmacokinetics  
Oral bioavailability (rat) >20% 
Stability rat liver microsomes T1/2 >60 mins 
Stability human hepatocytes T1/2 >30 mins 
Brain CSF levels 3xEC50 (free) at 2-3 hrs at 1-3 mg/kg 
In vitro plasma protein binding (rat) <99.5% 
Safety  
Functional hERG assay IC50 > 10µM 
Cytotoxicity HepG2 cells No cytotoxicity at 500x EC50 GlyR EC50 
Genotoxicity: Ames Negative 
Absence of metabolic alerts No alerts 
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2.5 Heterocycles and Solubilising groups (novel work) 
 
Previous work by Mohammadi, Bahram. Haeseler, Gertrud. Leuwer, Martin. 
Dengler, Reinhard. Krampfl, Klaus. & Bufler, Johannes3. has demonstrated that 
halogenation of phenols could significantly increase their potency at the GABAAR. 
This work was built upon by previous members of the group who demonstrated 
that halogenated propofol analogues (compounds 8-10) could target the α1 GlyR 
with EC50 values in the low nM region (compound 8 EC50 = 0.6 nM). This work led to 
the investigation of a series of bi-phenyl compounds (17-23), this progression 
improved the efficacy at the α1 GlyR as exemplified by compound 19 with an EC50 = 
70pM. From the initial in vitro studies of compound 19 it was apparent that 
solubility was an issue, with the compound being poorly absorbed (Figure 2.12).  
Therefore, in an effort to improve the physicochemical parameters, aqueous 
solubility and optimise CNS penetration of the propofol analogues, this study will 
focus on a series of bi-phenyl and direct linked heterocyclic substituents 
incorporated at the 4-position of propofol. Addition of heterocyclic substituents and 
protonatable groups can improve TPSA, reduce ClogP and improve solubility. With 
this in mind a small library of novel target molecules was decided upon and their 
physicochemical parameters were evaluated (Table 2.11). 
 As can be seen fromTable 2.11, whilst the ClogP and ClogD of the proposed 
compounds (28,32,33,40,41,44) have improved with respect to the bi-phenyl 
compounds they are still suboptimal for the highest probability of CNS penetration. 
It was decided that at this stage of the project it was important to synthesise these 
compounds and to subject them to the electrophysiology assays to determine their 
EC50 values. This would give a greater understanding of the SAR tolerance 
surrounding substitution at the 4-position and allow us to further probe the binding 
pocket for these analogues in terms of size, shape and the tolerance of chemical 
functionality (Table 2.11).  
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Table 2.11. Proposed heterocyclic analogues. ClogP, TPSA & MW values were 
generated using Chembiodraw ultra 12.0. ClogD was data was generated using ACD 
labs. 
Compound Structure Parameters 
28 
 
ClogP 5.56 
ClogD 4.70 
TPSA 32.70 
MW 353.30 
32 
 
ClogP 4.56 
ClogD 3.90 
TPSA 49.77 
MW 367.48 
33 
 
ClogP 5.0 
ClogD 3.40 
TPSA 43.78 
MW 380.52 
40 
 
ClogP 5.55 
ClogD 3.70 
TPSA 33.12 
MW 323.35 
41 
 
ClogP 5.02 
ClogD 5.70 
TPSA 38.04 
MW 326.36 
 
Chapter II 
 
 
81 | P a g e  
 
44 
 
ClogP 3.98 
ClogD 3.40 
TPSA 46.26 
MW 254.32 
2.6 Synthesis   
 
The synthesis of 28 began with bromination of propofol followed by Suzuki coupling 
with the appropriate boronic acid.  
Bromine was added drop wise to a solution of propofol in acetic acid to form 4-
bromopropofol in 75-80% yields (Scheme 2.1). Mass spectrometry showed 
characteristic isotopic peaks relating to Br 79 & 81 incorporated into the product. 
 
Scheme 2.1. Reagents and conditions: i) Bromine, AcOH, RT, 2hrs, 80% yield. 
2.6.1 Suzuki Coupling 
 4-Bromompropofol was reacted with the appropriate commercially available 
boronic acid under Suzuki conditions to give compound 28 in 48% yield. The Suzuki 
coupling is one of the most reliable methods for the preparation of bi-aryl 
containing compounds51.  
The first step in the mechanism of the Suzuki reaction is the oxidative addition of 
the aryl halide to the palladium (0) complex generating a palladium (ll) 
intermediate. The next step is transmetallation; this involves transfer of the aryl 
group from the boronic acid to the palladium complex with the loss of the halide. 
Finally reductive elimination sees the product released and the palladium complex 
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reduced back to a palladium(0) species ready for the next round of catalysis (Scheme 
2.2).  
 
 
Scheme 2.2. Reagents and conditions: i) Pd(PPh3)4, K2CO3, THF/H2O, 80
oC, 24hrs, 48-
60% yields. 
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2.6.2 Bi-Phenyl Amide Synthesis 
 
In order to synthesise amide analogues 32& 33, 4-bromopropofol was subjected to 
the Suzuki conditions outlined in scheme 2.2 with the commercially available 4-
methoxyphenyl boronic acid to yield the methyl ester  (60% yield) which was 
subsequently hydrolysed to the  carboxylic acid  by treatment with NaOH in MeOH. 
The acid chloride was obtained via addition of oxalyl chloride to a solution of 
carboxylic acid in anhydrous DCM in the presence of catalytic quantities of DMF. 
The acid chloride was not isolated from the reaction mixture but was placed under 
reduced vacuum to remove any traces of unreacted oxalyl chloride.  
 Compounds 32& 33 were prepared in moderate yields (47%-51%) by addition of 
the appropriate morpholino analogue to acid chloride (31) in anhydrous DCM in the 
presence of Et3N
53 (Scheme 2.2).  
 
 
Scheme 2.2. Reagents and conditions: i) NaOH (2M), MeOH, RT, 18hrs, 67% yield; ii) 
oxalyl chloride, DMF (1 drop), DCM, RT, 2hrs; iii) corresponding amine, Et3N, DCM, 
RT, 18hrs52.  
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2.6.3 Heterocycle synthesis  
 
In the case of compounds 40,41 & 44the corresponding boronic acids of the 
heterocycles were either not commercially available or they were prohibitively 
expensive. The halogenated analogues of the heterocycles were commercially 
available however, therefore, it was decided to synthesise the 4-boronic acid 
analogue of propofol and utilise the halogenated heterocycle in a Suzuki reaction to 
afford the desired products.  
The first step in this synthetic pathway was to protect the phenolic oxygen. The 
protecting group chosen was a methyl ether. Addition of the protecting group was 
facilitated by addition of NaH to a solution of 4-bromopropofol in THF at 0oC. After 
10 minutes MeI was added and the reaction was left to stir for 3hours giving the 
product in excellent yields (99%)54. The product was confirmed by the loss of the 
hydrogen atom at 4.81 ppm and the addition of a singlet peak at 3.71ppm 
integrating for 3 protons in the 1HNMR (Scheme 2.3). 
 
 
 
Scheme 2.3. Reagents and conditions: i) NaH, THF, 0oC, 10min; ii) MeI, 0oC, 3hrs, 
99% yield. 
The synthesis of the boronic acid was completed by lithium halogen exchange using 
n-butyl lithium to displace bromine and triisopropyl borate was utilised to trap out 
the lithiated species (Scheme 2.5).  
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Scheme 2. 4. Reagents and conditions: i) n-BuLi 2.5 M, THF, -78oC, 1hr; ii) 
triisopropyl borate, -78oC-RT, THF, 18hrs55.   
The boronic acid and the corresponding halogenated heterocycles were subjected 
to the Suzuki conditions outlined in scheme 2.3. Demethylation was performed with 
1.0 M boron tribromide solution in dichloromethane at room temperature for 5 
hours to give desired products 40& 41, (Scheme 2.5). 
 
Scheme 2.5. Reagents and conditions: i) BBr3, DCM, 0
oC, 5hrs56.  
In the case of the isoxazole analogue 44, it was found that when subjected to the 
demethylation conditions outlined in Scheme 2.5 the reaction failed to give the 
desired products. 
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 To overcome this problem a benzyl ether protecting group was employed. The 
benzyl ether was added to 4-bromopropfol by addition of benzyl bromide and 
potassium carbonate in acetone at room temperature overnight (Scheme 2.6).  
 
Scheme 2.6. Reagents and conditions: i) BnBr, acetone, K2CO3, RT, 18hrs
57. 
The benzyl protected 4-brompropofol was subjected to the lithium halogen 
exchange and subsequent trapping conditions outlined in Scheme 2. 4 to form the 
benzyl protected boronic acid (37a). The Suzuki product was formed utilising 
conditions shown in scheme 2.2, whilst benzyl deprotection was afforded by using 
hydrogen and palladium/carbon in methanol (Scheme 2.7) to give compound 44. 
 
 
 
Scheme 2.7. Reagents and conditions: i) H2, Pd/C, MeOH, 18hrs 42% yield
58. 
2.7 Biological Data 
Compounds 28, 32, 33, 40, 41 & 44 were tested for efficacy at the α1 GlyR,    
Chapter II 
 
 
87 | P a g e  
 
Table 2.12 shows EC50 values and physicochemical parameters for the phenyl and 
direct linked heterocycles. 
 To evaluate the potential for off target toxicity, compounds from both the biphenyl 
and heterocylic templates were sent for testing against the GABAAR. 
Table 2.12. In vitro EC50 values for heterocylic compounds tested against the 
recombinant α1GlyR 
Compound 
α1 GlyR 
EC50 
(µM)a 
ClogPb ClogDc 
GABAA EC50 
(µM)d 
 
28 
>1 µM 5.56 4.70 NT 
 
32 
ip 4.56 3.90 NT 
 
33 
ip 5.0 3.40 3.33 ± 0.058 
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40 
0.0001 5.55 3.70 0.12 ± 0.679 
 
41 
>1 µM 5.02 5.70 3.33 ± 0.177 
 
44 
ip 3.98 3.40 NT 
a, α1 GlyR EC50 values determination was carried out at the University of Tübingen under the 
supervision of Prof. Bodo Laube.b, ClogP values were determined using chembiodraw ultra 12 
software. c, In house algorithm. d, GABAA selectivity testing was carried out at BioFocus®, 
Chesterford Research Park, Saffron Walden, UK. Ip, denotes compounds awaiting testing (in 
progress). 
Of those compounds tested so far, only compound 40 has shown the low 
nanomolar activity seen with the compounds synthesised previously within the 
group. Compound 40 was also tested for activity at the GABAAR, it was found to be 
a highly potent modulator of the GABAA α1β2γ3 isoform with an EC50 = 0.12 µM. 
This is a highly undesirable attribute due to the off target effects seen with 
compounds that modulate the GABAAR such as dizziness, drowsiness and sedation. 
Therefore due to the combination of a lack of efficacy at the α1 GlyR, off target 
activity and unfavourable physicochemical properties, the decision was taken to 
terminate this series.  
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2.8 Multiparameter Optimisation  
 
During the synthesis of 28, 32, 33, 40, 41 & 44 a team at Pfizer headed by 
Villalobos59 released a series of papers describing the development and use of a 
multiparameter optimisation (MPO) tool, to aid in the development of drugs acting 
at sites within the central nervous system. The following is a review of the Pfizer 
papers and a discussion of how the MPO approach was used as a key element in the 
design of “pre-optimised compounds”. 
2.8.1 MPO Review      
 
The drug discovery process is a highly complex, slow and risky enterprise. On 
average it takes around 10-15 years and costs in the region of 1 billion US dollars to 
advance a drug from preclinical discovery to regulatory approval. The 
pharmaceutical industry faces substantial attrition rates of candidate drugs. 
Approximately only 1 in 10 drugs entering clinical development actually reaches the 
market place. 
 As a result of this high failure rate the pharmaceutical industry faces a huge 
amount of pressure to not only cut the cost but also the timeframe for drug 
discovery. Drug discovery is an iterative process of candidate selection, synthesis, 
testing and optimisation of the candidate’s pharmacological profile. Merely the fact 
that a compound shows potency against a therapeutic target is not sufficient for a 
candidate to progress through the drug development process. From an early stage a 
drug candidate must display favourable physicochemical properties i.e. absorption, 
distribution, metabolism and excretion (ADME) and exhibit a low risk of possible 
toxicologically adverse events.  
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The rate of novel drugs successfully entering development over the last 20 years 
has remained unchanged at around 11%.  Whilst many of the clinical failures can be 
attributed to a lack of efficacy at unvalidated targets, significant amounts were due 
to inadequate pharmacokinetic (PK) parameters. Interestingly a report published by 
Kola and Landis60, showed the clinical attrition rate due to poor PK  had dropped 
from 40% in 1991 to 10% in 2000 with failure rates due to safety and toxicology 
doubling to 30% over the same period.  The fall in clinical attrition rates due to poor 
PK was associated with an increase in failure rates at earlier developmental stages 
driven by the introduction of in silico predictive models and the use of high-
throughput assays.  
There are several protocols already in use to help the medicinal chemist assess the 
druglikness of a novel compound before the expensive and time consuming 
synthesis/optimisation iterative cycle begins, possibly the most well-known being 
Lipinski’s rule of 5 ( which was described earlier).  
These guidelines have been used with great success by medicinal chemists since 
they were introduced in the late 1990s and have spawned many more such “rules of 
thumb” for drug design including, Glaxo Smith Kline’s 4/400, which relates to 
compounds with a ClogP less than 4 and a MW less than 400 and how on average 
they have a more favourable ADMET profile61 and Pfizer’s 3/75 rule, which states 
that compounds that have a ClogP < 3 and TPSA > 75 gave a 6-fold reduction in 
prevalence of in vivo toxicity versus compounds with ClogP > 3 and TPSA < 75 (Table 
2.13) 62,63. 
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Table 2.13. Pfizer 3/75 rule for increased toxicity odds with TPSA and ClogP (data 
from ref.62) 
Toxicity 
Total-drug Free-drug 
TPSA > 75 TPSA < 75 TPSA > 75 TPSA < 75 
ClogP < 3 0.39 (57) 1.08 (27) 0.38 (44) 0.5 (27) 
ClogP > 3 0.41 (38) 2.4 (85) 0.81 (29) 2.59 (61) 
 
 Whilst these rules are easy to understand, calculate and apply, they should be used 
with an air of caution. All the above mentioned guidelines utilise hard cut-offs in 
their approach to drug design, this can draw artificially tough distinctions between 
compounds with similar chemical properties. The use of desirability functions, 
however, is one approach which could avoid the harsh cut-offs seen with the 
application of simple filters such as Lipinski’s guidelines. 
Desirability functions mathematically transform the value of a given property e.g. 
ClogP or MW into a dimensionless number between 0-1, with 0 being the least 
desirable outcome and 1 being the ideal. This method can be applied to a variety of 
PK properties with the summation of each of the desirability functions giving an 
overall desirability value. This method allows for a more holistic approach to drug 
design by allowing the refinement of multiple properties without applying the harsh 
cut-offs seen with single parameter evaluation methods.  
This method was exemplified by Villalobos, who whilst investigating the use of a 
multiparameter optimisation calculator (MPO) for optimal CNS penetration defined 
desirability scores for six key physicochemical parameters, ClogP, ClogD, MW, HBD, 
TPSA, and pKa. Each parameter was subjected to a desirability function and was 
assigned a desirability indices based upon a series of inflection points which serves 
to delineate the desirable regions from the undesirable regions (Figure 2.14).  
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ClogP, ClogD, MW, HBD, and pKa were subjected to a monotonic decreasing 
function whilst TPSA was subjected to a hump function, each of the transformed 
values were equally weighted. The summation of each of the desirability indices 
gives the overall CNS MPO score.  
 
Figure 2.14. Desirability functions, (A) showing a monotonic function which is 
defined by a desirable region of the property (x ≤ x1) and an undesirable region (x ≥ 
x2). A linear transformation is applied between the two inflection points (x1 < x ≤ x2) 
with those parameters  whose values lie closer to x2 having lower transformed 
values and are, therefore, less desirable . (B) a hump function, a desirable region 
flanked by two undesirable regions with linear transformation between the 
inflection points. Taken from ref 59 
           
The authors investigated the MPO score comparisons between 119 marketed CNS 
targeted drugs and 108 Pfizer CNS candidate drugs. It was found that of the 119 
marketed CNS drug set 74% had a CNS MPO score ≥ 4.0 whilst only 60% of the 108 
Pfizer candidate drugs had a CNS MPO score ≥ 4.0. This statistically significant 
difference shows the MPO calculator could possibly be used to identify compounds 
which could have a higher probability for success. The flexibility of the MPO 
calculator was demonstrated with three compounds contained in the Pfizer 
candidate set. 
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 Each of the compounds has PK parameters outside the optimal values for design 
space, if traditional rules of thumb were followed i.e. 3/75 rule, yet each compound 
has a MPO composite score of ≥ 4.5. This is because the CNS MPO score balances 
multiple variables without utilising hard cut-offs seen with single value evaluation 
methods (Figure 2.15).   
 
Figure 2.15.  Compounds displaying optimal MPO values, would not have been 
synthesised if traditional guidelines had been followed. Taken from ref 59 
 All of these compounds have completed preclinical toxicological assessment and 
have entered phase II clinical trials, yet they may not have been synthesised at all if 
hard cut-offs for ClogP ≤ 3 (3/75 rule) or TPSA ≤ 100 rule for greater CNS 
penetration, had been applied.  
In addition, the authors also investigated the relationship between the CNS MPO 
score and four key ADME and safety endpoints, membrane permeability (apparent 
permeability (Papp) measured in the Madin-Darby canine kidney (MDCK) cell line), P-
glycoprotein (P-gp) efflux liability (measured in MDCK cells transfected with the 
MDR1 gene), metabolic stability in human liver microsomes (HLM) (unbound 
intrinsic clearance), and general cellular toxicity (measured in a THLE Cv assay).        
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It was found that for both the marketed drug set (n = 119) and the candidate set (n 
= 108) compounds with a higher CNS MPO score (≥ 5) had significantly increased 
chances of favourable outcomes in each assay. It was shown that > 90% of the 
compounds in the marketed drug set with CNS MPO scores > 5 demonstrated high 
Papp, low P-gp liability, high cellular viability and favourable metabolic stability, 77% 
of these compounds displayed all three ADME attributes in one compound.  
Finally the MPO algorithm was used to evaluate a larger set of 11303 Pfizer 
compounds in order to extensively cover property space. Once again the CNS MPO 
scores of the compounds were plotted and the ADME endpoints were assessed as 
described earlier, with the addition of a dofetilide (Dof) binding assay to assess 
potential hERG effects. Again a high concordance was found with compounds with 
higher MPO values (> 5) showing the most desired attributes of ADME properties, 
82% showed high Papp, 78% had low P-gp, 69% with low Clint,u and a low Dof liability 
of 67%.  It was also noted that compounds with a high MPO score were found to 
have a greater chance of achieving favourable results in all four of the in vitro 
endpoints simultaneously. 
These results show that the CNS MPO calculator is a useful tool for evaluating 
design ideas for all compounds not just those designed for CNS penetration.  The 
use of the MPO calculator provides a holistic and flexible approach to drug design 
and increases the chances of discovering compounds with all the desired ADME and 
safety attributes aligned in one entity.   
 
2.8.2 MPO evaluation of heterocyclic compounds  
 
After evaluating the heterocyles synthesised so far it can be seen from Table 2.14 
that only one compound (22) meets the MPO criteria for a high probability of CNS 
penetration. Unfortunately this compound does not show activity below 1 µM at 
the α1 GlyR.   
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The rest of the compounds have a low MPO score (<4) and do not meet the criteria 
for a high probability of CNS penetration (MPO score 4-6).  Due to the colour coded 
nature of the MPO calculator (red = poor, yellow = moderate, green = good) for the 
transformed values, those parameters which fall short of the desired criteria are 
easily identified. From Table 2.14 it can be seen that the molecular weight, 
topological surface area and hydrogen bond donor values for the compounds are 
good to moderate. Those values that consistently fail are ClogP, ClogD and pKa.  
 
28 
 
32 
 
33 
Property Value T0 
ClogP 5.56 0.000 
ClogD 4.7 0.000 
TPSA 32.7 0.635 
MW 353.5 1.000 
HBD 1 0.833 
pKa 10.93 0.000 
CNS MPO 2.5 
 
Property Value T0 
ClogP 4.56 0.220 
ClogD 3.9 0.050 
TPSA 49.77 1.000 
MW 367.48 0.947 
HBD 1 0.833 
pKa 10.81 0.000 
CNS MPO 3.0 
 
Property Value T0 
ClogP 5 0.000 
ClogD 3.4 0.300 
TPSA 43.78 1.000 
MW 380.52 0.853 
HBD 1 0.833 
pKa 10.82 0.000 
CNS MPO 3.0 
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40 
 
41 
 
 
44 
Property Value T0 
ClogP 5.55 0.000 
ClogD 3.7 0.150 
TPSA 33.12 0.656 
MW 323.35 1.000 
HBD 1 0.833 
pKa 9.22 0.390 
CNS MPO 3.0 
 
Property Value T0 
ClogP 5.02 0.000 
ClogD 5.7 0.000 
TPSA 38.04 0.902 
MW 326.36 1.000 
HBD 1 0.833 
pKa 10.17 0.000 
CNS MPO 2.7 
 
Property Value T0 
ClogP 3.98 0.510 
ClogD 3.4 0.300 
TPSA 46.26 1.000 
MW 245.32 1.000 
HBD 1 0.833 
pKa 10.25 0.000 
CNS MPO 3.6 
 
 
Table 2.14. MPO evaluation of heterocylic compounds. 
 
Table 2.14 shows that all of the compounds synthesised so far have poor ClogP, 
ClogD and pKa values leading to low MPO scores and consequently, a reduced 
probability of CNS penetration. The decision was, therefore, taken to reassess the 
design approach to these molecules with respect to, the MPO calculator in an effort 
to increase the probability of CNS penetration and to increase the efficacy and 
metabolic stability of future analogues. 
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2.9 Summary  
 
In summary this chapter has shown the progression from propofol > halogenated 
series > 4-aryl series > 4- hetero/bi-phenyl series (Figure 2.16).  
 
Figure 2.16. Optimisation of propofol analogues targeting the α1 GlyR. 
 
Building upon work by Mohammadi, Bahram. Haeseler, Gertrud. Leuwer, Martin. 
Dengler, Reinhard. Krampfl, Klaus. & Bufler, Johannes.3 previous work within the 
group showed that halogenation at the 4-position of propofol could increase the 
efficacy for the α1 GlyR by ~3 orders of magnitude.  This led to further exploration 
of the binding pocket tolerances with respect to steric, electronic and hydrophobic 
interactions by incorporating a series of substituted aryl moieties at the 4-position 
(compounds 17-23). These compounds showed excellent in vivo activity with EC50 
values in the low nM/high pM region, exemplified by compound 19 (EC50 70pM). 
However, from the preliminary animal studies it was evident that the aqueous 
solubility needed to be enhanced in order to improve the pharmacokinetic profile of 
these compounds.  
A series of morphlino-bi-phenyl and heterocyclic containing compounds were 
synthesised in an effort to improve the physicochemical properties seen with the 
previous series, whilst retaining/improving efficacy at the α1 GlyR (Table 2.12). 
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From the compounds in this series tested so far only one compound (30) showed 
the low nM activity seen with the previous series.  
This compound has subsequently been tested for activity at the GABAA receptor and 
has been found to be an agonist at GABAA with an EC50 = 0.12 µM, rendering it 
unsuitable for this project.  
Evaluation of compounds 28, 32, 33, 40, 41 & 44  with the Pfizer MPO calculator has 
shown they all fall below the required score of ≥4 indicating a low probability of CNS 
penetration. With this in mind the decision was taken to redesign the series in order 
to synthesise molecules that retain low nM efficacy at the α1 GlyR and achieve MPO 
scores ≥4. 
The following chapters describe the rational design of a new series of compounds 
targeting the α1 GlyR from hit to lead optimisation.   
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3  Introduction 
 
It is evident from the previous chapter that the morphlino bi-phenyl and 
heterocyclic propofol analogues did not show desired efficacy at the α1 GlyR with 
only one compound (40) showing the low nanomolar activity seen with the 
halogenated and early biphenyl compounds.  
 
 
Figure 3.1. Compound 30 EC50  = 0.0001 µM at α1GlyR. 
 
 It was also shown in the previous chapter, via the MPO calculator, that the 
morphlino bi-phenyl and heterocyclic compounds had low probability of CNS 
penetration1. It was noted that the ClogP and ClogD of the compounds was, in 
general, too high (>5 & >3 respectively) and that this could have a negative effect 
on solubility and consequently oral bioavailability2.  
In order to identify molecules with a better profile we initially added solubilising 
groups to propofol in the form of morpholino substituents attached directly to the 
core of the propofol scaffold. We had incorporated morpholines to several of the bi-
phenyl compounds seen in the previous chapter (Table 2.12) but they were highly 
lipophilic and did not show any activity up to 1 µM at the α1 GlyR. 
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 We decided we wanted to keep the favourable solubilising properties of the 
morpholines but to remove the B-ring in an effort to lower ClogP and to reduce the 
overall steric bulk of the molecules. With this in mind, a review of the literature 
revealed a paper by Cooke, Anderson and Buchanan et al3. that described a series of 
propofol analogues containing para-aminoalkyl substituents (Figure 3.2). These 
molecules were designed as water-soluble versions of propofol  targeting the GABA 
receptor3.  
 
Figure 3.2. Para-aminoalkyl substituents described by Cooke and co-workers. 
In this work it was shown that whilst several para aminoalkyl analogues retained 
some hypnotic effect in mice (albeit with HD50 values in micromolar range), the para 
aminoalkyl analogues did not target the GABAA, receptor indicating the hypnotic 
effect was not mediated by the GABAA receptor as expected.  It is also of interest to 
note that none of the para aminoalkyl analogues synthesised by Cooke, Anderson 
and Buchanan et al. were tested for efficacy at the GlyR. It was thought that if the 
para aminoalkyl propofol analogues were active at the GlyR in the low nanomolar 
range, as seen with the halogenated and biphenyl series, this could confer 
selectivity over the GABAA receptor and significantly reduce off target hypnotic 
activity. It was therefore decided to synthesise a series of propofol analogues with 
para aminoalkyl groups for testing against the α1 GlyR. One of the ways in which 
the amino functionality can be introduced into the propofol core is via the Mannich 
reaction. 
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3.1 Mannich side chain 
 
The Mannich reaction is one of the most important and versatile C-C bond forming 
reactions in organic synthetic chemistry4. The widespread use of the Mannich 
reaction is undoubtedly due to the diversity of functional groups tolerated and the 
variety of applications found for this robust reaction5.  The introduction of Mannich 
side chains to biologically active compounds has been shown to improve solubility, 
bioavailability and, in some cases such as artemisinin (46), topotecan (47), and 
clioquinol (48), can result in increased potency6-9.   
 
 
Figure 3.3.  Mannich derivatives with increased biological activity with respect to 
parent compounds  
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The mechanism of the Mannich reaction proceeds via the formation of an imine salt 
from the amine and formaldehyde with the elimination of water. The electrophilic 
salt is then able to add into the phenolic ring (Scheme 3. 1). 
 
Scheme 3. 1. Mechanism of the Mannich reaction. 
 
The Mannich reaction can be accomplished in a variety of different ways10-12; we 
performed the reaction by sequentially adding propofol, the secondary amine of 
choice and formaldehyde to aqueous ethanol. The reaction mixture was heated to 
reflux for ~16 hours before being quenched with water, extracted with ethyl 
acetate and washed with brine (Scheme 3.2) 
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Scheme 3.2. Reagents and conditions: i) CH2O, secondary amine, EtOH/H2O, reflux 
16hrs  70-89% yields. 
Flash column chromatography gave the desired Mannich products, compounds 49-
55 (Figure 3.4).  
 
 
Figure 3.4. Mannich products. 
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In addition to saturated small molecule heterocycles we also considered the use of 
basic heterocycles. Imidazoles are present in many natural and synthetic 
pharmacologically active compounds including, antibacterial, antifungal, anticancer 
and anti-HIV agents. These nitrogen containing aromatic heterocycles are often 
incorporated into medicinal compounds where their polar and ionisable 
characteristics can optimise the solubility and bioavailability parameters of poorly 
soluble compounds13,14 (Figure 3.5).  
 
Figure 3.5. Imidazole Mannich side chain. 
The synthesis of the imidazole Mannich side chain began with the formylation of 
propofol. 4-Formyl propofol was prepared by addition of hexamethylenetetramine 
to a solution of propofol dissolved in acetic acid (Scheme 3.3)15,16. The reaction 
proceeded in good yields without the need for purification. The presence of the 
product was confirmed by a signature aldehyde shift at 10 ppm in the 1HNMR17.  
 
 
Scheme 3.3. Reagents and conditions: i) Hexamethylenetetramine, AcOH, reflux 
16hrs, 89% yield. 
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The aldehyde 56 was then reduced to the benzyl alcohol 57 using lithium aluminium 
hydride, this reaction was carried out in anhydrous THF at 0OC (Scheme 3.4). The 
newly formed alcohol was characterised by the loss of the aldehyde singlet at 
10ppm and by the appearance of a new singlet at 4.52ppm in the 1HNMR 
integrating for two protons corresponding to the benzyl alcohol linker.  
 
 
Scheme 3.4. Reagents and conditions: i) LiAlH, anhydrous THF, 0OC, 30min 80% 
yield. 
Addition of the imidazole ring was afforded by allowing the alcohol to stir in the 
presence of excess imidazole at 160OC to give compound 55 in 50% yield.  
 
 
 
Scheme 3.5. Reagents and conditions: i) Imidazole, 160OC, 2hrs, 50% yield18.   
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3.1.1 In silico testing  
Before being sent for in vitro testing against the α1 GlyR compounds 49-55 were 
screened in silico in order to predict their physicochemical parameters, ClogP, 
ClogD, aqueous solubility and for their predicted clearance from human 
microsomes and rat hepatocytes (Table 3.1)19. In silico QSAR models were built and 
validated (using cross validation) using a set of descriptors (structural counts, 
topological indices and physicochemical property descriptors) and standard 
statistical tools: a Support Vector Machine (SVM), partial least squares (PLS) and 
Random Forest (RF) models. QSAR modelling and validation practice maximizes the 
robustness of models that are built and selected for use. Following thorough 
analyses of historical data, the parameters for the statistical methods used in have 
been empirically chosen and fixed to maximize performance and reliability. 
Table 3.1. In silico prediction of physicochemical and pharmacokinetic parameters 
of benzyl compounds. Human Microsomes,  0-30 green, 30-60 yellow, 60 and above 
red. Rat Hepatocytes, 0-30 green, 30-60 orange, 60 and above red. ClogD7.4, 1-4 
green, <1 OR >4 red.          
Compound Parameters Radar plot 
 
49 
ClogD 7.4 3.45 
 
Human 
Mic 
(µl/min/mg) 
84.35 
Rat Hep 
(µl/min/106 
cells) 
333.5 
 
50 
 ClogD 7.4 4.26 
 
Human 
Mic 
(µl/min/mg) 
368 
Rat Hep 
(µl/min/106 
cells) 
83.50 
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51 
ClogD 7.4 2.95 
 
Human 
Mic 
(µl/min/mg) 
51.37 
Rat Hep 
(µl/min/106) 
205.3 
 
52 
ClogD 7.4 3.82 
 
Human 
Mic 
(µl/min/mg) 
57.90 
Rat Hep 
(µl/min/106 
cells) 
62.55 
 
53 
 ClogD 7.4 3.82 
 
 
Human 
Mic 
(µl/min/mg) 
57.90 
Rat Hep 
(µl/min/106 
cells) 
62.55 
 
54 
 ClogD 7.4 3.22 
 
Human 
Mic 
(µl/min/mg) 
57.17 
Rat Hep 
(µl/min/106 
cells) 
50.82 
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55 
ClogD 7.4 3.65 
 
Human 
Mic 
(µl/min/mg) 
54.21 
Rat Hep 
(µl/min/106 
cells) 
123.90 
 
It can be seen from . In silico QSAR models were built and validated (using cross 
validation) using a set of descriptors (structural counts, topological indices and 
physicochemical property descriptors) and standard statistical tools: a Support 
Vector Machine (SVM), partial least squares (PLS) and Random Forest (RF) models. 
QSAR modelling and validation practice maximizes the robustness of models that 
are built and selected for use. Following thorough analyses of historical data, the 
parameters for the statistical methods used in have been empirically chosen and 
fixed to maximize performance and reliability. 
Table 3.1 that ClogD remains high in many of the compounds with only 51 showing 
a ClogD value within the acceptable parameter of <3. Therefore more work needs 
to be done to lower the ClogD and this could be achieved by the addition of more 
polar substituents. The aqueous solubility of many of the compounds is high (>50 
µM), as expected those compounds with higher ClogP values (50, 52 &53, ) typically 
fall below the optimal solubility value as can be seen in the radar plots (Table 3.1).  
The radar plots give a good visual representation of the ideal values vs. the 
predicted values for ClogD, solubility, human microsomes and rat hepatocytes. The 
shaded areas of the plots show where the ideal values for each parameter should 
lie. 
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The predicted rate of clearance in both human liver microsomes (for phase I 
metabolism) and rat hepatocytes (phase I and phase II metabolism) was evaluated 
using our metabolism prediction software. It can be seen from Table 3.1 that all of 
the compounds are extensively metabolised in both models. It is thought that phase 
I metabolism would occur predominantly at the benzylic linker, with minor 
contributions from hydroxylation of the isopropyl and morpholino substituents20,21, 
whereas phase II  metabolism would mediated through glucuronidation (by uridine 
diphosphate glucuronosyltransferases) of both  the phenolic hydroxyl group and the 
hydroxy products of phase I metabolism. 
In addition to the 2,6-diisopropyl series we also examined a series of bis-tert-butyl 
propofol analogues since as it had previously been shown that 2,6-di-tert-
butylphenol displays no anaesthetic properties22. 
3.1.2 Tert-butyl analogues with Mannich side chains 
 
In a 2001 study by Krasowski  and co-workers, 27 different propofol analogues were 
screened for anaesthetic activity and for potentiation of the most common GABAA 
subtype (α1β2γ2s) 
23. Anaesthetic activity was determined by loss of righting reflex 
(LRR) in Xenopus laevis tadpoles, whilst GABA potentiation was determined via 
electrophysiological studies using HEK 293 cells24,25. 2,6-di-tert-butylphenol (Figure 
3.6) , was one of the compounds chosen by  Krasowski for this study not only 
because it is one of the closest structural analogues of propofol but  also because it 
had shown no anaesthetic properties in mice in previous studies by Glen and co-
workers26.  
 
Figure 3.6. 2,6-Di-tert-butylphenol.  
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The results of the study by Krasowski showed that 2,6-di-tert-butylphenol  did not 
display any anaesthetic activity in the Xenopus laevis tadpoles, but crucially 
electrophysiological results showed that 56 did not potentiate the GABAAR, either 
directly or by co-activation.  
These results lend weight to the hypothesis that alteration of GABA functionality is, 
at least in part, responsible for the anaesthetic effects of propofol. This hypothesis 
was tested once again by Ahrens and co-workers who tested 2,6-di-tert-butylphenol 
against rat GABA receptors within a mammalian expression system (HEK 293 cells). 
Once again it was determined that it showed no potentiation of GABA current22.  
In an earlier publication, Ahrens and co-workers had compared the effects of both 
propofol and 2,6-di-tert-butylphenol at the rat α1 GlyR (in HEK 93 cells)27.   
From this study it was determined that  propofol has the ability to both directly 
activate and co-activate the α1 GlyR (EC50 = 12.5 µM), addition of the GlyR 
antagonist strychnine increased the immobilising EC50 of propofol by ~50% whereas 
addition of GABA antagonist picrotoxin (57 & 58) or gabazine (59), gave a 400% 
increase in propofol’s immobilising EC50 (Figure 3.7).  
 
  
Figure 3.7.  Gaba antagonists picrotoxin (57 & 58) and gabazine (59). 
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These results give credence to the hypothesis that glycine potentiation is not 
required for the immobilising effects of propofol. Importantly this study also shows 
that the propofol analogue 2,6-di-tert-butylphenol can co-activate and directly 
activate the α1 GlyR (EC50 = 9.4 µM) from a distinct binding site (allosterically).  
 
Armed with the knowledge that 2,6-di-tert-butylphenol could selectively target the 
GlyR, with respect to the GABAAR, it was decided to synthesise a number of 2,6-di-
tert-butylphenol analogues with the Mannich side chains seen with the propofol 
analogues (Figure 3.4). 
 
Synthesis of the 2,6-di-tert-butylphenol Mannich analogues (Scheme 3.6) is 
analogous to that seen in Scheme 3.210. 
 
 Scheme 3.6. Reagents and conditions: i) CH2O, secondary amine, EtOH/H2O, reflux 
16hrs 70-89% yields. 
 
 
 
 
 
Chapter III 
 
 
119 | P a g e  
 
 
 
Figure 3.8. 2,6-Di-tert-butyl Mannich analogues.  
3.1.3 In silico testing 
 
The 2,6-di-tert-butyl Mannich analogues were also subjected to the same  in silico 
prediction model as the 2,6-di-i-pr Mannich analogues in an effort to determine the 
effect of adding the increasingly lipophilic tert-butyl groups upon the ColgP, ClogD, 
solubility and metabolism of the compounds (Table 3.2).  
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Table 3.2. In silico prediction of tert-butyl morpholino analogues.  
 
Compound Parameters Radar plot 
 
60 
 ClogD 7.4 4.14 
 
Human 
Mic 
(µl/min/mg) 
48.81 
Rat Hep 
(µl/min/106 
cells) 
293.6 
 
61 
 ClogD 7.4 4.82 
 
Human 
Mic 
(µl/min/mg) 
175.3 
Rat Hep 
(µl/min/106 
cells) 
592.4 
 
62 
 ClogD 7.4 3.93 
 
Human 
Mic 
(µl/min/mg) 
60.92 
Rat Hep 
(µl/min/106 
cells) 
228.0 
 
63 
 ClogD 7.4 4.48 
 
Human 
Mic 
(µl/min/mg) 
67.37 
Rat Hep 
(µl/min/106 
cells) 
288.8 
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64 
 ClogD 7.4 4.48 
 
Human 
Mic 
(µl/min/mg) 
67.37 
Rat Hep 
(µl/min/106 
cells) 
288.8 
 
As can be seen from Table 3.2 the addition of the tert-butyl group had a negative 
effect upon the distribution co-efficient with ClogD increasing to unacceptable 
levels. There is, in general no difference in the TPSA of the molecules as the overall 
polarity of the compounds has remained unchanged (Table 3.5) but the increased 
lipophilicity has had a detrimental effect upon the solubility of the compounds to 
such an extent that none of the compounds now hit the 50 µM solubility target. The 
phase I metabolism (human microsomes) of the compounds remains broadly similar 
to that of the i-pr-Mannich analogues with only slight reduction. 
Predicted phase II clearance (see predicted hepatocyte clearance data) for 60 and 
61, indicated some improvements compared with analogues 49 and 50. This 
reduction in predicted clearance could be due to the increased steric bulk of the 
tert-butyl group preventing gulcuronidation of the phenolic hydroxyl group.  
 
3.1.4 Biological results and MPO evaluation  
 
Due to the time consuming nature of developing a stable cell line and the large 
amounts of cells required for electrophysiological testing, only a small selection of 
compounds synthesised were able to be tested.  Several Mannich compounds were 
selected for testing against α1 GlyR, their EC50 values are shown in Table 3.3. In 
order to prevent the unwanted side effects seen with compounds that target the 
GABAAR, selected compounds were be tested for efficacy against the GABAAR 
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(α1β2γ3 subtype). Compounds that are selective need to display a 100 fold more 
efficacious EC50 at the GlyR than the GABAA receptor. 
Table 3.3. EC50 results from electrophysiology testing of compounds 49-51 & 55. 
Compound 
EC50 
(µM)a 
ClogP b ClogD c 
GABAA EC50 
(µM) d 
 
49 
>1 3.68 2.70 30 µM ± 0.120 
 
50 
>1 4.41 4.10 NT 
 
51 
>1 4.21 2.70 NT 
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55 
>1 3.84 3.60 NT 
a, α1 GlyR EC50 values determination was carried out at the University of Tübingen under the 
supervision of Prof. Bodo Laube.b, ClogP values were determined using chembiodraw ultra 12 
software. c, In house algorithm. d, GABAA selectivity testing was carried out at BioFocus®, 
Chesterford Research Park, Saffron Walden, UK. 
Disappointingly it can be seen from Table 3.3 that none of the Mannich base 
analogues have activity below 1 µM at the α1 GlyR.  We decided to examine the 
MPO scores of the both the i-pr and tert-butyl Mannich compounds in order to 
ascertain how their physicochemical parameters differ from the bi-phenyl 
compounds shown in chapter II. The results of the MPO evaluation for the i-pr and 
tert-butyl are shown in Table 3.4 and Table 3.5 respectively.  
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Table 3.4.  MPO evaluation of benzyl amine compounds. 
 
 
49 
 
 
50 
 
 
51 
   
 
 
52 
 
 
53 
 
 
54 
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55 
 
 
 
 
 
 
 
 
 
Table 3.4 depicts the MPO evaluations for the benzyl amine series. As can be seen 
from the table none of the compounds meet the criteria for optimal probability of 
CNS penetration (for optimal probability of CNS penetration the overall CNS MPO 
should be score >4)158. From the breakdown of the parameters for each compound 
it can be seen that the ClogP and ClogD values are marginally too high (transformed 
value,T0 of 1.000 is the optimal value) whilst the TPSA of the compounds is too low.  
The TPSA for many of the compounds falls outside the acceptable range of 40-120 Å 
(the ideal range being 60-90 Å)158. The TPSA is defined as the contributions of all of 
the polar atoms in a given molecule, therefore, addition of O or N bearing 
substituents could be incorporated in an effort to bring the TPSA above the 
acceptable parameters. The molecular weight (MW) of the compounds is in the 
optimal region but the hydrogen donor contribution of the compounds could be 
improved. The pKa of the compounds is also consistently too high, the optimal 
value for BBB penetration and, therefore, access to the CNS is between 4-1028,29.  
The pKa of the compounds can be modulated by addition of either an electron 
withdrawing group (NO2,CN,CO2Me) which can reduce the nucleophilicity of the 
hydroxyl group via the inductive effect when added ortho or para to the hydroxyl 
group.  
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Table 3.5. MPO evaluation of tert-butyl amine analogue 
 
 
60 
 
 
61 
 
 
62 
   
 
 
63 
 
 
64 
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Table 3.5 shows the substantial deleterious effects on the MPO scores of a simple 
substitution from an isopropyl to a tert-butyl group. The ClogP, ClogD and pKa 
values have all increased leading to a significant reduction in MPO scores. None of 
the compounds have MPO scores >3 which leads to a reduction in the probability of 
any of these compounds passing the BBB and reaching the target α1 GlyR located 
within the CNS.  
It is clear from the in silico screening EC50 results and MPO evaluations that none of 
the compounds synthesised in the Mannich series have the physicochemical 
characteristics (ClogP <3, ClogD <3), the optimal MPO scores (>4) or the potency to 
be viable CNS penetrant analgesic drugs targeting the α1 GlyR 1. These compounds 
are also predicted to be highly susceptible to both phase I & phase II metabolic 
clearance. As the data recorded in Table 3.3 reveals that this template has poor 
allosteric glycinergic activity making the decision to terminate this series relatively 
easy. An additional potential liability with this template is outlined in the following 
section.    
3.1.5 Quinone methides 
 
The benzyl amines depicted above (49-55 & 60-64) have a structural alert for the 
formation of a quinone methide reactive metabolic intermediate.  
Quinone methides (QM’s) (Figure 3.9) are reactive metabolites of a variety of ortho 
or para alkyl substituted phenolic compounds. QM’s are thought to be responsible 
for the cytotoxic/genotoxic effects of the parent compounds such as drug-induced 
liver injury (DILI) or idiosyncratic adverse drug reactions (IADR’s) 30,31. 
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Figure 3.9. Ortho  and para quinone methides. 
 
QM’s are highly reactive electrophilic species that react rapidly with a variety of 
biologically relevant nucleophiles including alcohols, thiols, proteins, water, and 
DNA. Due to their reactivity QM’s often go undetected, but their formation has 
been inferred by trapping them out with reactive nucleophiles such as N-
acetylcysteine or glutathione32,33. 
 
QM intermediates can be formed by three major pathways (Scheme 3. 7);  
1) Two electron enzymatic oxidation 
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2) Ortho-quinone isomerisation 
 
 
 
3) Elimination of a leaving group 
 
 
 
 
Scheme 3. 7. 3 major pathways of QM formation (adapted from Bolton 32) 
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QM formation has been implicated in the hepatotoxicity or IADR’s of several 
marketed drugs. Nevirapine (67 )is a non-nucleoside reverse transcription inhibitor 
(NNRTI) used in the treatment of HIV-1 and AIDS34. Nevirapine is known to cause 
idiosyncratic hetpatoxicity and adverse skin reactions. In 2000 the FDA issued a 
black box warning on nevirapine, warning that it could cause severe liver damage 
including liver failure35. It is thought that both mechanisms of toxicity could be due 
to the formation of o-QM intermediates (68) formed during the bioactivation of 
nevirapine (Scheme 3.8)36,37.   
 
 
Scheme 3.8. Two electron oxidation of nevirapine to the QM intermediate. 
The antidiabetic and anti-inflammatory agent troglitazone (59 )was withdrawn from 
the market after reports of idiosyncratic adverse reactions leading to drug induced 
hepatitis and liver failure38. The hepatotoxicity of troglitazone has also been 
ascribed to the formation of reactive o-QM metabolites (70) (Scheme 3.9)39.  
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Scheme 3.9. Two electron oxidation of troglitazone to the QM intermediate 
Similarly the anaesthetic agent phencyclidine (PCP, 71) was withdrawn from the 
market soon after introduction due to the emergence of adverse drug reactions 
which included a schizophrenia like psychosis40. It is thought the psychosis may be 
induced by the binding of reactive metabolites of PCP to crucial proteins within the 
CNS. Phencyclidine is also known to be a potent inhibitor of CYP450-2B6, it is 
thought that the formation of p-QM metabolites of PCP is responsible for both 
mechanisms of toxicity (Scheme 3.10)41,42.  
 
Scheme 3.10. CYP450 mediated hydroxylation and subsequent base catalysed 
elimination of piperidine to form the p-QM of PCP. 
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Therefore, in order to mitigate against potential p-QM formation we decided to 
introduce a substituent at the methylene position to block the formation of the 
reactive metabolite. There are several strategies available for blockade of the 
metabolic activation pathway including, introduction of steric hindrance in the 
vicinity of metabolic degradation43, structural modification in order to redirect 
metabolism44, or the introduction of a metabolically stable substituent at the site of 
metabolism, as seen with the fluorination of the antiepileptic agent felbamate 
(Scheme 3.11).     
 
Scheme 3.11.  Fluorination at the site of metabolic transformation of felbamate 
prevents formation of the toxic metabolite 2-penylpropenal33. 
 
It was, therefore, decided that in order to block the potential formation of the 
reactive QM intermediate we would introduce a carbonyl function at the site of the 
methylene linker.  
The introduction of an amide functionality will not only mitigate against the 
formation of the reactive intermediate but addition of the polar carbonyl group will 
also lower the lipophilicity of the molecules and increase the overall TPSA. The 
presence of the carbonyl might also influence the pKa and reduce the rate of phase 
II clearance by reduction of the nucleophilicity of the phenolic hydroxyl group.  
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3.2 Amide morpholino analogues 
 
Based upon the rationale noted above, we designed a series of series of amide 
analogues of the benzylamino series (49-54). A retrosynthetic analysis is depicted in 
Scheme 3.12 where disconnection takes us back to propofol as a starting material. It 
was proposed that formylation of propofol, oxidation and amide coupling of the 
acid would furnish the desired targets. 
 The acid can then undergo an amide coupling reaction with the appropriate 
secondary amine to form the desired amide (Scheme 3.12). 
 
 
Scheme 3.12. Retrosynthetic analysis. 
 
Target synthesis began with the formylation of propofol (as shown in Scheme 
3.3).The next step was to oxidise the aldehyde (56) to the carboxylic acid (80).  
Initial studies employed a Pinnick oxidation using sodium chlorite (NaClO2) (Scheme 
3.13)45,46 This reaction was first performed without the inclusion of 2-methyl-2-
butene. Whilst the reaction was successful the yield of the carboxylic acid was very 
poor, ~10%.   
  
Chapter III 
 
 
134 | P a g e  
 
 
 
Scheme 3.13. Reagents and conditions: i) NaClO2, t-BuOH, NaH2PO4, 2-methyl-2-
butene, RT, 16hrs 40% yield. 
It is thought that during the oxidation, hypochlorous acid (HOCl, 83) is formed 
which reacts with the NaClO2 rendering it unable to oxidise the aldehyde (44). To 
prevent this possible side reaction 2-methyl-2-butene (81) is added as a scavenger.  
HOCl reacts with double bonds of the 2-methyl-2-butene (83) via a halohydrin 
formation reaction and, therefore, HOCl reacts with the sacrificial 2-methyl-2-
butene before it can react with NaClO2 (Scheme 3.14). 
 
 
Scheme 3.14. Reaction of 2-methyl-2-butene scavenger with HOCl to form 
halohydrin.  
When the reaction was subsequently performed with the alkene scavenger present 
the yield did improve somewhat, giving ~40% yields. It was noted however, that 
there were many side products also formed in the reaction and purification of the 
carboxylic acid was very difficult. It was, therefore, decided to find a different route 
to oxidation of the aldehyde (56).  
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A search of the literature found an oxidation method using catalytic quantities of 
selenium (IV) oxide in hydrogen peroxide47.  The first step in the reaction sequence 
was to protect the phenolic hydroxyl group of the aldehyde as a benzyl ether (84).  
The benzyl ether protecting group was chosen because it is stable to both acidic and 
basic conditions and it is also resistant to many oxidants such as KMnO4, OsO4 and 
CrO3
48. Protection of the hydroxyl group was afforded by addition of benzyl bromide 
to a solution of aldehyde in acetone, in the presence of potassium carbonate. The 
facile reaction proceeded in high yields48 (>70%) (Scheme 3.15). 
 
 
 
Scheme 3.15. Reagents and conditions: i) BnBr, K2CO3, acetone, RT, 18hrs, 88% 
yield. 
The oxidation of the benzyl protected aldehyde (84) was carried out with hydrogen 
peroxide (27% solution) in the presence of catalytic amounts of Selenium (IV) oxide. 
The reaction was allowed to heat overnight and upon completion the remaining 
oxidant was quenched with palladium/carbon. The reaction proceeded well and 
gave the desired carboxylic acid (85) in good yields 70% (Scheme 3.16).    
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Scheme 3.16. Reagents and conditions: i) SeO2, H2O2, THF, reflux, 18hrs 70% yield. 
 
The amide bond was formed by the condensation of an acid chloride with the amine 
of choice. The first step in the amide formation was to synthesise the acid 
chloride49.  
This was achieved by addition of oxalyl chloride to a solution of 85 in the presence 
of triethylamine. The reaction is promoted by catalytic quantities of 
dimethylforamide (DMF), the catalytic role of DMF is shown in Scheme 3.17. 
 
 
Scheme 3.17. The catalytic role of dimethylformamide. 
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The acid chloride (86) is a very reactive species and, therefore, was not isolated and 
was taken through to the next stage (Scheme 3.18). 
 
 
 
Scheme 3.18. Reagents and conditions: i) Benzyl protected acid, oxalyl chloride, 
Et3N, DMF, DCM, RT, 2hrs. 
The amide coupling began with the addition of the amine of choice to a solution of 
acid chloride (86) and triethylamine in dichloromethane. The reaction was allowed 
to stir at room temperature overnight (Scheme 3.19).  
 
 
 
Scheme 3.19.  Reagents and conditions: i) Secondary amine, Et3N, DCM, RT, 18hr 
65-70% yields50.  
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There are several methods for benzyl deprotection including the use of strong acids 
or via oxidation of the benzyl to the benzoate and subsequent hydrolysis under 
basic conditions51,52. We chose to deprotect the amide analogues by palladium 
catalysed hydrogenation, delivering the free phenol and toluene (Scheme 3.20). 
This is a very simple easy method of deprotection which gave the desired product in 
very high yields (>95%)53.  
  
 
 
Scheme 3.20.  Reagents and conditions: i) Pd/C, H2, MeOH, RT, 18hrs, 95-98% 
yields. 
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3.2.1 i-pr-Amide  in silico testing 
 
The i-pr-amide analogues (77-79) were also screened in silico to determine the 
predicted physicochemical and metabolic stability parameters. 
Table 3.6. In silico predictions of the i-pr-amide analogues. 
Compound Parameters Radar 
 
77 
 ClogD 7.4 2.88 
 
Human 
Mic 
(µl/min/mg) 
31.21 
Rat Hep 
(µl/min/106 
cells) 
87.41 
 
78 
 ClogD 7.4 2.67 
 
Human 
Mic 
(µl/min/mg) 
30.28 
Rat Hep 
(µl/min/106 
cells) 
97.44 
 
79 
 ClogD 7.4 3.46 
 
Human 
Mic 
(µl/min/mg) 
93.33 
Rat Hep 
(µl/min/106 
cells) 
39.81 
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As expected addition of the carbonyl group has had the desired effect of reducing 
the predicted physicochemical parameters of ClogP and ClogD as well as increasing 
the TPSA.  
Inclusion of the amide functionality has also improved the predicted 
physicochemical properties and rate of metabolic turnover for the proposed target 
molecules.  
Table 3.7 shows a direct comparison between compounds 49 & 77. It can be seen 
that the ClogP of 77 has been reduced to 3.10, the ClogD has been reduced to 2.88 
whilst the TPSA has been increased to 49.80. this should enable better absorption 
membrane permeability and CNS penetration54-56. Predicted metabolism of 77 also 
has been significantly reduced in both microsomes and hepatocytes. 
 
Table 3.7. Direct comparison of physicochemical and metabolic predicted 
parameters for compounds 49 & 77. 
 
49 
 
77 
3.67 ClogP 3.10 
3.45 ClogD 7.4 2.88 
32.70 TPSA 49.80 
84.35 
Human 
Mic 
(µl/min/mg) 
31.21 
333.5 
Rat Hep 
(µl/min/106 cells) 
87.41 
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The MPO scores of the i-pr-amide analogues were examined in order to determine 
their probability for BBB penetration (Table 3.8). 
Table 3.8. MPO evaluation of the i-pr-amide analogues 
 
 
77 
 
 
78 
 
 
79 
   
 
With the reduction in both ClogP and ClogD increase in TPSA compounds 77 & 78 
now meet the criteria for optimal CNS penetration with overall CNS MPO scores 
>41.    
3.2.2 Tert-butyl amide analogues. 
 
With the improvements seen in the predicted physicochemical parameters and 
metabolic stability of the i-pr-amide compounds, it was decided to also synthesise 
several di-tert-butyl amide analogues in an effort to both improve the predicted 
properties and to confer selectivity for the GlyR as discussed earlier (section 3.1.2).  
The synthesis of the di-tert-butyl amide analogues began with the commercially 
available 3,5-di-tert-butyl-4-hydroxybenzoic acid. 
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 The benzoic acid was first converted to the acid chloride using the same conditions 
seen in Scheme 3.18, before being subjected to the amide coupling conditions 
analogous to Scheme 3.19 (Scheme 3.21).  
 
  
Scheme 3.21.  Reagents and conditions: i) Oxalyl chloride, Et3N, DMF, DCM, RT, 
2hrs. ii) Acid chloride, amine, Et3N, DCM, RT, 18hrs, 68-91 % yields. 
 
3.2.3 Tert-butyl in silico testing 
 
The tert-butyl amide compounds 92-96 were also put through the in silico screen to 
determine their predicted physicochemical and metabolic stability parameters 
(Table 3.9). 
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Table 3.9. In silico predictions of the tert –butyl amide analogues. 
 
Compound Parameters Radar plot 
 
92 
ClogD 7.4 3.51 
 
Human 
Mic 
(µl/min/mg) 
22.35 
Rat Hep 
(µl/min/106 
cells) 
78.68 
 
93 
ClogD 7.4 4.26 
 
Human 
Mic 
(µl/min/mg) 
112.9 
Rat Hep 
(µl/min/106 
cells106 
cells) 
378 
 
94 
ClogD 7.4 3.80 
 
Human 
Mic 
(µl/min/mg) 
49.48 
Rat Hep 
(µl/min/
106
) 
152.7 
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95 
ClogD 7.4 3.80 
 
Human 
Mic 
(µl/min/mg) 
49.48 
Rat Hep 
(µl/min/
106
) 
152.7 
 
96 
ClogD 7.4 4.33 
 
Human 
Mic 
(µl/min/mg) 
73.85 
Rat Hep 
(µl/min/
106
) 
250.5 
 
Again Table 3.9  shows that, in general, the addition of the amide function has 
reduced the ClogP and ClogD of compounds 92-96 and increased the TPSA. The 
predicted metabolic stability of 82, 83 & 86 has also improved, but interestingly 
compounds 94 & 95 (with the di-methyl morpholine substituents) have seen a 
predicted increase in their metabolic degradation. Table 3.10 shows a direct 
comparison between the predicted physicochemical and metabolic parameters of 
the tert-butyl Mannich morpholine and the tert-butyl amide morpholine. 
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Table 3.10. Direct comparison of the predicted physicochemical and metabolic 
parameters of the tert-butyl Mannich and amide morpholines. 
 
60 
 
92 
4.67 ClogP 4.10 
4.14 ClogD 7.4 3.51 
32.70 TPSA 49.77 
48.81 
Human 
Mic 
(µl/min/mg) 
22.35 
293.6 
Rat Hep 
(µl/min/106) 
78.68 
 
The same trend can be seen with the tert-butyl compounds 90 & 92 as was shown 
in Table 3.7 for the i-pr compounds 49 & 77, that is to say, a decrease in both 
predicted ClogP and ClogD values and an increase in TPSA. 
 Although an improvement has been seen with the physicochemical parameters 
ClogP and ClogD they both still exceed the optimal values of <3 for maximum 
probability of CNS penetration2. The TPSA has also improved although again it falls 
below the ideal value of  >60 Å it is now above the >40 Å minimum cut-off146. Again 
the metabolic stability for compound 92 has improved with respect to 49, with a 
predicted reduction in both phase I and phase II metabolic degradation. The MPO 
scores of the tert-butyl amide compounds 92-96 were also evaluated (Table 3.11). 
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Table 3.11. MPO evaluation of the tert-butyl amide analogues 
 
 
 
 
 
 
 
 
 
92 93 94 
   
 
 
95 
 
 
 
96 
  
Chapter III 
 
 
147 | P a g e  
 
As can be seen from  Table 3.11 the improvements in the physicochemical 
parameters ClogP and ClogD and an increase in the TPSA has improved the MPO 
scores, with respect to the tert-butyl Mannich analogues 60-64 (Table 3.5). But all of 
the compounds still fall short of reaching the optimal score of >4. For all of the 
compounds in the tert-butyl amide series 92-96, the ClogP and ClogD still exceed 
the optimal value <3, although the TPSA, MW and HBD values are in acceptable 
ranges the pKa values are also too high.   
Many of the compounds synthesised so far fall short of the desired criteria, in terms 
of the physicochemical parameters ClogP <3 , ClogD ,,3, the pKa ≤8 and the overall 
MPO score ≥4. It is, however, important to subject these compounds to the α1 GlyR 
in vitro assay in an effort to identify an early lead compound which could be taken 
through to a lead optimisation programme.  
  
3.3 Biological results 
 
The in vitro activities of compounds 77-79 & 92  were evaluated in the 
electrophysiology whole-cell voltage-clamp assay using HEK293 cell as described in 
chapter II. The results of the in vitro studies are shown in Table 3.12. 
Table 3.12. In vitro EC50 values for amide linked compounds tested against the 
recombinant α1GlyR 
Structure EC50 (µM) 
a ClogP b ClogD c GABAA (µM) 
d 
 
77 
0.00035 ± 0.00002 3.10 2.80 30 ± 0.120 
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78 
0.0000012 ± 0.4 3.54 2.30 NT 
 
79 
>1 3.83 4.40 NT 
 
92 
0.00046 ± 0.0002 4.10 4.70 30 ± 0.145 
a, α1 GlyR EC50 values determination was carried out at the University of Tübingen under the 
supervision of Prof. Bodo Laube. b, ClogP values were determined using chembiodraw ultra 12 
software. c, In house algorithm d, GABAA selectivity testing was carried out at BioFocus®, Chesterford 
Research Park, Saffron Walden, UK. NT = not tested. 
It can be seen from Table 3.12, several of the amide analogues (77, 78 & 92) have 
shown low nM efficacy at the α1GlyR. It was therefore, decided to send these 
compounds for further studies in order to assess their susceptibility to metabolism. 
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3.3.1 Metabolic stability studies 
Encouraged by the low EC50 values of i-pr-amides 77 & 78, and tert-butyl amide 92, 
these compounds were selected for further in vitro metabolism studies. Microsomal 
stability studies were carried out at the Liverpool School of Tropical Medicine. These 
investigations utilised human (HLM) and rat (RLM) liver microsomes (1mg/mL) at a 
concentration of 1 µ M in the presence of NADPH for 0, 10, 30 and 60 mins (Figure 
3.10).  
 
Figure 3.10. in vitro metabolism studies for compounds 77, 78 & 92 in human and 
rat liver microsomes. 
Figure 3.10 shows that compound 78 is extensively metabolised in HLM with only 
7% remaining after 60 mins. It is thought that the high rate of turnover seen with 78 
is a consequence of metabolism at the N-methyl moiety.  
Compounds 77 & 92 are relatively stable in both systems with 92 having 73% 
remaining in RLM and 90% remaining in HLM. Compound 77 proved to be the most 
resistant to phase I metabolic degradation with 94 % remaining in RLM and 90% in 
HLM.  The in vitro half-lives and intrinsic clearance values are recorded in Table 
3.13. 
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Table 3.13. Metabolic stability of compounds 77, 78 & 92 in human and rat 
microsomes. Human and rat liver microsomes (1mg/mL) at a concentration of 1 µ M 
in the presence of NADPH for 0, 10, 30 and 60 mins, n = 2. Studies carried out at the 
Liverpool School of Tropical Medicine. 
Compound 
In vitro half-life t 1/2 
(min) 
Intrinsic clearance 
mL/min/kg 
RLM HLM RLM HLM 
77 770 495 1.6 1.75 
78 46 126 26.88 6.9 
92 165 407 7.5 2.1 
 
Compounds 77 & 92 were selected to undergo further in vitro stability studies with 
human and rat liver hepatocytes to determine the extent of both phase I and phase 
II metabolism. These studies were carried out with human and rat hepatocytes at a 
concentration of 1 µM for 0, 15, 30, 60, and 120 mins*.   
 
Figure 3.11. in vitro metabolism studies for compounds 77 & 92 in human and rat 
hepatocytes. *These investigations were carried out by ChemPartners, Cai Lun Rd, 
Pudong, Shanghai, 201203, P.R. China. 
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The hepatocyte stability studies have shown that compound 77 is metabolised more 
quickly than 92 in human hepatocytes, which could be due to extensive 
glucuronidation of the hydroxyl moiety. Compound 92 is more sterically hindered 
around the hydroxyl group which may be preventing a high rate of metabolic 
turnover. The in vitro half-life and intrinsic clearance values from the hepatocyte 
studies are recorded in Table 3.14. 
Table 3.14. Metabolic stability of compounds 77 & 92 in human and rat 
hepatocytes. Human and rat hepatocytes concentration 1 µM, n=2.*These 
investigations were carried out by ChemPartners, Cai Lun Rd, Pudong, Shanghai, 
201203, P.R. China. 
Compound 
In vitro half-life t 1/2 
(min) 
Intrinsic clearance 
mL/min/kg 
Human Rat Human Rat 
77 59 429 28.69 7.55 
92 2387 324 0.72 9.99 
 
There appears to be inconsistencies between the in silicon predicted data (Table 
3.6) and the in vivo data for the clearance values in rat hepatocytes for this series 
(Table 3.14). Therefore, future predicted hepatocyte data will be interpreted 
cautiously.   
3.3.2 In vivo pharmacokinetic studies (rat) 
 
The in vivo pharmacokinetic (PK) parameters of compounds 77, 78, and 92 were 
also studied. The pharmacokinetic parameters of the i-pr-benzyl morpholine 
compound (49) were also studied to give a direct comparison between the i-pr-
amine and amide morpholine analogues (49 & 77). Compounds 77 and 92 stand out 
with excellent oral bio-availabilities, drug exposures and terminal half-lives. 
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Table 3.15. Pharmacokinetic profiles of compounds 49, 78, 78 and 92 in the rat (oral 
dose 10 mg/kg). Fasted, male, SD rats. n = 3/group. Vehicle: 10% DMSO, 10% Solutol 
HS15 and 80% saline at 1 mg/mL. *These investigations were carried out by 
ChemPartners, , Cai Lun Rd, Pudong, Shanghai, 201203, P.R. China. 
Compound 
Pharmacokinetic parameters 
Tmax 
(hr) 
Cmax 
(ng/mL) 
AUC 
(hr*ng/mL) 
T1/2 
(hr) 
F 
(%) 
49 0.5 429 ± 30.4 1242 ± 219 2.45 ± 0.833 35.8 ± 6.28 
77 0.5 4605 ± 745 20135 ± 826 2.58 ± 0.289 85.9 ± 3.63 
78 0.5 1533 ± 477 1556 ± 541 1.96 ± 0.619 38.1 ± 13.0 
92 3.00 2130 ± 133 16616 ± 1144 4.74 ± 0.316 129 ± 9.88 
 
3.3.3 In vivo neuropathic pain testing (Chung lesion model in the rat) 
 
The i-pr- amide compounds 77, 78 and the tert-butyl amide compound 92 were 
further selected to undergo in vivo studies in the Chung lesion model of chronic 
neuropathic pain (as described in Ch II, section 2.2.3)57. All in vitro neuropathic pain 
testing was carried out at King’s College London, under the supervision of Prof. S. 
McMahon. Groups of 6 rats were administered doses of 3, 10 and 30 mg/mg of 
each of the compounds being tested (77, 78, & 92). Each compound was tested at 1, 
3, 6 and 24hr time points for reversal of mechanical allodynia and hyperalgesia. 
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Figure 3. 12. The effect of  compound 77 on ipsilateral paw withdrawal thresholds 
to mechanical pressure in neuropathic rats.  In comparison with  lamotrigine. 
Fasted, male, Wistar rats. n = 6/group. Vehicle: 10% DMSO/10% Solutol HS15/80% 
saline. 10ml/kg p.o. One-way ANOVA, comparison with time-matched vehicle group 
using Tukey's HSD test,* p < 0.05, ** p < 0.01, *** p < 0.001. 
The results from the mechanical allodynia test (Figure 3.12) show that compound 
77 is absorbed rapidly, reaching an 80% reversal of painful symptoms 1 hour after a 
dose of 10 mg/kg.  After 3 hours, compound 77 gives a maximum of 90% reversal of 
neuropathic pain symptoms at 10 mg/kg.  
No increase in the maximum reversal is seen at the highest dose of 30 mg/kg. The 
positive control (lamotrigine, 30 mg/kg) reaches a maximum reversal of only 60 % 
after 3 hours which is consistent with the lowest dose of 77 administered (3 mg/kg). 
% Reversal of mechanical allodynia 
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Figure 3. 13. The effect of compound 77 on ipsilateral paw withdrawal thresholds to 
a cold (10°C) stimulus in neuropathic rats. In comparison with  lamotrigine. Fasted, 
male, Wistar rats. n = 6/group.Vehicle: 10% DMSO/10% Solutol HS15/80% saline. 
10ml/kg p.o. One-way ANOVA, comparison with time-matched vehicle group using 
Tukey's HSD test,* p < 0.05, ** p < 0.01, *** p < 0.001 
The results for the cold hyperalgesia test show that compound 77 reached peak 
reversal for all three doses at 1 hour. The peak analgesic effect for compound 77 
was 95% reversal at 30 mg/kg. 
 The analgesic effect for  77 declined slowly but after 6 hours there was still a 60% 
reversal of painful symptoms, this is consistent with a long half-life (t1/2 2.98hr) and 
a high exposure (AUC 20135 hr*ng/mL, (Table 3.15) seen with compound 77.   
% Reversal of cold hyperalgesia 
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At the 3 hour time point compound 77 is more than 3 times as effective as the 
positive control (lamotrigine) for comparable doses (Figure 3.13).  
 
 
Figure 3.14. The effect of  compound 78 on ipsilateral paw withdrawal thresholds to 
mechanical pressure in neuropathic rats. In comparison with gabapentin. Fasted, 
male, Wistar rats. n = 6/group. Vehicle: 10% DMSO/10% Solutol HS15/80% saline. 
10ml/kg p.o. One-way ANOVA, comparison with time-matched vehicle group using 
Tukey's HSD test,* p < 0.05, ** p < 0.01, *** p < 0.001 
Compound 78 achieved a maximum reversal of 75% after 3 hours at the highest 
dose of 30 mg/kg in the test for mechanical pressure. After 6 hours, however, the 
reversal of painful symptoms has dropped to 10%, which is consistent with the low 
half-life (t1/2 in 2.5 hr) and high rate of metabolism (CL 2.5 L/hr/kg) seen with 
compound 78 in rat pharmacokinetic studies  (Table 3.15). At the lowest dose of 3 
mg/kg compound 78 gave more than double the analgesic effect of the positive 
control gabapentin, considered the ‘gold standard’ of care for neuropathic pain, 
which only achieved a 10% reversal of painful symptoms (Figure 3.14) 
% Reversal of mechanical allodynia 
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Figure 3.15. The effect of compound 78 on ipsilateral paw withdrawal thresholds to 
a cold (10°C) stimulus in neuropathic rats. In comparison with  gabapentin. Fasted, 
male, Wistar rats. n = 6/group.Vehicle: 10% DMSO/10% Solutol HS15/80% saline. 
10ml/kg p.o. One-way ANOVA, comparison with time-matched vehicle group using 
Tukey's HSD test,* p < 0.05, ** p < 0.01, *** p < 0.001 
Compound 78 again showed a rapid onset of action with a 30 mg/kg dose reaching 
90% reversal of painful symptoms after 1 hour and reaching a maximum analgesic 
effect at 3 hours with a 105% reversal in pain symptoms. This effect was short lived 
however, as after 6 hours the effect had dropped to just 20%.  Once again 
compound 78 outperformed gabapentin which reached a maximum of 65% reversal 
at 1 hour (Figure 3.15). 
 
 
 
% Reversal of cold hyperalgesia 
Chapter III 
 
 
157 | P a g e  
 
 
 
Figure 3.16.  The effect of  compound 92 on ipsilateral paw withdrawal thresholds 
to mechanical pressure in neuropathic rats. In comparison with lamotrigine. Fasted, 
male, Wistar rats. n = 6/group.Vehicle: 10% DMSO/10% Solutol HS15/80% saline. 
10ml/kg p.o. One-way ANOVA, comparison with time-matched vehicle group using 
Tukey's HSD test,* p < 0.05, ** p < 0.01, *** p < 0.001 
 
Although the pharmacokinetic data for compound 92 would suggest it is absorbed 
slowly (Tmax 3hr, Table 3.15) a dose of 30 mg/kg reached a peak reversal of 75% 
after only 1 hour. Reversal of analgesic effects drops steadily for compound 92 and 
at 6 hours post dosing the reversal effect is only 20%. This could be a consequence 
of compound 92 not achieving the concentration levels seen with compound 77 
(Cmax 4605 for 77, Cmax 2130 for 77, Table 3.15). 
% Reversal of mechanical allodynia 
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 Figure 3.16 shows that compound 92 is as effective as the positive control in 
reversing the effects of mechanical allodynia at a dose of 30 mg/kg.  
 
 
Figure 3.17.  The effect of  compound 92 on ipsilateral paw withdrawal thresholds 
to a cold (10°C) stimulus in neuropathic rats. In comparison with  lamotrigine. 
Fasted, male, Wistar rats. n = 6/group.Vehicle: 10% DMSO/10% Solutol HS15/80% 
saline. 10ml/kg p.o. One-way ANOVA, comparison with time-matched vehicle group 
using Tukey's HSD test,* p < 0.05, ** p < 0.01, *** p < 0.001 
For the tert-butyl amide compound 92, again onset of analgesia was rapid with a 
peak reversal of 70% at 1 hour. The analgesic effect remained consistently high at 
the 3 hour time point but rapidly dropped to only 10% at 6 hours. Once again 
compound 92 (30 mg/kg dose) was as effective as lamotrigine (Figure 3.17). At the 
24 hour time point the response to painful stimuli for all compounds, at all 
doses,had reverted back to pre-dosing levels.  
% Reversal of cold hyperalgesia 
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This indicates that after 24 hours the concentration of all the compounds, even at 
the highest doses, had fallen below the therapeutic window58.   
The results of the in vivo tests for mechanical allodynia and cold hyperalgesia are 
summarised in tables Table 3.16 and Table 3.17 respectively.  
Table 3.16. In vivo results of the mechanical allodynia test, in the Chung lesion 
model of neuropathic pain.   
 
77 78 92 
3 
mg/kg 
10 
mg/kg 
30 
mg/kg 
3 
mg/kg 
10 
mg/kg 
30 
mg/kg 
3 
mg/kg 
10 
mg/kg 
30 
mg/kg 
% 
Reversal 
1hr 40 80 80 5 45 65 35 45 70 
3hr 70 90 90 20 70 75 20 40 50 
6hr 30 40 40 0 20 10 15 25 20 
24hr 0 0 0 0 0 0 0 0 0 
 
Table 3.17. In vivo results of the cold hyperalgesia test, in the Chung lesion model of 
neuropathic pain.   
 
77 78 92 
3 
mg/kg 
10 
mg/kg 
30 
mg/kg 
3 
mg/kg 
10 
mg/kg 
30 
mg/kg 
3 
mg/kg 
10 
mg/kg 
30 
mg/kg 
% 
Reversal 
1hr 60 85 95 20 50 90 65 70 70 
3hr 20 35 65 15 90 105 35 60 65 
6hr 20 35 60 0 20 20 10 10 10 
24hr 0 0 0 0 0 0 0 0 0 
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3.4 Summary    
 
This chapter has highlighted the synthesis and biological evaluation of a range of 
novel compounds targeting the α1 GlyR. Initial studies focused on the synthesis of a 
series of 2,6-diisopropyl and 2,6-di-tert-butylphenol analogues containing para-
amino alkyl substituents (49-55 & 60-64 respectively).  Compounds 49-51 & 55 were 
tested for efficacy at the α1 GlyR, however, none of the compounds tested showed 
any activity below 1 µM. In silico screening of the para-amino series also highlighted 
problems of a predicted high rate of clearance from both human microsomes and 
rat hepatocytes. Compounds 49-55 & 60-64 also displayed poor physicochemical 
properties, low MPO scores, which highlighted potential problems with CNS 
penetration, and the compounds also had the potential to from toxic quinone 
methide intermediates. All the factors detailed above made the decision to 
terminate this series easy.  
In an effort to improve the issues seen with the para-amino series we decided to 
install a carbonyl group at the site of quinone methide formation. In general the 
amide series (77-79 & 92-96) showed improved physicochemical properties, 
reduced metabolism and greater MPO scores than the para-amino alkyl analogues. 
Among the compounds synthesised we have identified several highly potent 
allosteric modulators of the α1 GlyR (77, 78, & 92), exemplified by the morpholine 
amide 77 (EC50 = 3.5 nM). 
 
77 
Figure 3.18. Morpholine amide compound 77. 
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The i-pr-amide morpholine compound 77 has been shown to be extremely potent 
at the α1 GlyR with an EC50 3.5 nM (Table 3.12).  It has also displayed a favourable 
physicochemical (Table 3.7) and pharmacokinetic profile (Table 3.15). MPO 
evaluation of compound 77 shows that it possesses the attributes required for a 
high level of CNS penetration (MPO score 4.4, Table 3.8) and the in vivo results from 
the Chung lesion model of chronic neuropathic pain show a peak of ≥ 90% reversal 
of painful symptoms in both mechanical allodynia and cold hyperalgesia.  
 Pharmacokinetic studies show that an oral dose of 67 (10 mg/kg) has a high level of 
absorption (Cmax = 4605 ng/mL) a large exposure (AUC = 20135 hr*ng/mL) a 
moderate half-life (2.58 hr) and a high bioavailability (F = 85%) (Table 3.15). 
With an overall CNS MPO score for of 4.4 for compound 77 was thought to have a 
high probability of crossing the BBB and entering the CNS to target the α1 GlyR.  
In vivo testing in the Chung lesion model for neuropathic pain showed that a dose 
10 mg/kg of compound 77 could perform better than the positive control 
(lamotrigine at 30 mg/kg) delivering 90% reversal of painful symptoms for 
mechanical allodynia and 30 mg/kg gave 95% reversal for cold hyperalgesia. 
Chapter IV details the lead optimisation of the propofol amide scaffold.  
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4 Introduction 
 
The previous chapter detailed the design and synthesis of a series of novel amide 
propofol analogues exemplified by compound 77 (Figure 4.1). 77 displayed low nM 
activity at the α1 GlyR, favourable physicochemical and pharmacokinetic profiles 
and has an MPO score>4.   
 
 
77 
Figure 4.1. Amide morpholine compound 77. 
 
Encouraged by these favourable results we embarked upon a lead expansion 
programme based around the i-pr-amide morpholine. Morphlino substituents were 
chosen to explore the steric and electronic constraints of the active site in an effort 
to gain a greater understanding of the SAR surrounding the α1 GlyR (Figure 4.1). 
The pKa of all of the compounds synthesised thus far has exceeded the optimal 
value, which according to reports by Fischer and co-workers and Palm co-workers, 
should be kept between 4-10. However Villalobos recommend that for maximum 
probability of CNS penetration the pKa should not exceed 81-3.  
Therefore in order to reduce the pKa of our compounds it was decided to include a 
variety of electronegative substituents at para positions of the propofol core in an 
effort to reduce electron density at the phenolic hydroxyl group (Figure 4.2)  
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Figure 4.2. Proposed lead optimisation compounds. 
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4.1 Amide synthesis 
 
During a search of the literature a report by Wu and co-workers was found which 
detailed the conversion of aryl bromides into secondary and tertiary benzamides. 
Aminocarbonylation was afforded by metal catalysed (Herrmann’s catalyst)  
carbonylation in microwave heated water, using Mo(CO)6 as the source of carbon 
monoxide4. If this method could be utilised to synthesise our proposed morpholino 
compounds (97-105) it would reduce the number of synthetic steps from 6 to 2.   
However, when this method was employed to resynthesize compound 77, we found 
these conditions gave only the benzoic acid (110) derivative shown in Scheme 4.15,6 
 
 
 
Scheme 4.1.  Reagents and conditions: i) Morpholine, Na2CO3,  trans-
bis(acetate)bis[o-(di-o-tolyphosphino)benzyl]dipaladium(II),  Mo(CO)6, H2O, 
microwave, 165OC, 10mins.  
 
It was though that the presence of water as the solvent may be responsible for the 
formation of the hydroxycarbonylation product (110) (Scheme 4.1).  
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Therefore, if an effort to mitigate against the formation of the unwanted product 
the aprotic solvent 1,4-dioxane was employed as the solvent instead of water 
(Scheme 4.2).  
 
 
Scheme 4.2.  Reagents and conditions: i) Morpholine, Na2CO3,  trans-
bis(acetate)bis[o-(di-o-tolyphosphino)benzyl]dipaladium(II),  Mo(CO)6, 1,4-dioxane, 
microwave, 165OC, 10mins, 60% yield. 
 
The change of solvent solved the problem and the aminocarbonylation product was 
afforded in 60% yield (after purification). However, when this method was utilised 
to synthesise compound 97 it was found that the reaction failed to produce the 
desired product. It was also noted that no hydroxycarbonylation was detected 
either.   This reaction was tried several times with substituted morpholines 100-106 
to no avail. It was, therefore, decided to revert back to the original 6 step synthetic 
scheme to synthesise compounds 97-105 (Scheme 4.3). 
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Scheme 4.3.  Reagents and conditions: i) Hexamethylenetetramine, AcOH, reflux 
16hrs, 89% yield7. ii) BnBr, K2CO3, acetone, RT, 18hrs, 88% yield
8. iii) SeO2, H2O2, 
THF, reflux, 18hrs 70% yield9. iv) Oxalyl chloride, Et3N, DMF, DCM, RT, 2hrs
10. v) 
Secondary amine, Et3N, DCM, RT, 18hr 42-95% yields
11. vi) Pd/C, H2, MeOH, RT, 
18hrs, 95-98% yields12. 
 
Synthesis of piperazine compound 106 followed Scheme 4.3 to produce BOC-
protected piperazine (111) which was further subjected to BOC deprotection using 
trifluoroacetic acid (TFA) in DCM (Scheme 4.4). 
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Scheme 4.4. Reagents and conditions: i)  TFAA, DCM, 18 hrs, RT, 60% yield13. 
In an attempt to further increase the metabolic stability of our compounds it was 
decided to include a spirocyclic analogue of morpholine (107). The initial synthesis 
of spirocyclic analogue 107 began with the synthesis of the 2-oxa-6-
azaspiro[3.3]heptane moiety (112). Tribromopentaerythritol and tosylamide were 
stirred in the presence of KOH for 5 days to give 112. This was then to be converted 
to the oxalate salt via cleavage of the tosylamide with Mg/MeOH and treatment 
with oxalic acid to give compound 113 (Scheme 4.5).  
 
 
Scheme 4.5. Reagents and conditions: i) Tosylamide, KOH, EtOH, 120hrs, reflux 55% 
yield. ii) Mg, Na2SO4.10H2O, oxalic acid, MeOH, sonicate 1hr
14. 
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Compound 112 was produced in reasonable yields (55%) and was characterised by 
1HNMR showing doublets at 7.71 ppm and 7.37 ppm integrating to 2 protons each 
corresponding to the aromatic protons on the tosylamide group, a singlet at 4.6 
ppm integrating for 4 protons corresponding to the O-(CH2)2 and another singlet at 
3.91 ppm integrating for 4 protons corresponding to the N-(CH2)2. However, when 
we attempted to convert compound 103 to the oxalate salt the reaction failed and 
only the staring material was recovered. This reaction was repeated several times 
varying the length of sonication time, using fresh Mg (granules) and employing 
anhydrous methanol all to no avail. Therefore we decided to find a commercial 
supplier for compound 113.  
Once compound 113 was in hand it was subjected to the amide coupling conditions 
outlined in. Unfortunately the reaction failed and only starting material was 
recovered. The reaction was repeated several times with varying equivalents of 
triethylamine to mop up the oxalate salt and the HCl produced from the coupling of 
the acid chloride and amide. Again the reaction was unsuccessful. We, therefore, 
decided to investigate the use of carbodiimides as coupling reagents. Dicyclohexyl 
carbodiimide (DCC, 114), diisopropyl carbodiimide (DIC, 115) and 1-ethyl-3-(3'-
dimethylamino) (EDC, 116) carbodiimide HCl salt  are amongst the most frequently 
used carbodiimides for amide bond formation (Figure 4.3)15.  
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Figure 4.3. DCC, DIC and EDC the most common carbodiimide reagents used in 
amide bond formation.  
The carbodiimide reacts with the carboxylic acid to form the O-acylisourea mixed 
anhydride (117). This intermediate can then react with the amine to yield the 
desired amide (118) and the urea by-product (119) (Figure 4.3)16. 
 
Scheme 4.6.  Amide bond formation using carbodiimide (EDC). 
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Often acyl transfer to the unreactive N-acylurea can be observed, to counter this, 
the reaction mixture is often cooled to 0oC before the amine is added. In order to 
further mitigate the unwanted acyl transfer a nucleophile (dimethylamino pyridine 
120 or hydroxybenzotriazole 110, Figure 4.4) is often added to the reaction mixture 
which reacts faster than the acyl transfer but generates an intermediate still active 
enough to couple with the amine17.  
 
Figure 4.4. Nucleophiles Dmap and HOBt used to minimise N-acylurea formation. 
However, when we subjected the spirocyclic amine (113) and carboxylic acid (85) to 
the coupling conditions shown in Scheme 4.7 the desired amide product was not 
observed.    
 
 
 
Scheme 4.7.  Reagents and conditions: i) Carboxylic acid, EDC, HOBt, spirocyclic 
oxalate salt, DMF, NMM, 0OC. 
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We therefore turned our attention to another coupling reagent, (1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxid 
hexafluorophosphate) (HATU, Figure 4.5). HATU (122) has been shown to be very 
efficient in the synthesis of sterically hindered amide bonds16.    
 
Figure 4.5. HATU. 
The spirocyclic amine (113) and the carboxylic acid (85) were dissolved in DMF 
before HATU (122) was added. The reaction mixture was allowed to stir at room for 
1 hour before TLC revealed that the reaction had been successful giving the desired 
amide (123) in 50% yield. Subsequent de-protection furnished the desired amide 
107 in excellent yields (Scheme 4.8). 
 
    
 
Scheme 4.8. Reagents and conditions: i) Spirocyclic amine, HATU,K2CO3, DMF, RT, 
1hr16. ii) Benzyl protected spirocylic amide, Pd/C, H2, MeOH, RT, 18hrs, 99% yield
12. 
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4.1.1 Trifluromethylation 
 
Incorporation of fluorine into drug candidates has become commonplace. Fluorine 
can impart a variety of properties to a new chemical entity including, metabolic 
stability, enhanced binding interactions and changes in physicochemical properties. 
The strongly electron withdrawing nature of the trifluromethyl group (CF3) can have 
a dramatic effect upon the acidity of carboxylic acids, alcohols, heterocycles and 
phenols. Therefore, we decided to introduce a CF3 group to our compounds in an 
effort to reduce the pKa of the phenolic hydroxyl group. It is thought that the 
reduction in the nucleophilicity of the hydroxyl group will, in turn, reduce the rate 
of phase II clearance. 
For the synthesis of compound 108 we utilised Friedel-Crafts acylation, employing 
trifluoroacetic anhydride to install the carbonyl CF3 group and aluminium trichloride 
(AlCl3) as the Lewis acid catalyst
18.   
 
 
Scheme 4.9.  Reagents and conditions: i) Trifluoroacetic anhydride, AlCl3, DCM, -
48OC-RT, 18hrs, 45% yield18. 
 
The installation of a CF3 moiety on an arene is typically carried out via cross coupling 
reactions catalysed by stoichiometric quantities metal salts or organometallic 
complexes of transition metals19.  
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More recently copper and palladium complexes have been successful in enabling 
this transformation in a catalytic fashion, using an electrophilic or nucleophilic 
source of CF3 (Umemoto’s or Ruppert-Prakash reagent respectively)
20. 
 However these methods rely on the Pre-functionalisation of the arene with 
activating groups such as Cl, I or B(OH)21-24. Nagib and MacMillan recently devised a 
method of direct trifluoromethylation of non-activated arenes by using photoredox 
catalysis to generate electrophilic CF3 radicals. Nagib and co-workers utilised 
Ru(phen)3Cl2, a polypyridyl organometallic complex which is excited by visible light 
(household light bulb) at room temperature to provide a strongly oxidising or 
reducing catalyst. Trifluoromethanesulphonyl chloride (TfCl) was chosen as the 
source of the CF3 radical due to the ease of handling and relative cost of the reagent 
(Scheme 4.10)25.  
 
Scheme 4.10.  Proposed mechanism for the direct trifluoromethylation of un-
functionalised arenes via photoredox catalysis (reproduced from Nagib25)  
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The mechanism of the reaction is thought to proceed via excitation of the 
photocatalyst (A) to the higher energy excited state (B) by light. 
 TfCl is reduced by B (via single electron transfer SET) to give the radical anion and 
oxidant C. The anion is thought to collapse to give the CF3 radical which combines 
with the aromatic system to give D. Oxidation of the radical arene by 3 (SET) and 
facile deprotonation of the resulting cation E provides the desired 
trifluoromethylated arene whilst restoring the catalyst (A).  
For the synthesis of compound 99 we followed the protocol devised by Nagib and 
co-workers224. The catalyst (Ru(phen)3Cl2) was added to a vial along with K2HPO4 
under a blanket of N2. MeCN, propofol and the TfCl reagent were added to the vial 
via syringe in order to maintain the anhydrous atmosphere. The vial was placed ~2 
cm from a 26 W household light bulb, and the reaction was allowed to stir for 24 
hrs. Upon completion the reaction was quenched with water and extracted into 
EtOAc. Flash chromatography gave the desired product in reasonable yield (42%). 
 
 
 
Scheme 4.11.  Reagents and conditions: i) Propofol, TfCl, Ru(phen)3Cl2, K2HPO4, 
MeCN, 26-W light source, RT, 24 hrs, 42% yield25. 
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4.2 In silico testing  
 
Compounds 97-109 were screened in silico in order to ascertain their predicted 
metabolic stability, aqueous solubility and their distribution co-efficient, ClogD. 
Table 4.1.  In silicoc predictions for compounds 97-109 
Compound Parameters Radar plot 
 
97 
ClogD 7.4 2.99 
 
Human 
Mic 
(µl/min/mg) 
32.36 
Rat Hep 
(µl/min/106 
cells) 
19.05 
 
98 
ClogD 7.4 3.81 
 
Human 
Mic 
(µl/min/mg) 
107.7 
Rat Hep 
(µl/min/106 
cells) 
396.6 
 
99 
ClogD 7.4 2.81 
 
Human 
Mic 
(µl/min/mg) 
44.02 
Rat Hep 
(µl/min/106 
cells) 
127.9 
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100 
ClogD 7.4 2.81 
 
Human 
Mic 
(µl/min/mg) 
44.02 
Rat Hep 
(µl/min/106 
cells) 
127.9 
 
101 
ClogD 7.4 3.0 
 
Human 
Mic 
(µl/min/mg) 
52.61 
Rat Hep 
(µl/min/106 
cells) 
147.1 
 
102 
ClogD 7.4 3.0 
 
Human 
Mic 
(µl/min/mg) 
52.61 
Rat Hep 
(µl/min/106 
cells) 
147.1 
 
103 
ClogD 7.4 3.48 
 
Human 
Mic 
(µl/min/mg) 
71.13 
Rat Hep 
(µl/min/106 
cells) 
138.9 
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104 
ClogD 7.4 3.12 
 
Human 
Mic 
(µl/min/mg) 
68.21 
Rat Hep 
(µl/min/106 
cells) 
203.3 
 
105 
ClogD 7.4 3.38 
 
Human 
Mic 
(µl/min/mg) 
54.95 
Rat Hep 
(µl/min/106 
cells) 
217.5 
 
106 
ClogD 7.4 1.54 
 
Human 
Mic 
(µl/min/mg) 
6.92 
Rat Hep 
(µl/min/106 
cells) 
4.27 
 
107 
ClogD 7.4 2.8 
 
Human 
Mic 
(µl/min/mg) 
23.25 
Rat Hep 
(µl/min/106 
cells) 
79.12 
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108 
ClogD 7.4 4.02 
 
Human 
Mic 
(µl/min/mg) 
106.3 
Rat Hep 
(µl/min/106 
cells) 
321.8 
 
109 
ClogD 7.4 2.54 
 
Human 
Mic 
(µl/min/mg) 
95.50 
Rat Hep 
(µl/min/106 
cells) 
47.86 
 c, In house algorithm.  
It can be seen from Table 4.1 that several of the compounds screened (97, 99-102 & 
105-107) are predicted to have an improved rate of phase I clearance, with respect 
to the previous series. As was noted in the previous chapter the data for the 
predicted rate of phase II metabolic clearance (rat hepatocytes) should be treated 
with caution as it does not appear consistent with in vitro  clearance values. 
Substituted morpholines 97 and 99-102 appear to have a reduced metabolic liability 
in human liver microsomes when compared to the unsubstituted morpholines. This 
may due to the blockade of CYP450 hydroxylation seen in the phase I metabolism of 
morpholino compounds26. All the compounds shown in Table 4.1 have ClogD 7.4 
values below 4, with several compounds (97-102, 106,107&109) now in the optimal 
range of 1.5-3.027.   
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4.2.1 Biological results 
Several compounds were selected for testing against α1 GlyR, their EC50 values are 
shown in Table 4.2   
Table 4.2. EC50 values and physicochemical properties for compounds 99-105, 107 
&108. 
Compound α1 GlyR EC50 (µM) 
a ClogP b ClogD c 
GABAA EC50 
(µM) d 
 
99 
>1 3.60 2.81 NT 
 
100 
>1 3.60 2.81 NT 
 
101 
0.00006 ± 2.6 3.60 2.81 30 ± 0.159 
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102 
>1 3.60 2.81 
No effect at 
the highest 
conc: 30 
 
103 
>1 3.80 3.48 3.3 ± 0.162 
 
104 
>1 2.90 3.12 NT 
 
105 
0.0000012 ± 0.016 3.30 3.38 NT 
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107 
0.0000016 ± 0.04 3.30 2.80 NT 
 
188 
0.00022 4.46 4.02 3.3 ± 0.489 
a, α1 GlyR EC50 values determination was carried out at the University of Tübingen under the 
supervision of Prof. Bodo Laube.b, ClogP values were determined using chembiodraw ultra 12 
software. c, In house algorithm. d, GABAA selectivity testing was carried out at BioFocus®, 
Chesterford Research Park, Saffron Walden, UK. NT = not tested. 
It can be seen from Table 4.2 that of the four monomethyl analogues tested 
compounds 99, 100 & 102 ((s)-3 monomethyl, (R)-3-monomethyl and (S)-2-
monomethyl morpholine respectively) show no activity below 1 µM at the α1 GlyR. 
However, compound 101 ((R)-2-monomethyl shows remarkable activity with an 
EC50 60 pM. One explanation for this profound increase in activity could be that the 
(R)-sterochemistry of the methyl group on compound 101 allows it to align with a 
hydrophobic pocket in the active site boosting potency28. 
 It is also possible that the increased affinity could stem from an increase in shape 
complementarity between compound 101 and the active site of the α1 GlyR in the 
bound sate, thus reducing the conformational reordering of the active site upon 
binding of the substrate29,30.  Interestingly ring expansion by only one methylene 
unit, from morpholine (77) to homo-morpholine (104) has reduced activity from 
0.35 nM (77) to >1 µM (104). 
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This could possibly be a consequence of a very constrained binding site. 4-
Fluoropiperidine analogue 103 was also shown to be devoid of activity below 1 µM, 
however, when the ring size was reduce to the more constrained 3-fluoroazatadine 
analogue, it was found to increase activity to give an EC50 of  1.2 pM. Compounds 
107 (the spirocylic surrogate for morpholine) and 108 (trifluoromethyl) were also 
found to be extremely potent with EC50 values of 1.2 pM and 0.22nM respectfully.   
4.2.2 MPO evaluation 
 
The MPO scores of compounds 97-109 were also evaluated to estimate their 
potential for CNS penetration (Table 4.3). 
Table 4.3. MPO evaluation for compounds 97-109. 
 
 
97 
 
 
98 
 
 
99 
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100 
 
101 
 
102 
   
 
 
103 
 
104 
 
105 
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106 
 
 
107 
 
 
 
 
108 
   
 
 
 
109 
 
 
 
 
 
As can be seen from Table 4.3 many of the compounds synthesised now meet the 
CNS MPO criteria for ClogP (<4 desirable, <3 optimal158), TPSA (>40, <120 Å2), and 
MW (<450), with compounds 105 & 106 achieving an overall CNS MPO score of >4 
giving rise to a high probability of CNS penetration.  
Chapter IV 
 
 
192 | P a g e  
 
4.2.3 In vivo pharmacokinetic studies (rat) 
 
Encouraged by the results of the in vitro electrophysiology studies (EC50 = 1.2 pM) 
and the high CNS MPO score (≥4) compound 105 was selected for in vitro PK 
investigations in the rat (Table 4.4). 
Table 4.4. PK parameters of compound 105 in the rat. 10 mg/kg p.o. Fasted, male, 
SD rats. n = 3/group. Vehicle: 10% DMSO, 10% Solutol HS15 and 80% saline at 1 
mg/mL. *These investigations were carried out by ChemPartners, Cai Lun Rd, 
Pudong, Shanghai, 201203, P.R. China 
Compound 
105 
Pharmacokinetic parameters 
Tmax 
(hr) 
Cmax 
(ng/mL) 
AUC 
(hr*ng/mL) 
T1/2 
(hr) 
F 
(%) 
0.5 995 ± 228 2390 ± 448  2.58 ± 0.308 38.8 ± 6.97 
 
Table 4.4 shows that although compound 105 is a highly potent modulator of the α1 
GlyR (EC50 =1.2 pM) it did not perform as well as compound 77 (chapter III, Table 
3.15) in the PK studies. Although both 77 & 105 reached Maximum concentration in 
30mins, 105 has a much lower exposure than 77 and less than half the 
bioavailability.  
4.2.4 In vivo neuropathic pain testing (Chung lesion model in the rat)  
 
Compound 105 (Table 4.3) was further selected for in vivo testing in the Chung 
lesion model of chronic neuropathic pain31 (described in Ch II, section 2.2.3), groups 
of 6 rats were administered doses of 3, 10 and 30 mg/mg of compound 105. The 
effect of 105 was tested at 1, 3, 6 and 24hr time points for reversal of mechanical 
allodynia and hyperalgesia. The results of the Chung lesion neuropathic pain test 
are captured below.   
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Figure 4.6. The effect of  compound 105 on ipsilateral paw withdrawal thresholds to 
mechanical pressure in neuropathic rats. In comparison with  gabapentin. Fasted, 
male, Wistar rats. n = 6/group.Vehicle: 10% DMSO/10% Solutol HS15/80% saline. 
10ml/kg p.o. 
The results from the mechanical allodynia test (Figure 4.6) show that compound 
105 performed better than the gabapentin at the 3 hour time point (at both 10 & 30 
mg/kg) with a 20% reversal of painful symptoms. However, 105 did not perform as 
well as compound 77 which reached 90% reversal of symptoms at 3 hours post 
dosing.  
 
 
 
% Reversal of mechanical allodynia 
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Figure 4.7. The effect of compound 105 on ipsilateral paw withdrawal thresholds to 
a cold (10°C) stimulus in neuropathic rats. In comparison with  gabapentin. Fasted, 
male, Wistar rats. n = 6/group.Vehicle: 10% DMSO/10% Solutol HS15/80% saline. 
10ml/kg p.o. 
In the cold hyperalgesia test compound 105 did not perform as well as compound 
77 or the positive control gabapentin. 105 only reached 25% reversal of symptoms 
at 3 hours, whereas, 77 peaked at 95% and gabapentin reached a maximum of 85% 
reversal of painful symptoms at the 1hour time point. These results could be a 
consequence of the lower Cmax, exposure (AUC) and lower bioavailability of 105 
lowering the systemic concentrations of the drug in comparison to 77. 
 
 
 
% Reversal of cold hyperalgesia 
 
 
Chapter IV 
 
 
195 | P a g e  
 
4.3 Target product profile  
 
The lead optimisation series has identified several highly potent allosteric 
modulators of the α1GlyR, exemplified by compound 105. However, of those 
compounds that have been examined to date 67 has displayed the most promising 
results. Encouraged by the potent EC50 = 3.5 nM at the α1GlyR, the favourable 
microsomal stability and PK results both in vitro and in vivo, the high CNS MPO 
score (4.4) and also from the high levels of analgesia seen in the Chung lesion 
neuropathic pain model;  compound 77 was chosen to undergo toxicity, 
cerebrospinal fluid (CSF) and protein binding studies. The results of these tests are 
summarised in the target product profile table (Table 4.5). 
Table 4.5. Target product profile for a novel analgesic compound. 
Assay/Model Desired Criterion 
Measured data for 
Compound 77 
Physicochemical properties   
Aqueous solubility1 >0.05 mg/mL (pH 7.4) 0.025 mg/mL (pH 7.4) 
ClogP2 <4 3.10 
MW2 <450 (Da) 291 (Da) 
TPSA2 < 90Å2 49.80 Å2 
Number of rotable bonds <8 7 
ClogD3 1-3 2.88 
Pka3 3-9 10.10 
Selectivity   
GABAAR (Ec50)
4 
GABAA EC50 >100x GlyR 
EC50 
30 µM (>1000x GlyR EC50) 
Pharmacokinetics   
Oral bioavailability (rat) 1 >20% >80% 
Stability rat liver5 
microsomes 
T1/2 >60 mins 741 mins 
Stability human1 hepatocytes T1/2 >30 mins 59 mins 
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Brain CSF levels1 
3xEC50 (free) at 2-3 hrs at 1-
3 mg/kg 
10 x EC50 
In vitro plasma protein 
binding (rat) 1 
<99.5% 62% 
Safety   
Functional hERG assay1 IC50 > 10µM IC50 > 30 µM 
Cytotoxicity HepG2 cells6 
No cytotoxicity at 500x EC50 
GlyR EC50 
No cytotoxicity below 
500 µM 
Genotoxicity: Ames6 Negative Negative 
Absence of metabolic alerts No alerts No alerts 
 1
Measurements carried out by ChemPartners, Cai Lun Rd, Pudong, Shanghai, 201203, P.R. China. 
Solubility testing in 100 mM phosphate buffer (pH 7.4), n=2. Oral bioavailability (oral dose 10 mg/kg). 
Fasted, male, SD rats. n = 3/group. Vehicle: 10% DMSO, 10% Solutol HS15 and 80% saline at 1 
mg/mL. Human and rat hepatocytes concentration 1 µM, n=2. Protein binding and CSF, 3 mg/kg dose 
p.o. vehicle solution in 10%DMSO, 10%Solutol HS 15 and 80%saline at 0.3 mg/mL, n=9. hERG testing 
using transfected Chinese hamster ovary cells 10
6
. 
2
Values were determined using chembiodraw 
ultra 12 software. 
3 
Values generated fromACD/labs software. 
4
BioFocus®, Chesterford Research 
Park, Saffron Walden, UK. 90 mM KCl, 50 mM KF, 11 mM EGTA, 10 mM HEPES, 1 mM MgCl2, 2 mM 
Mg-ATP, pH 7.35, n=6.
5
Human and rat liver microsomes (1mg/mL) at a concentration of 1 µ M in the 
presence of NADPH for 0, 10, 30 and 60 mins, n = 2. Studies carried out at the Liverpool School of 
Tropical Medicine.
6
CHO-K1 cells are incubated with test compound over a 10 point concentration 
range in duplicate. The in vitro micronucleus test (MNT) method uses automated fluorescent cellular 
imaging (Thermo Scientific Cellomics ArrayScan VTI HCS Reader) to assess cytotoxicity and 
quantification of micronuclei (genotoxicity).Ames test conc 250 µ/mL of 70 incubated at 37
o
C for 
48hrs with TA98 test strain bacteria, n=6. 
 
From Table 4.5 it can be seen that the physicochemical properties of compound 77 
match our desired criteria with only the solubility falling slightly below the desired 
level, but it is still within acceptable parameters.  Selectivity of 77 for the GlyR 
against the GABAA is greater than 1000 fold and the PK parameters all exceed our 
criteria including the CSF levels (a measure of how much free drug enters the CNS) 
which are 10 fold higher than the EC50 value (3.5 nM) and protein binding, which is 
62%, giving high levels of unbound drug to target the GlyR.  The results of the 
toxicity tests (described in chapter II, section 2.4.1) are very favourable. The hERG 
IC50 is 30 µM, 3 times higher than the minimum required, there appears to be no 
cytotoxicity detected up to the maximum concentration examined (500 µM) and 
the results of the Ames test showed no genotoxicity. 
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4.4 Summary  
This chapter has highlighted the lead optimisation and biological evaluation of a 
series of novel propofol amide analogues targeting the α1 GlyR. Among the 
compounds synthesised we have identified several highly potent allosteric 
modulators of the α1 GlyR (Table 4.6). 
Table 4.6. EC50 values and physicochemical properties for the most potent lead 
optimised compounds. 
Compound 
α1 GlyR EC50 
(µM) a 
ClogP b ClogD c 
GABAA EC50 
(µM) d 
 
101 
0.00006 ± 
2.6 
3.60 2.81 30 ± 0.159 
 
105 
0.0000012 ± 
0.016 
3.30 3.38 NT 
 
107 
0.0000016 ± 
0.04 
3.30 2.80 NT 
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108 
0.00022 4.46 4.02 3.3 ± 0.489 
a, α1 GlyR EC50 values determination was carried out at the University of Tübingen under the 
supervision of Prof. Bodo Laube.b, ClogP values were determined using chembiodraw ultra 12 
software. c, In house algorithm d, GABAA selectivity testing was carried out at BioFocus®, Chesterford 
Research Park, Saffron Walden, UK. 
Lead optimised compounds 97-109  were assessed in silico in order to ascertain 
their predicted metabolic clearance (Table 4.1). As noted earlier the predicted rat 
hepatocyte data was inconsistent with in vitro data, therefore it was treated with 
caution. In general the predicted microsomal data was improved and the MPO 
score of one of the most potent compounds 95 is in the optimal range of ≥4.  
Pharmacokinetic studies for compound 95 show that although an oral dose of 10 
mg/kg is absorbed quickly (Tmax = 0.5 hr) the Cmax is moderate (995 ng/mL) as is 
the exposure (AUC = 2390 hr*nh/mL) and bioavailability (F = 38.8%). 
In vivo testing in the Chung lesion model for neuropathic pain showed a 10 mg/kg 
dose of compound 105 could outperform a 30 mg/kg dose of the current ‘gold 
standard’ treatment for chronic pain, gabapentin, by delivering a 20% reversal of 
painful symptoms in the mechanical allodynia test.   In the cold hyperalgesia test 
compound 105 showed a 25% reversal of painful symptoms.  
At the time of writing this thesis work is on-going with the lead optimised series and 
we are awaiting further results from the α1 GlyR electrophysiology studies for 
compounds 97, 98,106 & 109.   
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5 Conclusions 
The aims of this thesis were to identify novel analgesic compounds based around a 
2,6-diisopropylphenol (propofol) core scaffold, which selectively target the α1 
subtype of the strychnine sensitive glycine receptor (α1 GlyR). Our objective was to 
generate lead optimised compounds which display favourable in vitro, in vivo 
activity, acceptable pre-clinical toxicology and ADME properties as defined in our 
target product profile (Table 5.1). 
Table 5.1. Target product profile for a novel analgesic compound 
Assay/Model Desired Criterion 
Physicochemical properties  
Aqueous solubility >0.05 mg/mL (pH 7.4) 
ClogP <4 
MW <450 (Da) 
TPSA < 90Å2 
Number of rotable bonds <8 
ClogD 1-3 
Pka 3-9 
Selectivity  
GABAAR (Ec50) GABAA EC50 >100x GlyR EC50 
Pharmacokinetics  
Oral bioavailability (rat) >20% 
Stability rat liver microsomes T1/2 >60 mins 
Stability human hepatocytes T1/2 >30 mins 
Brain CSF levels 3xEC50 (free) at 2-3 hrs at 1-3 mg/kg 
In vitro plasma protein binding (rat) <99.5% 
Safety  
Functional hERG assay IC50 > 10µM 
Cytotoxicity HepG2 cells No cytotoxicity at 500x EC50 GlyR EC50 
Genotoxicity: Ames Negative 
Absence of metabolic alerts No alerts 
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Chapter I described the background to the problem of chronic pain, the deficiencies 
of the current treatments and the clinical need, not only for new treatments but 
also for novel therapeutic targets. The α1 GlyR was introduced as one such novel 
target and the role the it plays in the nociceptive system was discussed as were the 
potential advantages of targeting the α1 GlyR.  The anaesthetic compound propofol 
was shown to be a modulator of the GlyR and the attributes of this compound were 
discussed in detail as were the potential disadvantages of off target effects at the 
GABAAR such as dizziness and sedation. The difficulties of crossing the blood brain 
barrier and entering the central nervous system to access the α1 GlyR were also 
presented.   
 
Chapter II focused upon optimising a series of bi-phenyl propofol analogues which 
had been previously synthesised within the group. Although the bi-phenyl 
analogues had been shown to be highly potent modulators of the α1 GlyR 
(exemplified by 19,Figure 5.1) they demonstrated very poor physicochemical and 
pharmacokinetic properties.   
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EC50 = 0.00007 µM 
ClogP = 6.75 
ClogD7.4 = 6.0 
Figure 5.1. Compound 19, the most potent of the bi-phenyl series previously 
synthesised within the group. 
 
Therefore in an effort to increase solubility, improve physicochemical parameters 
(ClogP & ClogD) and retain activity, a small library of compounds was synthesised 
containing ‘solubilising’ heterocylic groups (28-44, chapter II, section 2.7). Of the 
heterocyclic compounds tested only one compound (40) showed the low nM 
activity seen with the previously synthesised bi-phenyl compounds (Figure 5.2). 
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EC50 = 0.0001 µM 
ClogP = 5.55 
ClogD7.4 = 5.03 
Figure 5.2. Compound 40 the only heterocycle synthesised demonstrating low nM 
activity at the α1 GlyR. 
 
Although 40 was active against the α1 GlyR, it was apparent that  the ClogP and 
ClogD parameters were still above optimal (ClogP <3, ClogD, >1, <3) for maximum 
probability of crossing the BBB and entering the CNS1. However, compound 30 did 
not meet the criteria for GABAAR selectivity, set out in the target product profile 
(Table 5.1) as it was found to be a potent modulator of the GABAAR (EC50 = 0.12 µM 
± 0.012) and, therefore, was discontinued due to the unwanted sedative effect from 
this receptor. 
During the development of the heterocyclic compounds (28-44) a series of papers 
from a team at Pfizer were published detailing the use of a multiparameter 
optimisation (MPO) calculator to aid in the development of drugs acting within the 
CNS2.  The CNS MPO calculator gives compounds an overall score based upon the 
evaluation of six molecular descriptors, ClogP, ClogD, TPSA, MW, HBD and pKa. The 
summation of the transformed values for these descriptors is given as the overall 
CNS MPO score, with a score ≥4 being required for optimal probability of CNS 
penetration (chapter II, section 2.8.1).  
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MPO evaluation of the heterocyclic series showed that none of the compounds 
synthesised met this criteria, therefore, we terminated the bi-phenyl and 
heterocycle series and re-evaluated our design strategy.  
Chapter III detailed the synthesis of a series of 2,6-diisopropyl and 2,6-di-tert-butyl 
para-amino alkyl analogues of propofol (49-55 & 60-64). Several of the para-amino 
analogues were tested for efficacy against the α1 GlyR, however, none of the 
compounds tested showed activity below 1 µM. Furthermore MPO evaluation of 
compounds 49-55 & 60-64 revealed that, there was a low probability of CNS 
penetration with all compounds recording an overall MPO score <4. An additional 
potential liability with the para-amino alkyl template was the possible formation of 
a toxic metabolic intermediate (quinone methide)3,4.  
With these facts in mind, the decision was taken to install carbonyl functionality at 
the site of quinone methide formation to increase predicted metabolic stability and 
improve the MPO score (Table 5. 2).  
 
Table 5. 2. Improved predicted metabolic stability and MPO for amide analogues.  
 
49 
 
 
77 
84.35 Human 
Mic 
(µl/min/mg) 
31.21 
333.5 Rat Hep 
(µl/min/106) 
87.41 
3.8 MPO 4.4 
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Upon testing the amide series compounds 77 & 78 were shown to have low nM 
activity at the α1 GlyR (Table 5.3).  
Table 5.3. In vitro EC50 values for amide linked compounds tested against the 
recombinant α1GlyR 
Structure EC50 (µM) ClogP ClogD MPO 
 
77 
0.00035 ± 0.00002 3.10 2.80 4.4 
 
78 
0.0000012 ± 0.4 3.54 2.30 4.4 
 
MPO evaluation of compound 77 revealed a good MPO score of 4.4. In vivo 
pharmacokinetic (PK) analysis (rat) showed that compound 77 is well absorbed 
(Cmax = 4605 ng/mL) has a large exposure (AUC = 20135 hr*ng/mL) a moderate 
half-life (2.58 hr) and a high bioavailability (F = 85%) (chapter III, section 3.3.2).  
Compound 77 was also tested for off-target activity at the GABAAR no activity 
observed below 30 µM.    
In vitro proof of concept studies in the Chung lesion model of neuropathic pain 
showed compound 77 performed better than the positive control, lamotrigine, with 
a 10 mg/kg dose reversing the painful symptoms of mechanical allodynia by 90% 
and reversing the symptoms of cold hyperalgesia by 95% (at a dose of 30 mg/kg).  
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Chapter IV Lead optimisation of the amide template revealed several more 
compounds with low nM activity at the α1 GlyR (compounds 101, 105, 107 &108). 
Compound 95 was further selected to undergo in vitro neuropathic pain studies 
were it performed better than the current ‘gold standard’ treatment for chronic 
neuropathic pain, gabapentin, with a maximum reversal of 20% in the mechanical 
allodynia test.  
 
 
Figure 5.3. Compound 105 EC50 =1.2 pM at the α1 GlyR. 
 
However, compound 105 did not perform as well as the positive control, 
gabapentin, in the test for cold hyperalgsia, reaching a 25% reversal whereas 
gabapentin reached a maximum of 90%.   
To conclude, we have identified several highly potent allosteric modulators of the 
α1 GlyR, exemplified by compound 107 (EC50 = 3.5 nM), which displays favourable 
DMPK properties, no toxicity (Table 5.4) and has demonstrated a high level of 
analgesia (>90% in both mechanical allodynia and cold hyperalgesia) in the Chung 
lesion model for neuropathic pain.  
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Table 5.4. Compound 77 mapped onto our target product profile. 
Assay/Model Desired Criterion 
Measured data for 
Compound 67 
Physicochemical properties   
Aqueous solubility >0.05 mg/mL (pH 7.4) 0.025 mg/mL (pH 7.4) 
ClogP <4 3.10 
MW <450 (Da) 291 (Da) 
TPSA < 90Å2 49.80 Å2 
Number of rotable bonds <8 7 
ClogD 1-3 2.88 
Pka 3-9 10.10 
Selectivity   
GABAAR (Ec50) 
GABAA EC50 >100x GlyR 
EC50 
30 µM (>1000x GlyR EC50) 
Pharmacokinetics   
Oral bioavailability (rat) >20% >80% 
Stability rat liver microsomes T1/2 >60 mins 741 mins 
Stability human hepatocytes T1/2 >30 mins 59 mins 
Brain CSF levels 
3xEC50 (free) at 2-3 hrs 
at 1-3 mg/kg 
10 x EC50  
In vitro plasma protein binding 
(rat) 
<99.5% 62% 
Safety   
Functional hERG assay IC50 > 10µM IC50 > 30 µM 
Cytotoxicity HepG2 cells 
No cytotoxicity at 500x 
EC50 GlyR EC50 
No cytotoxicity below 
 500 µM  
Genotoxicity: Ames Negative Negative 
Absence of metabolic alerts No alerts No alerts 
 
At the time of writing this thesis compound 77 is undergoing further in vivo testing 
in an animal model of diabetic neuropathy. 
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This study has also identified several other potential lead compounds with low nM 
activity at the α1 GlyR (101, 105 & 107) from the i-pr-amide template. Development 
of these compounds is on-going. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter V 
 
 
213 | P a g e  
 
5.1 References  
 
1 Pajouhesh, H. & Lenz, G. R. Medicinal chemical properties of successful 
central nervous system drugs. NeuroRx : the journal of the American Society 
for Experimental NeuroTherapeutics 2, 541-553, (2005). 
2 Wager, T. T., Hou, X., Verhoest, P. R. & Villalobos, A. Moving beyond Rules: 
The Development of a Central Nervous System Multiparameter Optimization 
(CNS MPO) Approach To Enable Alignment of Druglike Properties. ACS 
Chemical Neuroscience 1, 435-449, (2010). 
3 Monks, T. J. & Jones, D. C. The Metabolism and Toxicity of Quinones, 
Quinonimines, Quinone Methides, and Quinone-Thioethers. Current Drug 
Metabolism 3, 425-438, (2002). 
4 Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G. & Monks, T. J. Role of 
Quinones in Toxicology†. Chemical Research in Toxicology 13, 135-160, 
(2000). 
 
 
  
 
 
 
 
 
 
 
 
Chapter VI 
Experimental 
Chapter VI 
 
 
215 | P a g e  
 
Chemistry 
General 
Reactions that were air and moisture sensitive were performed under a nitrogen 
atmosphere. This was achieved with oven dried or flame dried glassware sealed 
with a rubber septa. Dry nitrogen gas was introduced via a manifold or balloon.  
Reactions were stirred using Teflon-coated magnetic stir bars. Organic solutions 
were concentrated using a Büchi rotary evaporator with a diaphragm vacuum 
pump. Anhydrous solutions and sensitive liquids were transferred via syringe. 
 
Purification of solvents and reagents 
Anhydrous solvents were obtained from commercial sources or dried and distilled 
prior to use. The distillation was under the flow of dry nitrogen. THF was distilled 
from sodium. Dichloromethane was distilled from calcium hydride. All reagents 
were purchased from Sigma Aldrich or Alfa Aesar and were used without 
purification unless otherwise indicated.  
 
Purification of products 
Analytical thin layer chromatography (TLC) was performed with 0.25 mm Merck 
silica gel 60 F254 plates with 254 nm fluorescent indicator. Plates were visualised by 
U.V. at 254 nm or treated with p-anisaldehyde solution , ninhydrin or potassium 
permanganate followed by gentle heating. Chromatographic purification of 
products was accomplished by flash column chromatography unless otherwise 
indicated. 
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Analysis 
1H NMR spectra were measured on a Brucker AMX400 (400 MHz) nuclear magnetic 
resonance spectrometer. The data for 1H NMR spectra are reported as follows: 
chemical shifts ware described in parts per million (δ, ppm) downfield from an 
internal reference of trimethylsilane. Integration. Multiplicities: (s = singlet, d = 
doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, td 
= triplet of doublets, m = multiplet and Hept = heptet). Coupling (J, Hz). 13C NMR 
spectra were measured on a Brucker AMX400 (100 MHz) and are reported in terms 
of chemical shift (δ, ppm) relative to residual solvent peak.  Mass spectrometry (MS) 
and High Resolution Mass Spectrometry (HRMS) were recorded on a VG analytical 
7070E machine, Frisons TRIO spectrometers or Agilent QTOF 7200 using chemical 
ionisation (CI) or electron ionisation (EI). Micromass LCT mass spectrometer used 
electron spray ionisation (ESI). Elemental analysis (%C, %H, %N) were determined 
by the University of Liverpool Microanalysis Laboratory. Melting points were 
determined on a Gallenkamp melting point apparatus in degrees Celsius and are 
uncorrected. Full characterisation was performed on final compounds that were 
tested in various assays. Intermediates were characterised 1HNMR 13CNMR and 
Mass spectrometry techniques.  
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6.0 Synthesis 
 4-Bromo-2-6-diisopropylphenol1 
 
 
27 
 
Bromine (1.2 mL, 24 mmol) was added drop wise to a stirred solution of 2-6-
diisopropylphenol (3.7 mL, 20 mmol) in glacial acetic acid (60 mL). The resulting 
solution was allowed to stir at room temperature for 1 hour. Upon completion the 
reaction was quenched with H2O (50 mL), extracted with EtOAc (3 x 50 mL) and 
washed with brine. The resulting organic extracts were dried over MgSO4 and 
concentrated under vacuum. The product was purified by column chromatography 
(10:90 EtOAc/Hexane) to afford the product as an orange oil (4.0 g, 80% yield) 1H 
NMR (400 MHz, CDCl3) δ 7.14 (s, 2H), 4.81 (s, 1H), 3.12 (hept, J =, 6.8 Hz, 2H), 1.24 
(d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 149.43, 136.43, 126.85, 113.57, 
27.46, 22.97. MS: [M+H]+   C12H18BrO requires: 257.0536, found: 257.0530.  
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  General procedure 1. Suzuki coupling reaction 
 
4-Bromo-2-6-diisopropylphenol (1eq) was added to a stirred suspension of 
substituted boronic acid (2.0 eq), tetradiphosphininopalladium (5 mol%) and 
potassium carbonate (3.2 eq) in a solution of THF (10 mL/g) and H2O (5 mL/g) in THF 
(10 mL/g). The resulting mixture was heated under reflux for 24 hours at 80oC. The 
reaction was monitored by TLC (EtOAc/n-Hexane) and upon completion the 
reaction was quenched with HCl (50 mL/g) and was extracted with EtOAc (3 x 30 
mL). The combined organic extracts were washed with H2O, brine, dried over 
MgSO4 and concentrated under vacuum. The products were purified by column 
chromatography (EtOAc/n-Hexane).  
3,5-diisopropyl-4-(morpholinomethyl)-(1-1-biphenyl)-4-ol 
 
 
28 
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4-Bromo-2-6-diisopropylphenol (318mg, 1.24mmol) was reacted with (4-
orpholinomethyl)phenyl)boronic acid (548 mg, 2.47 mmol) according to general 
procedure 1, the crude product  was  purified by column chromatography (80:20 
EtOAc/Hexane)to afford the product  as a white solid (210mg, 48% yield). mp = 178-
180oC: 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.2 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 
7.26 (s, 2H), 4.87 (s, 1H), 3.74 – 3.71 (m, 4H), 3.21 (hept, J = 6.8 Hz, 2H), 2.48 (s, 4H), 
1.32 (d, J = 6.8 Hz, 12H).).13C NMR (101 MHz, CDCl3) δ 150.17 – 149.70, 141.12, 
134.09, 129.86, 126.94, 122.62, 67.53, 63.59, 54.06, 31.34, 27.73, 22.98. MS:[M+H]+  
C23H32NO2 requires: 354.2427, found: 354.2433.CHN requires C: 78.15% H: 8.84% N: 
3.96, found C: 77.75% H: 8.81% N: 4.00% 
Methyl-4’-hydroxy-3’-5’-diisopropyl-(1-1’-biphenyl)-4-carboxylate 
 
 
29 
4-Bromo-2-6-diisopropylphenol (500 mg, 1.95 mmol)  was reacted with (4-
methoxycarbonyl)phenyl) boronic acid (702 mg, 3.90 mmol) according to general 
procedure 1, the crude product  was  purified by column chromatography (40:60 
EtOAc/Hexane) to afford the product  as a white solid (365 mg, 60% yield): 1H NMR 
(400 MHz, CDCl3) δ 8.08 (d, J = 8.3 Hz, 2H), 7.62 (d, J = 8.3 Hz, 2H), 7.32 (s, 2H), 4.94 
(s, 1H), 3.94 (s, 3H), 3.27 (hept, J = 6.8 Hz, 2H), 1.33 (d, J = 6.8 Hz, 12H). MS:[M-H]-, 
C20H23O3 requires: 311. 3954, found: 311.3952.  
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4’-Hydroxy-3’-5’-diisopropyl-(1-1’-biphenyl)-4-carboxylic acid 
 
 
30 
To a stirred solution of Methyl-4’-hydroxy-3’-5’-diisopropyl-(1-1’-biphenyl)-4-
carboxylate (312 mg, 3.2 mmol) in MeOH (15 mL) was added NaOH (10 mL, 2M). 
The resulting solution was allowed to stir at room temperature for 18 hours. The 
reaction was monitored by TLC (40:60 EtOAc/n-Hexane) and upon completion the 
solution was acidified with HCl (pH 3-4) washed with brine and extracted with 
EtOAc (3 x 30 mL). The combined organic extracts were dried over MgSO4   and 
concentrated under vacuum to afford the product as a white solid (639 mg, 67% 
yield). 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 
7.34 (s, 2H), 3.32 (hept, J = 6.8 Hz, 2H), 1.34 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, 
CDCl3) δ 172.24, 150.61, 147.24, 134.26, 132.28, 130.72, 127.12, 126.78, 122.7, 
27.37, 22.78. MS:[M-H]-: C19H21O3 requires: 297.1496, found: 297.1491. 
General procedure 2 . Synthesis of acid chlorides 
 
Oxalyl chloride (2.0 eq) was added to a solution of appropriate carboxylic acid (1 eq) 
in DCM (10 mL/g) at room temperature and under an inert atmosphere. 1 drop of 
DMF (from a Pasture pipette) was added. The reaction mixture was allowed to stir 
for 2 hours. Upon completion the solvent was removed under vacuum. The product 
from this reaction was not isolated. 
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4’-Hydroxy-3’-5’-diisopropyl-(1-1’-biphenyl)-4-carbonyl chloride 
 
 
31 
4’-Hydroxy-3’-5’-diisopropyl-(1-1’-biphenyl)-4-carboxylic acid  (200 mg, 0.67 mmol) 
was reacted with oxalyl chloride (169 mg, 1.3 mmol) according to general 
procedure 2 to afford the product  as a pale yellow oil. The product from this 
reaction was not isolated and was carried through crude. 
 
General procedure 3 . Amide coupling 
 
The appropriate morpholine derivative (1.2 eq) was added to a stirred solution of 
the acid chloride (1.0 eq) dissolved in DCM (10 mL/g). Et3N (1.5 eq) was added and 
the resulting solution was allowed to stir at room temperature for 1.5 hours. The 
reaction was monitored by TLC and upon completion the reaction mixture was 
quenched with H2O (50 mL) and extracted with EtOAc (3 x 50 mL). The combined 
organic extracts were washed with Na2CO3, dried over MgSO4 and the solvent was 
removed under vacuum.  
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(4’-Hydroxy-3’-5’-diisopropyl-(1-1’-biphenyl)-4-
yl)(morpholino)methanone 
 
32 
4’-Hydroxy-3’-5’-diisopropyl-(1-1’-biphenyl)-4-carbonyl chloride (211 mg, 0.67 
mmol) was reacted with morpholine (0.07 mL, 0.80 mmol) according to general 
procedure 3 . The crude product was purified by column chromatography (60:40 
EtOAc/n-Hexane) to afford the product as a white solid (121 mg, 51% yield). mp = 
191-193oC:  1H NMR (400 MHz, CDCl3) δ 7.67 d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 
2H), 7.26 (s, 2H), 5.33 (s, 1H), 3.73 (s, 8H), 3.23 (hept, J = 6.8 Hz, 2H), 1.31 (d, J = 6.8 
Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 170.98, 150.66, 144.04, 134.82, 133.36, 
132.70, 128.07, 127.18, 122.80, 67.35, 60.83, 27.66, 23.21. MS:[M+Na]+ 
C23H29NNaO3  requires: 390.2045, found: 390.2051.  CHN omitted due to 
inconsistent results. 
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(4’-Hydroxy-3’-5’-diisopropyl-(1-1’-biphenyl)-4-yl)(methylpiperazin-1-
yl)methanone 
 
33 
4’-Hydroxy-3’-5’-diisopropyl-(1-1’-biphenyl)-4-carbonyl chloride (200 mg, 0.67 
mmol) was reacted with N-methylpiperazine (0.07 mL, 0.80mmol) according to 
general procedure 3 . The crude product was purified by column chromatography 
(60:40 EtOAc/n-Hexane) to afford the product as an off white solid (117 mg, 47% 
yield). mp = 184-186oC:  1H NMR (400 MHz, CDCl3) δ 7.58 – 7.06 (m, 6H), 4.91 (s, 
1H), 3.62 (m, 4H), 3.28 (hept, J = 6.8 Hz, 2H), 2.40 (m, 4H), 1.23 (d, J = 6.8 Hz, 12H). 
13C NMR (101 MHz, CDCl3) δ 170.55, 150.63, 143.95, 134.87, 133.40, 132.93, 128.02, 
126.71, 122.79, 55.56, 46.34, 27.78, 23.23. MS:[M+Na]+: C24H32N2NaO2 requires: 
381.2542, found: 381.2527. CHN omitted due to inconsistent results. 
 
4-(Hydroxymethyl)-2,6-diisopropylphenol2 
 
 
57 
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4-Hydroxy-3-5-diisopropylbenzaldehyde (530 mg, 2.5 mmol) was dissolved in dry 
THF and cooled to 0oC. Lithium aluminium hydride was added (100 mg, 2.5 mmol) 
and the solution was allowed to stir at 0oC for 1hr. Upon completion acetone (5 mL) 
was added along with HCl (5 mL, 1 M). The resulting solution was diluted with H2O 
(50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were 
dried over MgSO4 and concentrated under vacuum to afford the product as a white 
solid (415 mg, 80% yield). 1H NMR (400 MHz, CDCl3) δ 6.98 (s, 2H), 4.99 (s, 1H), 4.52 
(s, 2H), 3.09 (hept, J = 6.8 Hz, 2H), 1.18 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, 
CDCl3) δ 171.65, 151.45, 133.69, 122.84, 27.14, 22.62, 15.28. 
 
4-((1H-imidazol-1-yl)methyl) -2-6-diisopropylphenol 
 
 
55 
Imidazole (100 mg, 1.6 mmol) was added to 4-(Hydroxymethyl)-2,6-
diisopropylphenol (325 mg, 1.6 mmol). The resulting mixture was heated to 160oC 
and stirred for 2 hours. Upon completion the reaction mixture was cooled and the 
solid precipitate was isolated. The crude product was purified by column 
chromatography (20:80 EtOAc/n-Hexane) to give the product as a white solid (205 
mg, 50% yield). 1H NMR (400 MHz, CDCl3) δ 7.51 (s, 1H), 7.07 (s, 1H), 6.90 (s, 1H), 
6.86 (s, 2H), 5.02 (s, 1H), 3.15 (hept, J = 6.8Hz, 2H), 1.23 (d, J = 6.8 Hz, 12H). mp = 
156-158oC: 13C NMR (101 MHz, CDCl3) δ 150.61, 137.39, 135.03, 129.37, 127.82, 
123.44, 119.64, 51.60, 27.58, 23.05. MS:[M+H]+: C16H23N2O, requires 259.1810, 
found 259.1809.  CHN omitted due to inconsistent results. 
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 5-Bromo-1,3-diisopropyl-2-methoxybenzene3 
 
 
34 
4-Bromo-2-6-diisopropylphenol (4.4 g, 17.1 mmol) was dissolved in THF (10 mL) and 
the resulting solution was cooled to 0oC. NaH (821 mg, 34.22 mmol) was added and 
the solution was allowed to stir for 10 mins before MeI (3.2 mL, 51.3 mmol) was 
added. The reaction mixture was stirred for a further 3 hours. The reaction was 
monitored by TLC and upon completion the reaction mixture was quenched with 
brine (50 mL), extracted with EtOAc (3x50 mL). The combined extracts were washed 
with NaOH (50 mL, 1M), dried over MgSO4 and concentrated under vacuum to 
afford the product as a pale yellow oil (4.3g, 99% yield). 1H NMR (400 MHz, CDCl3) δ 
7.18 (s, 2H), 3.71 (s, 3H), 3.28 (hept, J = 6.8 Hz, 2H), 1.21 (d, J = 6.8 Hz, 12H). 13C 
NMR (101 MHz, CDCl3) δ 154.03, 144.42, 127.68, 118.04, 62.49, 26.99, 24.17. 
MS:[M+H]+: C13H20BrO, requires: 272.0620, found 272.0614.   
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(3,5-diispropyl-4-methoxyphenyl)boronic acid 
 
37 
5-Bromo-1,3-diisopropyl-2-methoxybenzene (4.0 g, 14.7 mmol) was dissolved in 
anhydrous THF (30 mL) under a blanket of N2. The resulting solution was cooled to -
78oC before n-BuLi (9.5 mL, 23.6 mmol, 2.5M) was added. The resulting mixture was 
allowed to stir at -78oC for 1 hour before B(O-ipr)3 (6.8 mL, 29.5 mmol) was added. 
The reaction mixture was allowed to stir for 18 hours. Upon completion HCl (30 mL, 
2M) was added and the solution was stirred for a further 30 mins. The product was 
extracted with EtOAc (3x50 mL) and the combined organic extracts were washed 
with H2O (50 mL), brine (50 mL), dried over MgSO4 and the solvent was removed 
under vacuum. The product from this reaction was not isolated and was carried 
through crude. 
5-(3,5-diisopropyl-4-methoxyphenyl)-2-(trifluoromethyl)pyridine 
 
 
38 
(3,5-Diispropyl-4-methoxyphenyl)boronic acid (300 mg, 1.27 mmol) was reacted 
with 5-bromo-2-(trifluoromethyl)pyridine (203 mg, 1.01 mmol) according general 
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procedure 1. The crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as a white solid (234 mg, 69% yield). 1H 
NMR (400 MHz, CDCl3) δ 8.83 (s, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 8.1 Hz, 1H), 
7.22 (s, 2H), 3.72 (s, 3H), 3.32 (hept, J = 6.8 Hz, 2H), 1.21 (d, J = 6.8 Hz, 12H). 13C 
NMR (101 MHz, CDCl3) δ 155.93, 148.78, 146.38, 143.24, 140.19, 135.60, 132.91, 
123.75, 120.73, 62.73, 27.00, 24.42. 19F NMR (376 MHz, CDCl3) δ -68.12. MS:[M+H]
+  
C19H23NOF3, requires: 338.1732, found: 338.1734. 
General procedure 4. Demethylation  
 
 
 
The appropriately methylated reagent (1eq) was taken in DCM (10 mL/g) and 
cooled to 0oC before BBr3 (2.0eq) was added. The resulting solution was allowed to 
stir for 5 hours. Upon completion the reaction mixture was quenched with 
methanol (1 mL/g) and water (10 mL/g). The product was extracted with EtOAc (3 x 
30 mL) and the combined organic extracts were washed with brine (50 mL), dried 
over MgSO4 and concentrated under vacuum. The products were purified by 
column chromatography (EtOAc/n-Hexane).  
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2,6-Diisopropyl-4-(6-(trifluoromethyl)pyridine-3-yl)phenol 
 
 
40 
5-(3,5-diisopropyl-4-methoxyphenyl)-2-(trifluoromethyl)pyridine  (210 mg, 0.62 
mmol) was reacted with BBr3 (0.12 mL, 1.2 mmol) according to general procedure 
4.  The crude product was purified by column chromatography (60:40 EtOAc/n-
Hexane) to afford the product as a white solid. (96 mg, 48% yield). mp = 176-178oC: 
1H NMR (400 MHz, CDCl3) δ 8.90 (s, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.71 (d, J = 8.1 Hz, 
1H), 7.27 (s, 2H), 5.00 (s, 1H), 3.22 (hept, J = 6.8 Hz, 2H), 1.33 (d, J = 6.8 Hz, 12H). 13C 
NMR (101 MHz, CDCl3) δ 151.54, 148.63, 146.44, 146.10, 145.75, 140.55, 135.42, 
135.15, 123.16, 27.75, 23.08. 19F NMR (376 MHz, CDCl3) δ -67.99. MS:[M-H]
-  
C18H19NOF3, requires: 322.1419, found: 322.1425. CHN requires C: 66.86%, H6.23%, 
N: 4.33%, found C: 66.86%, H: 6.10%, N: 4.11%.  
4-(3,5-Diisopropyl-4-methoxyphenyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole 
 
 
39 
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 (3,5-Diispropyl-4-methoxyphenyl)boronic acid (280 mg, 1.20 mmol) was reacted 
with 4-Bromo-1-methyl-3-(trifluoromethyl)-1H-pyrazole (229 mg, 1.0 mmol) 
according to general procedure 1. The crude product was purified by column 
chromatography (40: 60 EtOAc/n-Hexane) to afford the product as a white solid. 
(197 mg, 58% yield). 1H NMR (400 MHz, CDCl3) δ 7.48 (s, 1H), 7.12 (s, 2H), 3.98 (s, 
3H), 3.76 (s, 3H), 3.35 (hept, J = 6.8 Hz, 2H), 1.25 (d, J = 6.8 Hz, 12H). 13C NMR (101 
MHz, CDCl3) δ 154.52, 142.05, 130.80, 126.90, 124.57, 123.30, 120.76, 62.68, 39.92, 
26.89, 24.39. 19F NMR (376 MHz, CDCl3) δ -59.24. MS:[M+H]
+ C18H24FNO2, requires: 
341.1835, found: 341.1837. 
 
2,6-Disopropyl-4-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)phenol 
 
 
41 
4-(3,5-Diisopropyl-4-methoxyphenyl)-1-methyl-3-(trifluoromethyl)-1H-
pyrazole(120mg, 0.35 mmol) was reacted with BBr3 (0.7 mL, 0.70 mmol) according 
to general procedure 4.The crude product was purified by column chromatography 
(60:40 EtOAc/n-Hexane) to afford the product as a white solid. (78 mg, 68%). mp = 
165-167oC:  1H NMR (400 MHz, CDCl3) δ 7.46 (s, 1H), 7.09 (s, 2H), 4.87 (s, 1H), 3.98 
(s, 3H), 3.17 (hept, J = 6.8 Hz, 2H), 1.28 (d, J = 6.8 Hz, 12H).  13C NMR (101 MHz, 
CDCl3) δ 154.52, 142.05, 130.80, 126.90, 124.57, 62.68, 26.89, 24.39.  
19F NMR (376 
MHz, CDCl3) δ -59.25. MS:[M-H]
- C17H20F3N2O, requires: 325.1528, found: 325.1526.   
CHN omitted due to inconsistent results. 
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2-(Benzyloxy)-5-bromo-1,3-diisopropylbenzene4 
 
42 
To a solution of 4-bromopropofol (500 mg, 1.44 mmol) in acetone (10 mL) was 
added BnBr (0.19 mL, 1.59 mmol) and K2CO3 (390 mg, 2.88 mmol). The resulting 
mixture was allowed to stir at room temperature for 18 hours and the reaction was 
monitored by TLC. Upon completion the mixture was filtered through Celite and the 
solvent was removed under vacuum to give the product as a white solid. The 
product was from this reaction was not isolated and was taken through crude. 
 
(4-(Benzyloxy)-3,5-diisopropylphenyl)boronic acid4 
 
 
37a 
4-Bromopropofol (300 mg, 0.96 mmol) was dissolved in anhydrous THF (5 mL) 
under a blanket of N2. The resulting solution was cooled to -78
oC before n-BuLi (0.61 
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mL, 1.54 mmol, 2.5M) was added. The resulting mixture was allowed to stir at -78oC 
for 1 hour before B(O-ipr)3 (0.44 mL, 1.92 mmol) was added. The reaction mixture 
was allowed to stir for 18 hours. Upon completion HCl (10 mL, 2M) was added and 
the solution was stirred for a further 30 mins. The product was extracted with 
EtOAc (3x30 mL) and the combined organic extracts were washed with H2O (30 mL), 
brine (30 mL), dried over MgSO4 and the solvent was removed under vacuum to 
give the product as a white solid. The product was from this reaction was not 
isolated and was taken through crude. 
 
4-(4-(Benzyloxy)-3,5-diisopropylphenyl)isoxazole 
 
 
43 
 (3,5-diispropyl-4-methoxyphenyl)boronic acid (200 mg, 0.85 mmol) was reacted 
with 4-bromoisoxazole (103 mg, 0.71 mmol) according to general procedure 1. The 
crude product was purified by column chromatography (30: 70 EtOAc/n-Hexane) to 
afford the product as an off white solid (32 mg, 62% yield). mp = 171-173oC: 1H NMR 
(400 MHz, CDCl3) δ 8.64 (s, 1H), 8.54 (s, 1H), 7.56 – 7.30 (m, 5H), 7.20 (s, 2H), 4.82 
(s, 2H), 3.42 (hept, J = 6.8 Hz, 2H), 1.27 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, 
CDCl3) δ 153.64, 153.41, 148.61, 143.43, 137.78, 129.02, 128.48, 127.81, 125.36, 
122.88, 122.05, 31.30, 27.09, 24.42.  
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 General procedure 5. Hydrogenation 
 
 
 
The benzyl protected phenol was dissolved in MeOH (20 mL/g). Pd/C (10 mol%) was 
added to the solution and the resulting mixture was degassed and placed under a 
blanket of H2. The mixture was allowed to stir for 18 hours. The reaction was 
followed by TLC and upon completion the reaction mixture was filtered through 
Celite and the solvent was removed under vacuum. 
2,6-Diisopropyl-4-(isoxazol-4-yl)phenol 
 
 
44 
4-(4-(Benzyloxy)-3,5-diisopropylphenyl)isoxazole  (180 mg, 0.65 mmol ) was reacted 
with Pd/C (35 mg, 0.03 mmol) according to general procedure 5. The crude product 
was purified by column chromatography (40:60 EtOAc/n-Hexane) to afford the 
product as a white solid. (80mg, 42% yield). mp = 156-158oC: 1H NMR (400 MHz, 
CDCl3) δ 8.59 (s, 1H), 8.51 (s, 1H), 7.13 (s, 2H), 4.95 (s, 2H), 3.19 (hept, J = 6.8 Hz, 
5H), 1.30 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 152.90, 150.70, 149.56, 
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135.01, 128.13, 122.28, 121.25, 27.66, 23.06. MS:[M+H]+ C15H19NO2 requires: 
246.1489, found: 246.1490. CHN omitted due to inconsistent results. 
General procedure 6. Mannich reaction 
 
 
To a solution of 2,6-Diisopropylphenol (1 eq) in ethanol/H2O (70:30)  was added the 
appropriate morpholine derivative (1.5 eq) and paraformaldehyde (1.5 eq). The 
resulting mixture was heated to reflux under stirring for 16 hours. The reaction was 
monitored by TLC (EtOAc/n-Hexane) and upon completion the reaction was 
quenched with H2O (50 mL/g) and extracted with EtOAc (3 x 30 mL). The combined 
organic extracts were dried over MgSO4 and reduced under vacuum. The crude 
product was purified by column chromatography (EtOAc/n-Hexane). 
 
2,6-Diisopropyl-4-(morpholinomethyl)phenol5 
 
 
49 
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2-6-Diisopropylphenol  (1 g, 5.6 mmol) was reacted with Morpholine (0.7 mL, 8.4 
mmol) and formaldehyde (0.72 mL, 8.4 mmol) according to general procedure 6. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as a white solid (1.28 g, 83% yield). mp = 122-
124oC:1H NMR (400 MHz, CDCl3) δ 6.97 (s, 2H), 4.91 (s, 1H), 3.74 – 3.63 (m, 4H), 3.43 
(s, 2H), 3.14 (hept, J = 6.8 Hz, 2H), 2.51 – 2.31 (m, 4H), 1.26 (d, J = 6.8 Hz, 12H). 13C 
NMR (101 MHz, CDCl3) δ 149.48, 133.88, 129.65, 124.89, 67.31, 63.86, 53.59, 27.46, 
23.19. MS:[M+H]+ C17H28NO2 requires: 278.2120, found: 278.2121.  CHN requires C: 
73.61%, H: 9.81%, N: 5.05, found C: 73.53%, H: 9.83%, N: 5.03%. 
 
2,6-Diisopropyl-4-((4-methylpiperazin-1-yl)methyl) phenol 
 
 
51 
2-6-Diisopropylphenol (1 g, 5.6 mmol) was reacted with N-methylpiperazine (0.9 
mL, 8.4 mmol) and formaldehyde (0.72 mL, 8.4 mmol) according to general 
procedure 6. The crude product was purified by column chromatography (20:80 
EtOAc/n-Hexane) to afford the product as a brown solid (1.27 g, 78% yield). mp = 
128-130oC: 1H NMR (400 MHz, CDCl3) δ 6.95 (s, 2H), 3.45 (s, 2H), 3.19 (hept, J = 6.8 
Hz, 2H), 2.48 (s, 8H), 2.27 (s, 3H), 1.23 (d, J = 6.8 Hz, 12H).13C NMR (101 MHz, CDCl3) 
δ 149.69, 134.59, 129.56, 124.78, 63.42, 54.26, 53.00, 46.42, 27.50, 23.34. 
MS:[M+H]+  C18H31N2O requires: 291.2436, found: 291.2437.  CHN omitted due to 
inconsistent results. 
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2,6-Diisopropyl-4-(thiomorpholinomethyl) phenol5 
 
 
50 
2-6-Diisopropylphenol (1 g, 5.6 mmol) was reacted with thiomorpholine (0.8 mL, 8.4 
mmol) and formaldehyde (0.72 mL, 8.4 mmol) according to general procedure 6. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as a light green solid (1.4 g, 87% yield). mp = 126-
128oC: 1H NMR (400 MHz, CDCl3) δ 6.95 (s, 2H), 4.72 (s, 1H), 3.45 (s, 2H), 3.14 (hept, 
J = 6.8 Hz, 2H), 2.68 (s, 8H), 1.26 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 
149.47, 133.82, 124.57, 63.93, 54.87, 28.26, 27.46, 23.19 . MS:[M+H]+  C17H28NOS 
requires: 294.1892, found: 294.1895.  CHN requires C: 69.58%, H: 9.27%, N: 4.77, 
found C: 68.40%, H: 9.32%, N: 4.82% 
2,6-Disopropyl-4-(piperidine-1-ylmethyl)phenol6 
 
 
54 
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2-6-Diisopropylphenol (1 g, 5.6 mmol) was reacted with piperidine (0.63 mL, 8.4 
mmol) and formaldehyde (0.72 mL, 8.4 mmol) according to general procedure 6. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as a light pink solid (1.17 g, 76% yield). mp = 134-
136oC: 1H NMR (400 MHz, CDCl3) δ 6.97 (s, 2H), 4.83 (s, 1H), 3.42 (s, 2H), 3.14 (hept, 
J = 6.8Hz, 2H), 2.36 (s, 4H), 1.62 – 1.52 (m, 4H), 1.42 (s, 2H), 1.26 (d, J = 6.8 Hz, 
12H).13C NMR (101 MHz, CDCl3) δ 149.47, 133.84, 129.64, 124.81, 72.10, 63.44, 
59.58, 27.46, 23.18, 19.38. MS:[M+H]+ C18H30NO requires: 275.2249, found: 
275.2242. CHN requires C: 78.49%, H: 10.61%, N: 5.09, found C: 78.19%, H: 10.59%, 
N: 4.97%. 
4-((2,6-Dimethylmorpholino)methyl)-2,6-diisopropylphenol 
 
52 
2-6-Diisopropylphenol (1 g, 5.6 mmol) was reacted with 2,6-dimethylpiperidine (1.0 
mL, 8.4 mmol) and formaldehyde (0.72 mL, 8.4 mmol) according to general 
procedure 6.  The crude product was purified by column chromatography (20:80 
EtOAc/n-Hexane) to afford the product as an off white solid (1.35 g, 79% yield). mp 
= 132-134oC: 1H NMR (400 MHz, CDCl3) δ 6.97 (s, 2H), 4.86 (s, 1H), 3.72 – 3.66 (m, 
2H), 3.41 (s, 2H), 3.15 (hept, J = 6.8 Hz, 2H), 2.71 (d, J = 10.5 Hz, 2H), 1.75 – 1.66 (m, 
2H), 1.26 (d, J = 6.8 Hz, 12H), 1.14 (d, J = 6.3 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 
149.47, 133.84, 129.64, 124.81, 72.10, 63.44, 59.58, 27.46, 23.18, 19.38. MS:[M+H]+  
C19H32NO2 requires: 306.2428, found: 306.2423. .  CHN omitted due to inconsistent 
results. 
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4-(((2S,6R)-2,6-dimethylmorpholino)methyl)-2,6-diisopropylphenol 
 
 
53 
2-6-Diisopropylphenol (500 mg, 2.8 mmol) was reacted with (2S,6R)-2,6-
dimethylmorpholine (0.52 mL, 4.2 mmol) and formaldehyde (0.35 mL, 4.2 mmol) 
according to general procedure 6. The crude product was purified by column 
chromatography (20:80 EtOAc/n-Hexane) to afford the product as a yellow solid 
(608 mg, 76% yield). mp = 144-146oC: 1H NMR (400 MHz, CDCl3) δ 6.98 (s, 1H), 4.77 
(s, 1H), 3.77 – 3.59 (m, 2H), 3.41 (s, 2H), 3.14 (hept, J = 6.8 Hz, 2H), 2.71 (d, J = 10.8 
Hz, 2H), 1.72 (t, J = 10.7 Hz, 2H), 1.27 (d, J = 6.8 Hz, 12H), 1.14 (d, J = 6.3 Hz, 6H). 13C 
NMR (101 MHz, CDCl3) δ 148.77, 133.34, 129.23, 124.48, 71.72, 63.06, 59.38, 27.10, 
22.80, 19.20. MS:[M+H]+  C19H32NO2 requires: 307.2428, found: 307.2421.  CHN 
omitted due to inconsistent results. 
2,6-Di-tert-butyl-4-(morpholinomethyl)phenol6 
 
 
60 
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2-6-Di-tert-butylphenol (1 g, 4.8 mmol) was reacted with Morpholine (0.6mL, 7.3 
mmol) and formaldehyde (0.6 mL, 7.3 mmol) according to general procedure 6. The 
crude product was purified by column chromatography (20:80 EtOAc/n-Hexane) to 
afford the product as a white solid 1.3g, 88% yield). mp = 138-140oC:  1H NMR (400 
MHz, CDCl3) δ 7.09 (s, 2H), 5.13 (s, 1H), 3.72 (s, 4H), 3.42 (bs, 2H), 2.44 (bs, 4H), 1.44 
(s, 18H).  13C NMR (101 MHz, CDCl3) δ 153.08, 135.85, 128.35, 126.31, 67.48, 63.92, 
53.89, 34.69, 30.62. MS [M+H]+:C19H32NO2 requires: 306.2433, found: 306.2442. 
CHN requires C: 74.71%, H: 10.23%, N: 4.59, found C: 74.65%, H: 10.29%, N: 4.92% 
2,6-Di-tert-butyl-4-(piperidin-1-ylmethyl)phenol6 
 
 
62 
2-6-Di-tert-butylphenol (1 g, 4.8 mmol) was reacted with piperidine (0.7 mL, 7.3 
mmol) and formaldehyde (0.6 mL, 7.3 mmol) according to general procedure 6.  
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as a white solid (1.2g, 86% yield). mp = 127-129oC:  1H 
NMR (400 MHz, CDCl3) δ 7.08 (s, 2H), 5.11 (s, 1H), 3.40 (bs, 4H), 2.37 (bs, 4H), 1.57 
(bs, 4H), 1.44 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 152.67, 135.32, 128.91, 125.96, 
64.04, 54.39, 34.37, 30.46, 26.09, 24.55. . MS [M+H]+:C20H34NO requires: 306.2640, 
found: 306.2635. CHN requires C: 79.15%, H: 10.96%, N: 4.62, found C: 78.98%, H: 
10.54%, N: 4.10% 
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2,6-Di-tert-butyl-4-(thiomorpholinomethyl)phenol6 
 
 
61 
2-6-Di-tert-butylphenol  (1.0 g, 4.8 mmol) was reacted with thiomorpholine (0.7 mL, 
7.3 mmol) and formaldehyde (0.6 mL, 7.3 mmol) according to general procedure 6. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product  as a white solid. (1.1g, 70% yield). mp = 124-126oC:    
1H NMR (400 MHz, CDCl3) δ 7.06 (s, 2H), 5.13 (s, 1H), 3.44 (s, 2H), 2.69 (bs, 8H), 1.44 
(s, 18H). 13C NMR (101 MHz, CDCl3) δ 153.31, 135.85, 129.90, 126.02, 64.17, 55.08, 
34.46, 30.61, 28.26. MS [M+H]+:C19H32NOS requires: 322.2205, found: 322.2193. 
CHN requires C: 70.98%, H: 9.72%, N: 4.36, found C: 70.78%, H: 9.74%, N: 4.32% 
2,6-Di-tert-butyl-4-(2,6-dimethylmorpholino)phenol 
 
 
63 
2-6-Di-tert-butylphenol (1.0 g, 4.8 mmol) was reacted with 2,6-dimethylmorpholine 
(830 mg, 7.3 mmol) and formaldehyde (0.6 mL, 7.3 mmol) according to general 
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procedure 6. The crude product was purified by column chromatography (20:80 
EtOAc/n-Hexane) to afford the product as an off white solid (1.4g, 89% yield). mp = 
132-134oC:  1H NMR (400 MHz, CDCl3) δ 7.08 (s, 2H), 5.14 (s, 1H), 3.77 – 3.62 (m, 
2H), 3.39 (s, 2H), 2.73 (d, J = 12.0 Hz, 2H), 1.73 (t, J = 12.0 Hz, 2H), 1.44 (s, 18H), 1.15 
(d, J = 4.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 153.09, 135.85, 127.39, 126.02, 
63.45, 59.88, 34.69, 30.78, 19.61. MS [M+H]+:C21H36NO2 requires: 334.2, found: 
334.4. CHN requires C: 75.63%, H: 10.58%, N: 4.20, found C: 75.25%, H: 10.63%, N: 
4.08% 
 
2,6-Di-tert-butyl-4-(((2S,6R)-2,6-dimethylmorpholino)methyl)phenol 
 
64 
2-6-Di-tert-butylphenol (500 mg, 2.4 mmol) was reacted with (2S,6R)-2,6-
dimethylmorpholine (0.45 mL, 3.6 mmol) and formaldehyde (0.30 mL, 3.6 mmol) 
according to general procedure 6. The crude product was purified by column 
chromatography (20:80 EtOAc/n-Hexane) to afford the product as a white solid (608 
mg, 76% yield). mp = 138-140oC:  1H NMR (400 MHz, CDCl3) δ 7.08 (s, 2H), 5.14 (s, 
1H), 3.70-3.63 (m, 2H), 2.89 – 2.79 (m, 4H), , 1.44 (s, 18H), 1.15 (s, 6H). 13C NMR (101 
MHz, CDCl3) δ 152.64, 135.32, 128.24, 125.68, 71.76, 63.03, 59.43, 34.14, 30.28, 
18.95. MS [M+H]+:C21H36NO2 requires: 334.2732, found: 334.4.2732. CHN requires 
C: 75.63%, H: 10.58%, N: 4.20, found C: 75.18%, H: 10.48%, N: 4.11% 
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4-Hydroxy-3-5-diisopropylbenzaldehyde7 
 
 
56 
Hexamethylenetetramine (15.8 g, 56 mmol) was added to a solution of 2,6-
Diisopropylphenol (10.4 mL) in glacial acetic acid (50 mL) and H2O (10 mL). The 
resulting mixture was heated to reflux for 6 hours and the reaction was monitored 
by TLC. Upon completion of the reaction the solution was cooled to 0oC and the 
resulting orange precipitate was isolated and washed with H2O (3 x 50 mL) to afford 
product as a pale orange solid (10.3 g, 89% yield). 1H NMR (400 MHz, CDCl3) δ 9.86 
(s, 1H), 7.63 (s, 2H), 5.49 (s, 1H), 3.21 (hept, J = 6.8 Hz, 2H), 1.31 (d, J = 6.8 Hz, 12H). 
13C NMR (101 MHz, CDCl3) δ 191.82, 156.02, 134.45, 129.66, 126.22, 27.06, 22.54 
.MS:[M+H]+  C13H19O2 requires: 207.1380, found: 207.1378.   
 
(4-Hydroxy-3-5-diisopropylphenyl)(morpholino)methanone 
 
 
77 
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4-Hydroxy-3-5-diisopropylbenzoyl chloride (130 mg, 0.54 mmol) was reacted with 
morpholine  (0.071 mL, 0.81 mmol) according to general procedure 3 to afford the 
product  as a white solid. The crude product was purified by trituration with EtOAc 
(120 mg, 76% yield). mp = 162-164oC: 1H NMR (400 MHz, CDCl3) δ 7.14 (s, 2H), 5.00 
(s, 1H), 3.70 (s, 4), 3.28 (hept, J = 6.8 Hz, 2H), 1.56 (s, 4H), 1.27 (d, J = 6.8 Hz, 12H). 
13C NMR (101 MHz, CDCl3) δ 134.05, 123.61, 77.74, 77.43, 77.11, 67.36, 27.56, 
23.01.MS:[M+Na]+ C17H25NNaO3  requires: 314.1740, found: 314.1732.  CHN omitted 
due to inconsistent results. 
 
(4-Hydroxy-3-5-diisopropylphenyl)(4-methylpiperazin-1-yl)methanone 
 
78 
4-Hydroxy-3-5-diisopropylbenzoyl chloride (160 mg, 0.66 mmol) was reacted with 
N-methylpiperazine (0.088 mL, 0.80 mmol) according to general procedure 3 to 
afford the product as a brown solid. The crude product was purified by trituration 
with EtOAc (109mg, 55% yield). mp = 154-156oC: 1H NMR (400 MHz, CDCl3) δ 7.13 
(s, 2H), 5.18 (s, 1H), 3.74 (s, 4H), 3.16 (hept, J = 6.8 Hz, 2H), 2.44 (s, 4H), 1.26 (d, J = 
6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 171.24, 151.59, 133.65, 127.18, 123.19, 
65.87, 54.82, 45.78, 27.12, 22.62. MS: C18H28N2O2  requires: 305.2229, found: 
305.2224.  CHN omitted due to inconsistent results. 
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 (4-Hydroxy-3-5-diisopropylphenyl)(thiomorpholino)methanone 
 
 
79 
4-Hydroxy-3-5-diisopropylbenzoyl chloride  (200 mg, 0.83 mmol) was reacted with 
thiomorpholine (102 mg, 0.095 mL) according to general procedure 3 to afford the 
product  as a pale blue solid. The crude product was purified by trituration with 
EtOAc (153 mg, 60% yield). mp = 122-124oC: 1H NMR (400 MHz, CDCl3) δ 7.10 (s, 
2H), 5.36 (s, 1H), 3.86 (s, 4H), 3.16 (hept, J = 6.8 Hz 2H), 2.66 (s, 4H), 1.24 (d, J = 6.8 
Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 171.60, 151.37, 133.69, 127.59, 122.84, 
65.87, 27.14, 22.62, 15.28.MS: C17H25NO2S  requires: 308.1684, found: 308.1672.  
CHN requires C: 66.41%, H: 8.20%, N: 4.56, found C: 66.13%, H: 8.28%, N: 4.49%. 
4-(benzyloxy)-3,5-diisopropylbenzaldehyde8 
 
84 
To a solution of 4-Hydroxy-3-5-diisopropylbenzaldehyde (4.18 g, 20.3 mmol) in 
acetone (50 mL) was added benzyl bromide (2.6 mL, 22.4 mmol) and potassium 
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carbonate (5.6 g, 40.6 mmol). The resulting mixture was allowed to stir at room 
temperature for 18 hours and the reaction was monitored by TLC. Upon completion 
the mixture was filtered through Celite™ and the solvent was removed under 
vacuum. The product was purified by column chromatography (10:90 EtOAc/n-
Hexane) to afford the product as a grey solid (5.3 g, 88% yield).  1H NMR (400 MHz, 
CDCl3) δ 9.96 (s, 1H), 7.69 (s, 2H), 7.55 – 7.30 (m, 5H), 4.85 (s, 2H), 3.40 (hept, J =6.8, 
2H), 1.27 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 192.03, 158.71, 143.34, 
136.93, 133.25, 128.70, 128.28, 127.44, 126.35, 66.35, 26.82, 23.92. MS: C20H24O2 
requires: 319.1679, found: 319.1674 
4-(benzyloxy)-3,5-diisopropylbenzoic acid 
 
 
85 
4-(benzyloxy)-3,5-diisopropylbenzaldehyde (1.74 g, 5.87 mmol) was dissolved in THF 
(5 mL) under a blanket of N2. Selenium dioxide (325 mg, 2.94 mmol) was added to 
the solution along with hydrogen peroxide (1.5 mL, 27 wt %) and the mixture was 
heated to reflux for 18 hours. Upon completion Pd/C (10 mg) was added and the 
reaction mixture was allowed to stir for 10 mins. The mixture was filtered through 
Celite™ and the solvent was removed under vacuum.  The product was purified by 
column chromatography (80:20 EtOAc/n-Hexane) to afford the product as a white 
solid (1.6 g, 85% yield). 1H NMR (400 MHz, CDCl3)
 δ 7.92 (s, 2H), 7.57 – 7.27 (m, 5H), 
4.85 (s, 2H), 3.40 (hept, J = 6.8Hz, 2H), 1.27 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, 
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CDCl3) δ 171.53, 158.06, 142.57, 137.06, 128.65, 128.19, 127.43, 126.77, 125.49, 
76.51, 26.76, 23.93. MS [M+Na]+: C20H24NaO3 requires: 335.1625, found: 335.1623 
 
4-(benzyloxy)-3,5-diisopropylbenzoyl chloride 
 
86 
4-(benzyloxy)-3,5-diisopropylbenzoic acid (200 mg, 0.6 mmol) was reacted with 
oxalyl chloride (0.12 mL, 0.72 mmol) according to general procedure 2. The product 
was not isolated and was taken through crude. 
(4-Benzyloxy-3-5-diisopropylphenyl)(morpholino)methanone 
 
 
87 
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Morpholine (0.23 mL, 2.25 mmol) was reacted with 4-(benzyloxy)-3,5-
diisopropylbenzoyl chloride (500 mg, 1.5 mmol) according to general procedure 3. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as a white solid (493 mg, 86% yield). 1H NMR (400 
MHz, CDCl3) δ 7.54 – 7.33 (m, 5H), 7.18 (s, 2H), 4.80 (s, 2H), 3.73 (s, 8H), 3.39 (hept, 
J = 6.8 Hz, 2H), 1.24 (d, J = 6.8 Hz, 12H). MS [M+Na]+:C24H31NaNO3 requires: 
404.2202, found: 404.2196.  
(4-(Benzyloxy)-3,5-diisopropylphenyl)(piperidin-1-yl)methanone 
 
 
86b 
Piperidine (0.23 mL, 2.25 mmol) was reacted with 4-(benzyloxy)-3,5-
diisopropylbenzoyl chloride (500 mg, 1.5 mmol) according to general procedure 3. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as an off white solid (546 mg, 95% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.52-7.32 (m, 5H), 7.16 (s, 2H), 4.80 (s, 1H), 3.71 (s, 4H), 3.39 
(hept, J = 6.8 Hz, 2H), 1.69 (s, 6H), 1.23 (d, J = 6.8 Hz, 12H).  13C NMR (101 MHz, 
CDCl3) δ 170.89, 154.06, 142.07, 137.43, 132.63, 128.61, 128.04, 127.39, 123.09, 
26.69, 24.70, 24.03. [M+H]+:C25H34NNaO2 requires: 380.2590, found: 380.257 
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(4-(Benzyloxy)-3,5-diisopropylphenyl)(2,6-
dimethylmorpholino)methanone 
 
 
86a 
Dimethylmorpholine (0.28 mL, 2.25 mmol) was reacted with 4-(benzyloxy)-3,5-
diisopropylbenzoyl chloride (500 mg, 1.52 mmol) according to general procedure 3 . 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as an off white solid (550 mg, 90% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.42(m, 5H), 7.17 (s, 2H), 4.81 (s, 2H), 3.62 (s, 2H), 3.39 (hept, J = 
6.8 Hz, 2H), 2.57 (s, 4H), 1.23 (d, J = 6.8 Hz, 12H), 1.14 (s, 6H). 13C NMR (101 MHz, 
CDCl3) δ 170.63, 154.46, 142.33, 137.31, 131.58, 128.63, 128.10, 127.37, 123.52, 
72.08, 26.69, 24.00. MS [M+Na]+:C26H35NNaO3 requires: 432.2515, found: 432.2520 
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(S)-(4-(Benzyloxy)-3,5-diisopropylphenyl)(3-
methylmorpholino)methanone 
 
86c 
(S)-3-Methyl morpholine (0.12 mL, 1.2 mmol) was reacted with 4-(benzyloxy)-3,5-
diisopropylbenzoyl chloride (264 mg, 0.8 mmol) according to general procedure 3. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as an off white solid (164 mg, 52% yield).  1H NMR 
(400 MHz, CDCl3) δ 7.51 – 7.32 (m, 5H), 7.15 (s, 2H), 4.80 (s, 2H), 4.05 – 3.55 (m, 
5H), 3.39 (hept, J = 6.8 Hz, 2H) 1.41 (d, 3H), 1.24 (d, J = 6.8 Hz, 12H). 13C NMR (101 
MHz, CDCl3) δ 154.31, 142.42, 137.30, 132.01, 128.61, 128.08, 127.36, 122.88, 
71.05, 67.18, 26.69, 24.00. MS [M+H]+:C25H34NO3 requires: 396.2533, found: 
396.22546. 
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 (R)-(4-(Benzyloxy)-3,5-diisopropylphenyl)(3-
methylmorpholino)methanone 
 
86d 
(R)-3-Methyl morpholine (0.12 mL, 1.2 mmol) was reacted with 4-(benzyloxy)-3,5-
diisopropylbenzoyl chloride (264 mg, 0.8 mmol) according to general procedure 3. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as an off white solid (145 mg, 46% yield).  1H NMR 
(400 MHz, CDCl3) δ 7.52 – 7.31 (m, 5H), 7.15 (s, 2H), 4.80 (s, 2H), 3.92 – 3.66 (m, 
6H), 3.38 (hept, J = 6.8 Hz, 2H), 1.41 (d, 3H), 1.24 (d, J = 6.8 Hz, 12H). 13C NMR (101 
MHz, CDCl3) δ 154.31, 142.42, 137.30, 132.01, 128.62, 128.09, 127.36, 122.88, 
71.05, 67.18, 26.69, 24.00. MS [M+H]+:C25H34NO3 requires: 396.2533, found: 
396.22540. 
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(S)-(4-(Benzyloxy)-3,5-diisopropylphenyl)(2-
methylmorpholino)methanone 
 
86f 
(S)-2-Methyl morpholine (0.12 mL, 1.2 mmol) was reacted with 4-(benzyloxy)-3,5-
diisopropylbenzoyl chloride (264 mg, 0.8 mmol) according to general procedure 3. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as an off white solid (132 mg, 42% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.52 – 7.31 (m, 5H), 7.18 (s, 2H), 4.81 (s, 2H), 4.59 (s, 1H), 3.99 – 
3.51 (m, 7H), 3.38 (hept, J = 6.8 Hz, 2H), (d, J = 6.8 Hz, 12H), 1.15 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.82, 154.47, 142.36, 137.28, 128.62, 128.09, 127.37, 123.46, 
72.14, 26.69, 23.99. MS [M+H]+:C25H34NO3 requires: 396.2533, found: 396.22547. 
R)-(4-(Benzyloxy)-3,5-diisopropylphenyl)(2-methylmorpholino)methanone 
 
86e 
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(R)-2-Methyl morpholine (0.12 mL, 1.2 mmol) was reacted with 4-(benzyloxy)-3,5-
diisopropylbenzoyl chloride (264 mg, 0.8 mmol) according to general procedure 3. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as an off white solid (151 mg, 48% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.52 – 7.34 (m, 5H), 7.18 (s, 2H), 4.81 (s, 2H), 4.59 (s, 1H), 4.13 – 
3.31 (m, 7H), 3.15 (hept, J = 6.8 Hz, 2H), 1.24 (d, J = 6.8 Hz, 12H), 1.22 (d, 3H). 13C 
NMR (101 MHz, CDCl3) δ 170.84, 154.49, 142.37, 137.29, 128.63, 128.03, 127.38, 
123.47, 76.46, 72.16, 66.57, 26.49, 24.01. MS [M+H]+:C25H34NO3 requires: 396.2533, 
found: 396.22539. 
(4-(Benzyloxy)-3,5-diisopropylphenyl)(4-fluoropiperidin-1-yl)methanone 
 
 
86g 
4-Fluoropiperidine hydrochloride (167 mg, 1.2 mmol) was reacted with 4-
(benzyloxy)-3,5-diisopropylbenzoyl chloride (264 mg, 0.8 mmol) according to 
general procedure 3.The crude product was purified by column chromatography 
(20:80 EtOAc/n-Hexane) to afford the product as an off white solid (158 mg, 50% 
yield). 1H NMR (400 MHz, CDCl3) δ 7.32-7.24 (m, 5H), 7.09 (s, 2H), 4.87 (d, J = 48.4 
Hz, 1H) 4.72 (s, 2H), 3.88-3.56 (m, 4H), 3.30 (hept, J =, 6.8 Hz, 2H), 1.80 (s, 4H), 1.15 
(d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 171.44, 154.81, 142.70, 137.72, 
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132.35, 129.01, 128.48, 127.78, 123.55, 89.07, 87.36, 76.85, 27.11, 24.41. MS 
[M+H]+:C25H33FNO3 requires: 398.2490, found: 398.2490. 
(4-(Benzyloxy)-3,5-diisopropylphenyl)(1,4-oxzepan-4-yl)methanone 
 
86h 
1,4-Oxazepane (121mg, 1.2 mmol) was reacted with 4-(benzyloxy)-3,5-
diisopropylbenzoyl chloride (264 mg, 0.8 mmol) according to general procedure 3. 
The crude product was purified by column chromatography (20:80 EtOAc/n-
Hexane) to afford the product as an off white solid (190mg, 78% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.51 – 7.34 (m, 5H), 7.17 (s, 2H), 4.80 (s, 2H), 3.84-3.53 (m, 8H), 
3.39 (hept, J = 6.8 Hz, 2H), 2.07 (s, 2H), 1.23 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, 
CDCl3) δ 154.12, 148.46, 142.32, 137.35, 132.79, 128.35, 127.38, 26.70, 24.03. MS 
[M+H]+:C25H33FNO3 requires: 396.2533, found: 396.2538. 
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tert-Butyl 4-(4-(bezyloxy)-3,5-diisopropylbenzoyl)piperazine-1-
carboxylate 
 
86j 
tert-Butyl piperazine-1-carboxylate (418 mg, 2.25  mmol) was reacted with 4-
(benzyloxy)-3,5-diisopropylbenzoyl chloride (500 mg, 1.5 mmol) according to 
general procedure 3 . The crude product was purified by column chromatography 
(20:80 EtOAc/n-Hexane) to afford the product as a white solid. The product from 
this reaction was not isolated and was carried through crude. 
4-(benzyloxy)-3,5-diisopropylphenyl)(3-fluoroazetidin-1-yl)methanone 
 
 
86i 
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3-Fluoroazetidine hydrochloride (250 mg, 2.25  mmol) was reacted with 4-
(benzyloxy)-3,5-diisopropylbenzoyl chloride (500 mg, 1.5 mmol) according to 
general procedure 3 . The product from this reaction was not isolated and was 
carried through crude. 
(4-hydroxy-3,5-diisopropylphenyl)(piperidine-1-yl)methanone 
 
 
98 
(4-hydroxy-3,5-diisopropylphenyl)(piperidine-1-yl)methanone (520 mg, 1.37 mmol) 
was reacted with Pd/C (32 mg, 0.27 mmol) General procedure . The crude product 
was purified by column chromatography (40:60 EtOAc/n-Hexane) to afford the 
product as an off white solid (111 mg, 96% yield). mp = 172-174oC: 1H NMR (400 
MHz, CDCl3) δ. 7.13 (s, 2H), 5.17 (s, 1H), 3.74 (s, 4H), 3.15 (hept, J = 6.8 Hz, 2H), 2.74 
(s, 6H), 1.26 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 171.43, 152.11, 134.14, 
126.52, 123.21, 72.14, 66.68, 26.88, 22.68, 18.61. MS [M+Na]+:C18H27NNaO3 
requires: 328.1899, found: 328.1889. CHN requires C: 70.79%, H: 8.91%, N: 4.59, 
found C: 70.56%, H: 8.55%, N: 4.61% 
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(2,6-Dimethylmorpholino)(4-hydroxy-3,5-diisopropyl)methanone 
 
 
99 
(4-(Benzyloxy)-3,5-diisopropylphenyl)(2,6-dimethylmorpholino)methanone (520 
mg, 1.27 mmol) was reacted with Pd/C (32 mg, 0.27 mmol) according to General 
procedure . The crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as an off white solid (385 mg, 95% yield). 
mp = 168-170oC:1H NMR (400 MHz, CDCl3) δ 7.12 (s, 2H), 5.24 (s, 1H), 3.62 (s, 4H), 
3.16 (hept, J = 6.8 Hz, 2H), 2.59 (s, 2H), 1.24 (d, J = 6.8 Hz, 12H), 1.22 (s, 6H). 13C 
NMR (101 MHz, CDCl3) δ 170.97, 151.60, 133.67, 127.21, 123.27, 72.06, 65.88, 
27.10, 22.63, 18.70, 15.28. MS [M+H]+:C19H30NO3 requires: 320.2220, found: 
320.2230. CHN requires C: 71.44%, H: 9.15%, N: 4.38, found C: 70.98%, H: 8.87%, N: 
5.11% 
(4-(hydroxy)-3,5-diisopropylphenyl)(morpholino)methanone 
 
 
77a 
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(4-Benzyloxy-3-5-diisopropylphenyl)(morpholino)methanone (470 mg, 1.3 mmol) 
was reacted with Pd/C (32 mg, 0.27 mmol) according to General procedure . The 
crude product was purified by column chromatography (40:60 EtOAc/n-Hexane) to 
afford the product as an off white solid (366 mg, 97% yield). Analysis consistent 
with 77. 
(S)-(4-Hydroxy-3,5-diisopropylphenyl)(3-methylmorpholino)methanone 
 
 
99 
(S)-(4-(Benzyloxy)-3,5-diisopropylphenyl)(3-methylmorpholino)methanone (120 mg, 
0.30 mmol) was reacted with Pd/C (35 mg, 0.03 mmol) according to General 
procedure . The crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as an off white solid (84 mg, 90% yield). mp 
= 174-178oC: 1H NMR (400 MHz, CDCl3) δ 7.11 (s, 2H), 5.05 (s, 1H), 3.90 – 3.31 (m, 
7H), 3.15 (hept, J = 6.8 Hz, 2H), 1.24 (d, 3H) 1.24 (d, J = 6.8 Hz, 12H). 13C NMR (101 
MHz, CDCl3) δ 142.28, 128.51, 128.03, 127.38, 123.47, 72.16, 26.62, 23.80.MS 
[M+Na]+:C18H27NNaO3 requires: 328.1889, found: 328.1884. CHN requires C: 
70.79%, H: 8.91%, N: 4.59, found C: 70.68%, H: 8.74%, N: 4.14% 
 
 
Chapter VI 
 
 
257 | P a g e  
 
(R)-(4-Hydroxy-3,5-diisopropylphenyl)(3-methylmorpholino)methanone 
 
 
100 
(R)-(4-(Benzyloxy)-3,5-diisopropylphenyl)(3-methylmorpholino)methanone (300 mg, 
0.75 mmol) was reacted with Pd/C (89 mg, 0.075 mmol) according to gGeneral 
procedure . The crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as an off white solid (227 mg, 98% yield). 
mp = 182-184oC:  1H NMR (400 MHz, CDCl3) δ 7.11 (s, 2H), 3.97 – 3.29 (m, 7H), 3.15 
(hept, J =, 6.8 Hz, 2H), 1.39 (d, 3H), 1.27 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, 
CDCl3) δ 171.35, 151.42, 133.72, 127.70, 122.68, 71.07, 67.22, 27.15, 22.63, 15.48. 
MS [M+Na]+:C18H27NNaO3 requires: 328.1889, found: 328.1901. CHN requires C: 
70.79%, H: 8.91%, N: 4.59, found C: 70.24%, H: 8.87%, N: 4.52% 
(S)-(4-Hydroxy-3,5-diisopropylphenyl)(2-methylmorpholino)methanone 
 
 
102 
(S)-(4-(Benzyloxy)-3,5-diisopropylphenyl)(2-methylmorpholino)methanone (100 mg, 
0.25 mmol) was reacted with Pd/C (29 mg, 0.025 mmol) according to General 
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procedure . The crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as an off white solid (74 mg, 96% yield). mp 
= 188-190oC:  1H NMR (400 MHz, CDCl3) δ 7.13 (s, 1H), 5.07 (s, 1H), 4.94 – 3.28 (m, 
7H), 3.21 (hept, J = 6.8 Hz, 2H), 1.26 (d, J = 6.8 Hz, 12H), 1.18 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 171.69, 152.26, 134.31, 127.24, 123.63, 72.54, 67.11, 27.41, 23.05, 
19.03. MS [M+Na]+:C18H27NNaO3 requires: 328.1889, found: 328.1892. CHN requires 
C: 70.79%, H: 8.91%, N: 4.59, found C: 70.20%, H: 8.58%, N: 4.62% 
 
(R)-(4-Hydroxy-3,5-diisopropylphenyl)(2-methylmorpholino)methanone 
 
 
101 
(R)-(4-(Benzyloxy)-3,5-diisopropylphenyl)(2-methylmorpholino)methanone (100 mg, 
0.25 mmol) was reacted with Pd/C (29 mg, 0.025 mmol) according to General 
procedure 5. The crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as an off white solid (75 mg, 97% yield). mp 
= 176-178oC:  1H NMR (400 MHz, CDCl3) δ 7.13 (s, 2H), 5.17 (s, 1H), 4.72 – 3.35 (m, 
6H), 3.16 (hept, J = 6.8 Hz, 2H), 2.75 (s, 1H), 1.26 (d, J = 6.8 Hz, 12H), 1.18 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 171.43, 152.11, 134.14, 126.52, 123.21, 77.29, 72.14, 
66.68, 26.88, 22.68, 18.61. MS [M+Na]+:C18H27NNaO3 requires: 328.1889, found: 
328.1899. CHN requires C: 70.79%, H: 8.91%, N: 4.59%, found C: 70.56%, H: 8.55%, 
N: 4.61% 
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(4-Fluoropipereridin-1-yl)(4-hydroxy-3,5-diisopropyl)methanone 
 
 
103 
(4-(Benzyloxy)-3,5-diisopropylphenyl)(4-fluoropiperidin-1-yl)methanone (278 mg, 
0.70 mmol) was reacted with Pd/C (83 mg, 0.07 mmol according to General 
procedure . The crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as an off white solid (197 mg, 92% yield). 
mp = 188-190oC: 1H NMR (400 MHz, CDCl3) δ 7.13 (s, 2H), 5.06 (s, 1H), 4.97 (d, J = 
48.4 2H), 3.64 (s, 4H), 3.15(hept, J = 6.8 Hz 2H), 1.88 (s, 4H), 1.26 (d, J = 6.8 Hz, 12H). 
13C NMR (101 MHz, CDCl3) δ 171.44, 151.56, 133.67, 127.49, 122.95, 88.81, 87.11, 
27.11, 22.64. MS [M+Na]+:C18H26FNNaO2 requires: 330.1845, found: 330.1842. CHN 
requires C: 70.33%, H: 8.53%, N: 4.56%, found C: 69.68%, H: 8.56%, N: 4.43% 
 
(4-Hydroxy-3,5-diisopropylphenyl)(1,4-oxzepan-4-yl)methanone 
 
 
104 
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(4-(Benzyloxy)-3,5-diisopropylphenyl)(1,4-oxzepan-4-yl)methanone (150 mg, 0.38 
mmol) was reacted with Pd/C (45 mg, 0.04 mmol) according to General procedure . 
The crude product was purified by column chromatography (40:60 EtOAc/n-
Hexane) to afford the product as an off white solid (82 mg, 71% yield). mp = 184-
186oC: 1H NMR (400 MHz, CDCl3) δ 7.12 (s, 2H), 3.83 – 3.80 (m, 8H), 3.15 (hept, J =, 
6.8 Hz, 2H), 1.93 (s, 2H), 1.26 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 
172.71, 151.33, 133.72, 128.33, 122.59, 69.81, 69.28, 52.68, 48.91, 48.57, 31.21, 
27.08, 22.67. MS [M+Na]+:C18H27NNaO3 requires: 328.1889, found: 328.1886. CHN 
omitted due to inconsistent results. 
(3-Fluoroazetidin-1-yl)(4-hydroxy-3,5-diisopropylphenyl)methanone 
 
 
105 
4-(benzyloxy)-3,5-diisopropylphenyl)(3-fluoroazetidin-1-yl)methanone (387 mg, 
1.05 mmol) was reacted with Pd/C (32 mg, 0.27 mmol) according to general 
procedure 5. The crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as a white solid (223 mg, 76% yield). mp = 
182-184oC:  1H NMR (400 MHz, CDCl3) δ 7.36 (s, 2H), 5.66 (s, 1H), 5.36 (m, 1H), 4.58  
– 4.26(m, 4H), 3.19 (hept, J = 6.8 Hz, 2H), 1.25 (d, J = 6.8 Hz, 12H).  13C NMR (101 
MHz, CDCl3) δ 154.52, 142.05, 130.80, 126.90, 124.57, 85.61, 62.68, 26.89, 
24.39.MS [M+H]+:C16H23FNO3 requires: 280.1711, found: 280.1707 CHN requires C: 
68.79%, H: 7.94%, N: 5.01, found C: 68.55%, H: 7.89%, N: 4.92% 
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tert-Butyl 4-(4-(hydroxy)-3,5-diisopropylbenzoyl)piperazine-1-
carboxylate 
 
 
111 
tert-Butyl 4-(4-(bezyloxy)-3,5-diisopropylbenzoyl)piperazine-1-carboxylate (200 mg, 
0.42 mmol) was reacted with Pd/C (49 mg, 0.04 mmol) according to general 
procedure 5. The crude product was purified by column chromatography (20:80 
EtOAc/n-Hexane) to afford the product as a white solid (159 mg, 98% yield). 1H 
NMR (400 MHz, CDCl3) δ 7.13 (s, 2H), 5.26 (s, 1H), 3.46 (s, 8H), 3.16 ( hept, J = 6.8 
Hz, 2H), 1.48 (s, 9H), 1.25 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 171.50, 
154.68, 151.70, 133.74, 127.14, 123.17, 28.39, 27.11, 22.63.  
(4-(hydroxy)-3,5-diisopropylphenyl)piperazine-1-yl)methanone 
 
106 
tert-Butyl 4-(4-(hydroxy)-3,5-diisopropylbenzoyl)piperazine-1-carboxylate (140 mg, 
0.36 mmol) was added to a stirred solution of trifluoroacetic acid (0.41 mL, 5.4 
mmol) in DCM (5 mL). The resulting reaction mixture was allowed to stir for 18 
hours. The reaction was followed by TLC and upon completion the solvent was 
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removed under vacuum. NaHCO3 (10 mL) was added to the reaction mixture and 
the crude compound was extracted with EtOAc (3 x 20 mL) washed with H2O (20 
mL) and brine (20 mL). The combined organic extracts were dried over MgSO4 and 
the solvent was removed under vacuum. The crude product was purified by 
trituration with EtO2 to give the pure product as a white solid (62 mg, 60% yield) mp 
= 155-157oC:  1H NMR (400 MHz, CDCl3) δ 7.13 (s, 2H), 5.26 (s, 1H), 3.16 (hept, J = 
6.8 Hz, 2H), 1.48 (s, 9H), 1.26 (d, J = 6.8 Hz, 12H). 3C NMR (101 MHz, CDCl3) δ 
171.29, 150.90, 133.57, 127.57, 122.98, 46.17, 34.37, 27.12, 22.35. MS 
[M+H]+:C17H27N2O2 requires: 291.2067, found: 291.2077. CHN omitted due to 
inconsistent results. 
(4-Hydroxy-3-5-diisopropylphenyl)(morpholino)methanone (Microwave 
Reaction)  
 
77b 
4-Bromopropofol (1 g, 3.9 mmol) was dissolved in 1,4-dioxane 20 added to a 
microwave vial (30 mL) along with morpholine (0.67 mL, 7.7 mmol), Na2CO3 (1.17 
mg, 11.6 mmol), MO(CO)6 (601 mg, 2.3 mmol) and trans-Bis(acetato)bis[o-(di-o-
tolylphosphino)benzyl]dipalladium(II) (178 mg, 0.19 mmol). The reaction mixture 
was placed in a microwave reactor for 20 minutes at 165oC. Upon completion the 
mixture was diluted with H2O (20 mL) and the crude product was extracted with 
EtOAc (3 x 30 mL). The combined organic extracts were washed with  H2O (20 mL) 
and brine (20 mL) before being dried over MgSO4. The solvent was removed under 
vacuum and the crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as a white solid (60% yield).  The analysis 
was consistent with 77. 
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2,2,2-Trifluoro-1-4(-hydroxy-3,5-diisopropylphenyl)ethanone9 
 
 
108 
AlCl3 (1.1 g, 8.4 mmol) was suspended in DCM and cooled to -48 
oC. Trifluoroacetic 
anhydride (0.86 mL, 6.2 mmol in 2 mL DCM) was added drop wise and the resulting 
suspension was allowed to stir at -48oC for 30 mins. Propofol (1 g, 5.6 mmol in 2 mL 
DCM) was added drop wise and the reaction mixture was stirred at -48oC for 3 
hours before being allowed to come to room temperature overnight. The reaction 
was monitored by TLC and upon completion the mixture was poured onto a mixture 
of ice and 2M HCl (150 mL of each) and stirred for 1 hour. The mixture was 
extracted with EtOAc (3x100 mL) and the combined organic extracts were washed 
with brine (100 mL) and dried over MgSO4. The solvent was removed under 
vacuum. The crude product was purified by column chromatography (60:40 
EtOAc/n-Hexane) to afford the product as a brown oil (2.7g, 45% yield).  1H NMR 
(400 MHz, CDCl3) δ 7.83 (s, 2H), 5.57 (s, 1H), 3.17 (hept, J = 6.8 Hz, 2H), 1.31 (d, J = 
6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 179.91, 157.17, 134.58, 127.17, 123.12, 
115.94, 27.45, 22.79. 19F NMR (376 MHz, CDCl3) δ -70.48.MS [M+Na]
+:C14H17F3NaO2 
requires: 297.1078, found: 297.1079. 
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3,5-Di-tert-butyl-4-hydroxybenzoyl chloride 
 
 
91 
3,5-Di-tert-butyl-4-hydroxybenzoic acid  (2 g, 8.5 mmol) was reacted with oxalyl 
chloride (1.4 mL, 17 mmol) according to general procedure 2 to afford the product  
as a pale yellow oil. The product from this reaction was not isolated and was carried 
through crude. 
(3,5-Di-tert-butyl-4-hydroxyphenyl)(piperidin-1-yl)methanone10 
 
 
96 
3,5-Di-tert-butyl-4-hydroxybenzoyl chloride (1 g, 3.7 mmol) was reacted with 
piperazine (0.6 mL, 5.6 mmol) according to general procedure 3   . The crude 
product was purified by column chromatography (40:60 EtOAc/n-Hexane) to afford 
the product as an off white solid (916 mg, 91% yield). mp = 147-149oC:  1H NMR (400 
MHz, CDCl3) δ 7.23 (s, 2H), 5.37 (s, 1H), 3.75 – 3.29 (m, 4H), 1.73 – 1.54 (m, 6H), 1.43 
(s, 18H). 13C NMR (101 MHz, CDCl3) δ 171.79, 155.38, 135.99, 127.66, 124.73, 34.76, 
30.58, 25.14. MS [M+H]+:C20H32NO2 requires: 318.2433, found: 318.2431. CHN 
requires C: 75.67%, H: 9.84%, N: 4.41, found C: 75.48%, H: 9.88%, N: 4.44% 
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(3,5-Di-tert-butyl-4-hydroxyphenyl)(morpholino)methanone10 
 
 
92 
3,5-Di-tert-butyl-4-hydroxybenzoyl chloride (1 g, 3.7 mmol) was reacted with 
morpholine (0.5 mL, 5.6 mmol) according to general procedure 3  . The crude 
product was purified by column chromatography (40:60 EtOAc/n-Hexane) to afford 
the product as an off white solid (957 mg, 81% yield). mp = 174-176oC:  1H NMR 
(400 MHz, CDCl3) δ 7.24 (s, 2H), 5.43 (s, 1H), 3.71 (s, 8H), 1.44 (s, 18H).
13C NMR (101 
MHz, CDCl3) δ 171.98, 155.70, 136.06, 126.20, 124.86, 67.30, 34.70, 30.38. MS 
[M+Na]+:C19H29NNaO3 requires: 342.2045, found: 342.2056. CHN requires C: 
71.44%, H: 9.15%, N: 4.38, found C: 71.03%, H: 9.13%, N: 4.28% 
(3,5-Di-tert-butyl-4-hydroxyphenyl)(thiomorpholino)methanone10 
 
 
93 
3,5-Di-tert-butyl-4-hydroxybenzoyl chloride (1 g, 3.7 mmol) was reacted with 
thiomorpholine (0.5 mL, 5.6 mmol) according to general procedure 3  . The crude 
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product was purified by column chromatography (40:60 EtOAc/n-Hexane) to afford 
the product as an off white solid (1.04 g, 84% yield). mp = 182-184oC:  1H NMR (400 
MHz, CDCl3) δ 7.21 (s, 2H), 5.42 (s, 1H), 3.88 (bs, 4H), 2.68 (bs, 4H), 1.44 (s, 18H). 
13C 
NMR (101 MHz, CDCl3) δ 172.30, 155.68, 136.30, 126.72, 124.83, 34.71, 30.38, 
28.27, 28.02. MS [M+Na]+:C19H29NNaO2 requires: 358.1817, found: 358.1825 CHN 
requires C: 71.44%, H: 9.15%, N: 4.38, found C: 71.25%, H: 9.09%, N: 4.19% 
(3,5-Di-tert-butyl-4-hydroxyphenyl)(2,6-dimethylmorpholino)methanone 
 
 
94 
3,5-Di-tert-butyl-4-hydroxybenzoyl chloride (1 g, 3.7 mmol) was reacted with 2,6-
dimethylmorpholine (0.7 mL, 5.6 mmol) according to general procedure 3. The 
crude product was purified by column chromatography (40:60 EtOAc/n-Hexane) to 
afford the product as an off white solid (820 mg, 68% yield). mp = 171-173oC:  1H 
NMR (400 MHz, CDCl3) δ 7.25 (s, 2H), 5.58 (s, 1H), 4.54-3.64 (m, 4H), 2.65 (s, 2H), 
1.44 (s, 18H), 1.19 (d, 6H). 13C NMR (101 MHz, CDCl3) δ 135.85, 126.02, 64.17, 55.08, 
34.46, 30.61, 28.26. MS [M+H]+:C21H34NNaO3 requires: 348.2539, found: 348.2526. 
CHN requires C: 71.44%, H: 9.15%, N: 4.38, found C: 71.78%, H: 9.58%, N: 3.88% 
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(3,5-Di-tert-butyl-4-hydroxyphenyl)((2S,6R)-2,6-
)dimethylmorpholino)methanone 
 
 
95 
3,5-Di-tert-butyl-4-hydroxybenzoyl chloride (1 g, 3.7 mmol) was reacted with 2,6-
dimethylmorpholine (0.7 mL, 5.6 mmol) according to general procedure 3. The 
crude product was purified by column chromatography (40:60 EtOAc/n-Hexane) to 
afford the product as an off white solid (820 mg, 68% yield). mp = 181-183oC:  1H 
NMR (400 MHz, CDCl3) δ 7.40 (s, 2H), 5.80 (s, 1H), 3.64 (bs, 4H), 2.68 (bs, 2H), 1.50 
(s, 18H), 1.44 (bs, 6H). 13C NMR (101 MHz, CDCl3) δ 166.81, 158.67, 143.47, 136.02, 
127.80, 71.97, 34.15, 31.43, 30.18. MS [M+H]+:C21H34NO3 requires: 348.2539, found: 
348.2533. CHN requires C: 71.44%, H: 9.15%, N: 4.38, found C: 71.27%, H: 8.98%, N: 
3.54% 
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(4-(Benzyloxy)-3,5-diisopropylphenyl)(2-oxa-6-azaspiro[3.3]heptan-6-
yl)methanone 
 
123 
To a solution of 4-(benzyloxy)-3,5-diisopropylbenzoic acid (100 mg, 0.32 mmol) in 
DMF (5 mL) was added HATU (180, 0.48 mmol), K2CO3 (220 mg, 1.6 mmol) and 2-
oxa-6-azaspiro[3.3]heptan-6-ium carboxyformate (101 mg, 0.35 mmol). The 
resulting solution was allowed to stir for 1hour. Upon completion the reaction 
mixture was quenched with H2O (20 mL) and extracted with EtOAc (3 x 30 mL). The 
combined organic extracts were washed with H2O (3 x 30 mL), brine (20 mL), dried 
over MgSO4 and the solvent was removed under vacuum. The crude product was 
purified by column chromatography (20:80 EtOAc/n-Hexane) to afford the product 
as a white solid (62 mg, 50% yield). 1H NMR (400 MHz, CDCl3) δ 7.54 – 7.31 (m, 7H), 
4.83 (d, J = 11.7 Hz, 6H), 4.40 (d, J = 42.4 Hz, 4H), 3.39 (hept, J = 6.8 Hz, 2H), 1.25 (d, 
J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 170.82, 157.83, 142.63, 128.66, 
128.31, 127.37, 126.60, 125.44, 72.92, 60.89, 53.37, 26.39, 24.02. MS 
[M+Na]+:C25H31NNaO3 requires: 416.2202, found: 416.2186.  
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(4-Hydroxy-3,5-diisopropylphenyl)(2-oxa-6-azaspiro[3.3]heptan-6-
yl)methanone 
 
 
107 
(4-(Benzyloxy)-3,5-diisopropylphenyl)(2-oxa-6-azaspiro[3.3]heptan-6-yl)methanone 
(50 mg, 0.13 mmol) was reacted with Pd/C (15 mg, 0.12 mmol) according to general 
procedure 5. The crude product was purified by column chromatography (40:60 
EtOAc/n-Hexane) to afford the product as a white solid (38 mg, 99% yield) 1H NMR 
(400 MHz, CDCl3) δ 7.35 (s, 2H), 5.43 (s, 1H), 4.82 (s, 4H), 4.39 (d, J = 41.9 Hz, 4H), 
3.16 (hept, J = 6.8 Hz, 2H), 1.26 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 
172.27, 154.00, 134.78, 125.74, 125.05, 82.10, 39.57, 28.22, 23.79. MS 
[M+H]+:C18H26NO3 requires: 304.1907, found: 304.1906. CHN requires C: 71.26%, H: 
8.31%, N: 4.62, found C: 71.12%, H: 8.16%, N: 4.38% 
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4-Hydroxy-3-5-diisopropylbenzoic acid7 
 
 
80 
NaClO2 (1.3 g, 14.4 mmol) was added to a solution of  (1.0 g, 4.8 mmol) NaH2PO4 
(2.2 g, 14.4 mmol) and 2-methyl-2-butene (9.5 mL, 2M in THF) in BuOH/H2O (1:1, 15 
mL). The reaction was allowed to stir at room temperature for 16 hours. Upon 
completion the reaction mixture was diluted with Na2CO3 (50 mL) and was washed 
with EtOAc (50 mL). The aqueous layer was acidified to pH 1 (20 mL HCl, 1M) and 
extracted with EtOAc (3 x 30 mL). The organic extracts were collected and dried 
over MgSO4 and concentrated under vacuum to afford the product. The product 
was purified column chromatography (80:20 EtOAc/n-Hexane) to give the product 
as a white solid (739 mg, 68% yield). 1H NMR (400 MHz, CDCl3) δ 7.85 (s, 2H), 5.30 
(s, 1H), 3.21- 3.11 (m, 2H), 1.30 (d, J = 6.8 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 
172.25, 155.07, 133.42, 126.77, 121.39, 27.27, 22.45.MS: C13H22NO3  
[M+NH4]
+requires 240.1595, found 240.1590.   
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2,6-Diisopropyl-4-(trifluoromethyl)phenol 
 
 
109 
 
To an oven dried borosilicate vial (8 mL) was added Ir(Fppy)3 (3.8 mg, 0.0056 mmol) 
and K2HPO4 (261 mg, 1,5 mmol). The vial was degassed by alternating vacuum 
evacuation and N2 backfill (x3) before MeCN (4 mL) and propofol (0.89 mL, 0.5 
mmol) were added. The resulting solution was again degassed by alternating 
vacuum evacuation at -78 oC and allowing the solution to come to room 
temperature under N2 (x3).  Trifluoromethanesulfonyl chloride (0.105 mL, 1.0 mmol) 
was added and the vial was placed 2 cm from a 26W compact fluorescent light bulb 
(daylight GE Energy Smart™ 1600 lumens). After 24 hours the reaction mixture was 
quenched with H2O (10 mL) and the crude product was extracted with EtOAc (2 x 20 
mL) washed with H2O (20 mL), brine (20 mL). The combined organic extracts were 
dried over MgSO4 and concentrated under vacuum to afford the product as a yellow 
oil (52 mg, 42% yield). 1H NMR (400 MHz, CDCl3) δ 7.30 (s, 2H), 5.16 (s, 1H), 3.17 
(hept, J = 6.8 Hz, 2H), 1.28 (d, J = 6.8 Hz, 12H).19F NMR (376 MHz, CDCl3) δ -61.26 (s).
 
13C NMR (101 MHz, CDCl3) δ 152.65, 126.16, 120.71,120.51, 27.11, 22.36. MS 
[M+H]+:C13H18FO3 requires: 247.1305, found: 247.1302. CHN requires C: 63.40%, H: 
6.96 found C: 63.94%, H: 6.98%. 
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